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SUMMARY 
The sequence of events between mitogen-receptor interactio!l and DNA synthesis was 
examined using T lymphocytes as a model system. The ability of four ligands 
(Concanavalin A (Con A), interleukin 2 (IL2), anti-TI antibody and anti-Thy 1 antibody) 
to stimulate proliferation of two cell types (BALB/c thymocytes and a constitutive IL2r-
. expressing T cell line, clone 4) was determined. Clone 4 proliferated in response to IL2 
and anti-Thy 1 antibody, but not Con A or anti-T3 antibody. BALB/c thymocytes 
responded strongly to Con A, but anti-Thy 1 antibody and anti-T3 antibody were only 
poor mitogens. IL2 alone was ineffective as a mitogen for thymocytes, but synergised 
with Con A, anti-Thy 1 antibody or anti-TI antibody, suggesting that the failure of the 
latter two to activate significant DNA synthesis in thymocytes was due to the failure of 
these ligands to induce appreciable IL2 secretion. Anti-IL2 receptor (IL2r) antibody 
inhibited proliferation in response to all ligands tested, suggesting that ligand-induced 
proliferation required IL2-IL2r interaction. 
The effect of each ligand on the intracellular free calcium concentration ([Ca2+]i) and 
the amounts of inositol phosphates and c-myc mRNA in both cell types was determined. 
Except for IL2 on thymocytes, all ligands stimulated c-myc mRNA accumulation in both 
cell types. Con A, anti-T3 antibody and anti-Thy 1 antibody stimulated increases in 
inositol phosphates in both cell types. Stimulation of thymocytes with Con A resulted in 
rapid, transient accumulation of Ins(l,4,5)P3, rapid persistent elevation of InsP4 and 
slow monotonic production of Ins(l,3,4)P3. The amount of InsPs was not changed by 
Con A and InsP6 was not detected. Calcium-depletion experiments and data from a 
permeabilised thymocyte system suggest that Ins(l,4,5)P3 is phosphorylated to give 
InsP4 by a Ca2+-dependent enzyme. Activation of InsP3 kinase by the Con A-stimulated 
[Ca2+]i increases may be sufficient to account for the transience of Ins(l,4,5)P3 
accumulation. 
Increases in [Ca2+]i were stimulated by Con A and anti-Thy 1 antibody in both cell 
types, but interaction of IL2 with IL2r on clone 4 failed to induce [Ca2+]i elevation or 
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inositol phosphate accumulation. The ability of anti-Thy 1 antibody and anti-T3 antibody 
to stimulate PtdlnsP2 hydrolysis and [Ca2+Ji elevation but not appreciable thymocyte 
proliferation in the absence of exogenous IL2 suggests that increases in inositol 
phosphates and [Ca2+Ji are insufficient to stimulate IL2 secretion, but may be required for 
induction of IL2r expression. 
Several inhibitory receptor interactions were observed. IL2 and anti-Thy 1 antibody 
mutually antagonised clone 4 mitogenesis, and anti-CD4 antibody was a potent inhibitor 
of clone 4 proliferation induced by anti-Thy 1 antibody. The mechanism of antagonism 
of IL2 and anti-Thy 1 antibody was unclear, IL2-induced c-myc mRNA accumulation was 
unaffected by anti-Thy 1 antibody and IL2 caused only a small reduction in [Ca2+Ji and 
inositol phosphate responses to anti-Thy 1 antibody. The ability of anti-CD4 antibody to 
inhibit ligand-stimulated increases in [Ca2+Ji, inositol phosphates and c-myc mRNA in 
clone 4 suggests that, although not sufficient to stimulate proliferation, these events may 
be important for the transition from quiescence to DNA synthesis. 
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CHAPTER 1 
INTRODUCTION 
1.1 Mitogenic stimulation of T lymphocytes a model for eukaryotic cell 
growth control 
Mitotic cell division is an integral process both in growing and mature organisms, 
where cells divide to replace dying or damaged cells. Cell division is stimulated by the 
interaction of a ligand, or mitogen, with either a cell surface receptor or an intracellular 
receptor. Many mitogens and complementary receptors have been characterised, and 
selective expression of these allows rigorous control of the transition from quiescence to 
mitosis of individual cells and populations. Mitogen-receptor interaction triggers 
quiescent cells to pass through a defined sequence of stages prior to division (Pardee et 
al., 1978). DNA synthesis and mitosis are separated by two periods of macromolecular 
synthesis, G1 and G2 (Fig. 1.1). Cells entering G1 after mitosis may arrest in response 
to nutrient deprivation or mitogen removal and are then said to be in Go. Subsequent re-
entry into the cell cycle requires renewed mitogen-receptor interaction. This interaction 
must trigger a primary response (or responses) capable of initiating a sequence of events 
culminating in DNA synthesis and cell division. The identity of this primary response 
and the subsequent sequence of events are currently the subjects of intense investigation. 
D NA synthesis 
MITOOEN / ~ 
Go (quiescence) G1 G2 
NUTRIENT ~ / DEPRNATION 
Mitosis 
Fig. 1.1 The Cell Cycle 
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Lymphocytes, the effector cells of the immune system, are useful model cells for 
studying mitogenesis. Lymphocytes are small, non-adherent cells found in the bone 
marrow, thymus, spleen, lymph nodes and tonsils, in addition to those circulating in the 
blood (Ling and Kay, 1975). Lymphocytes are easily isolated from blood or other 
organs, and can be obtained in ample quantities for biochemical analysis. After isolation, 
lymphocytes grow readily but will remain quiescent until stimulated. Problems associated 
with the use of heterogeneous preparations such as thymocytes, splenocytes, or 
peripheral blood lymphocytes (PBL's) can be overcome by the use of monoclonal cell 
lines with defined growth requirements. In addition, lymphocytes are particularly suitable 
model systems for the analysis of mitogenic responses since clonal proliferation is an 
integral component of their physiological role in the immune response. 
Two major classes of mature lymphocyte exist, distinguishable on the basis of their 
cell surface proteins (Ling and Kay, 1975), both originating from pluripotent 
haematopoietic stem cells in the bone marrow. B lymphocytes employ membrane-bound 
immunoglobulin molecules to recognise soluble foreign proteins (antigens). 
Immunoglobulin-antigen interaction results in secretion of immunoglobulins of identical 
specificity to the surface expressed-form and therefore capable of interaction with, and 
removal of, that antigen from the bloodstream. T lymphocytes respond to cell surface 
antigen displayed in association with major histocompatibility complex (MHC) proteins 
either by secreting lymphocyte growth factors (which facilitate the B cell response) or by 
lysing infected cells (Marrack and Kappler, 1986). T cells achieve antigen recognition 
through a polymorphic antigen receptor analogous to the B cell immunoglobulin molecule 
(reviewed in Clevers et al., 1988). Antigen recognition by either lymphocyte class . 
stimulates proliferation; thus antigen-reactive clones are expanded as the need arises. 
T lymphocytes originate as bone marrow stem cells. Pre-T cells developed from these 
migrate to the thymus, where the antigen receptor locus is progressively re-arranged and 
expressed (reviewed in Davis and Bjorkman, 1988). Subsequently mature antigen 
· receptor-expressing cells are exported to the periphery. Thus antigen receptor is 
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expressed only by peripheral T cells and a small fraction of thymocytes, and in the latter 
may not be fully immuno-competent. Therefore immature T cell proliferation must be 
induced via additional mitogenic receptors. Several such receptors, physically distinct 
from the antigen receptor, have been identified (see below, also reviewed in Weiss and 
hnboden, 1987), although the functional independence of these from the antigen receptor 
is controversial (see Section 1.3). The presence of additional mitogenic receptors on T 
cells enhances their attractiveness as a model system for the study of eukaryotic cell 
growth. Not only can the sequence of responses to antigen receptor stimulation be 
elucidated, but this sequence can be compared with that obtained via stimulation of 
receptor molecules distinct from the antigen receptor. 
L2 Mitogenic stimulation of T lymphocytes through the antigen receptor 
Antigenic stimulation of T cells can be mimicked by antibodies directed against various 
components of the antigen receptor, or by polyvalent plant lectins. The recognition sites 
for these ligands can best be understood by considering the structure of the antigen 
receptor. (Antigen receptor complexes isolated from human and murine ly~phocytes are 
essentially similar, therefore all reports cited refer to the murine system unless otherwise 
stated in the text). 
1.2.1 Structure of the antigen receptor 
The antigen receptor consists of two major components Ti and T3 which themselves 
are composed o_f several protein chains. (T cell surface proteins, often assigned 'T' 
(human) or 'Ly' (murine) designations initially, are subsequently assigned to Clusters of 
Differentiation (CD) on the basis of common recognition by a panel of antibodies. T3 has 
been designated as CD3, and the acronyms T3 and CD3 are used interchangeably 
throughout this thesis.) Ti is a polymorphic disulphide-linked heterodimer Mr 80-90K 
(Meuer et al., 1983), composed of Tia, an acidic chain of 43-54K, and a less acidic Ti~ 
chain Mr 38-44K. Tia and TiB are integral membrane proteins with 2-6 N-linked 
glycosylation sites within the extracellular domain, but both have only short cytoplasmic 
· tails and thus are thought to be unlikely to transduce signals into the cytoplasm. This 
function has therefore been ascribed to the monomorphic T3 complex, which co-
modulates, co-cross-links and co-immunoprecipitates with Ti and is therefore assumed to 
be physically associated with Ti on the cell surface. The identified T3 proteins do have 
significant cytoplasmic domains, but cloning of the genes has so far not revealed any 
kinase domains or OTP-binding sites (Clevers et al., 1988). Five members of the T3 
complex have been described; three of which - y, o, and E - are present as single copies. 
While the 21.kDa (y) and 26.kDa (o) components are glycoproteins bearing N-linked 
carbohydrate side chains, the 25k:Da chain (E) is unglycosylated but may contain internal 
disulphide bonds (Samelson et al., 1985; Oettgen et al., 1986). All three chains contain 
conserved acidic residues of aspartic or glutamic acids within their hydrophobic putative 
transmembrane domains, which may stabilise the T3-Ti complex by interaction with 
corresponding basic lysine residues in the Ti protein transmembrane domains. The two 
additional T3 components ~ and 11 are non-glycosylated and are present in variable 
stoichiometry relative to they& core. The 16.kDa chain~ is present as a homodimer in 
the majority of complexes, but may alternatively exist as a heterodimer linked to the 
22.kDa protein 11 (Oettgen et al., 1986; Baniyash et al., 1988a; Weissman et al., 1988a,b). 
A previously described protein, p21, of apparent Mr 21.kDa (Samelson et al., 1986a,b) 
has been established as a phosphotyrosine-containing form of the 16.kDa ~ peptide 
(Baniyash et al., 1988b ). This peptide is apparently important in signal transduction (see 
below) and cell surface expression of the T cell receptor complex (TCR); a~- mutant 
hybridoma line. expresses only 5% cell surface receptor compared with the parental line; 
the other 95% being rapidly degraded in the lysosomes (Sussman et al., 1988a). 
However, the ~ protein is clearly not the only protein required for surface TCR 
expression since cell lines defective in the Tia or Ti~ locus also fail to express surface 
TCR complexes (Saito et al., 1987a). 
Recent studies focussing on the intracellular assembly of the T3-Ti complex suggest 
that assembly occurs within the endoplasmic reticulum where intermediate complexes of 
~2 and yo£ bind independently to the a/~ heterodimer (Bonifacino et al., 1988a; Alarcon 
· et al., 1988). Sub-complexes consisting of yo or ye, with the capacity to bind ex/~, have 
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also been observed (Berkhout et al., 1988; Bonifacino et al., 1988a). Correct TCR 
assembly may also require the involvement of auxiliary proteins, which dissociate before 
export of the complex to the Golgi apparatus. Two reports of such proteins in human 
cells identified one protein associated with the 8 and£ chains (T3-p28; Pettey et al., 1987) 
and another associated with both CD3 components and free ex. and J3 chains (CD3-co; 
Alarcon et al., 1988). A similar protein, the T cell receptor associated protein (TRAP), 
has also been identified in murine T cells (Bonifacino et al., 1988b). 
A second form of the Ti heterodimer has been observed complexed with T3 in non-
cx./J3-bearing cells (Brenner et al., 1986; Pardoll et al., 1987; Krangel et al., 1987; 
Reinherz, 1987). This y/o heterodimer is only expressed on a small percentage of T cells, 
which appear to arise by a distinct lineage compared with cx./'3-bearing cells; y/o+ cells are 
first detectable in developing murine thymi 2 days prior to cx.113+ cells and the y protein is 
transcribed from a re-arranged locus not observed in a113+ cells (Pardoll et al., 1987; 
Winoto and Baltimore, 1986). In addition to this early foetal subset, a minor 
subpopulation of peripheral T lymphocytes express y/o TCRs, including some natural 
killer cells (Alarcon et al., 1987), intestinal intraepithelial lymphocytes (Goodman and 
LeFrancois. 1988) and dendritic epidermal cells (Stingl et al., 1987). Despite differences 
in the carbohydrate processing of the T3o oligosaccharide in some y/o+ cells, T3 co-
modulates with the y/o heterodimer and is implicated in functional activity mediated via 
this heterodimer (Alarcon et al., 1987; Krangel et al.,1987). No separate function for y/8-
bearing cells has so far been identified which would account for the existence of this 
distinct lineage. 
1.2.2 T3-Ti·Stimulated proliferation of T lymphocytes 
T cell proliferation, as measured by [3H]thymidine incorporation, can be induced by 
antibodies directed against T3 or Ti. Anti-human T3 antibodies have been available for 
some time (OKT3, Van Wauwe et al., 1980; antiT3c, Meuer et al., 1983; UCH-Tl, 
Beverley and Callaro, 1981), but an anti-murine CD3-£ hybridoma has only recently been 
cloned (Leo et al., 1987b). Since T3 is monomorphic these antibodies should recognise 
. all TI-bearing cells. In contrast, Ti-directed antibodies, raised by immunisation with a 
clonal T cell line, fall into 3 categories: those specific for the idiotypic receptor on the 
immunising clone (e.g. 103, Tomonari et al., 1985); those capable of recognising an 
element repeated in many receptors, such as the V~6 (Payne et al., 1988); V~g (Staerz et 
al.,1985) or V~u (Tomonari and Lovering, 1988) -encoded fragments; and those which 
interact with non-polymorphic determinants of Ti such as WT31 (Tax et al., 1983). 
These antibodies are predominantly mitogenic for T3-Ti-bearing cells, although they 
are also capable of inhibiting antigen-directed T cell function, presumably by hindering 
interaction between antigen and receptor (e.g. Leo et al., 1987b). The T3-Ti complex 
expressed on y/o-bearing cells can also function to stimulate proliferation; both anti-Tio 
and anti-T3 antibodies stimulate proliferation of y/o+ cells (Wu et al.,1988; Bluestone et 
al .• 1987). 
T cell proliferation can also be stimulated by lectins (e.g. Meuer et al., 1984b), as 
mentioned above. Lectins are glycoproteins, extracted from plants, which have the ability 
to bind specific saccharide groups on the cell surface. The most commonly used lectins 
Concanavalin A (Con A), from Canavalia ensiformis, and phytohaemagglutinin (PHA), 
from Phaseolus vulgaris, are both mitogenic for a wide range of T cells (Ling and Kay, 
1975). Con A binds to a-D-mannopyranoside and a-D-glycopyranoside residues 
including the 3,6-di-o-(a-D-mannopyranosyl)-D-mannosyl moiety (Brewer and 
Bhattacharyya. 1986), and can therefore interact with any cell surface receptors bearing 
these residues. On the T cell surface, the T3-Ti complex is bound both by Con A and 
PHA (Chilson .et al., 1984; Kanellopoulos et al., 1985), and both of these lectins also 
interact with a variety of other surface glycoproteins. PHA may also bind to CD45 
(Bemabeu et al., 1987) and CD2 (O'Flynn et al., 1985), both of which may be involved 
in mitogenesis (see below). The interaction of Con A with CD45, LFA-1 (CD18), Lyt 2 
(CD8), and at least five other unidentified proteins has been demonstrated (Sitkovsky et 
al., 1984). Thus, although lectins bind to the TCR complex, other interactions may also 
be important for their mitogenic action. 
1.2.3 The requirement for accessory cells in T3m Ti-stimulated T cell 
proliferation 
A common feature of T cell proliferation evoked by T3-Ti-directed antibodies and 
lectins. is the requirement for accessory cells. In the absence of macrophages or 
monocytes putative mitogenic ligands provoke little or no proliferation. This requirement 
for accessory cells can be partially overcome by cross-linking the antibodies either with an 
anti-immunoglobulin antibody or by prior immobilisation of the antibodies on Sepharose 
beads (e.g. Meuer et al., 1984a,b), or on the surface of culture dishes. This suggests the 
accessory cells to be capable of cross-linking the antibodies, presumably via Fe receptors 
(Benichous et al., 1987; Ceuppens and Van Vaeck, 1989). It is likely that formation of a 
cross-linked matrix of antibody and T3-Ti more closely resembles the "in vivo" 
interaction of T cell with antigen-presenting cell, and the resultant stabilisation may be 
important for preventing premature ligand internalisation. However, even immobilised 
ligand is insufficient to stimulate highly purified resting T cells in the absence of 
accessory cells, suggesting the latter must supply an additional signal, possibly a soluble 
mediator. The best candidate for this function is the lymphokine interleukin 1, of which 
two forms exist, IL 1 a and Il .. 1 ~. both of Mr 17kDa. 
Receptors for ILl have been identified on several T cell lines including LBRM-33-
1A5, a murine T cell leukemic line (Dower et al., 1985) and the T cell lymphoma EL4 
(Lowenthal and Macdonald, 1986). EL4 cells express 2 classes of ILl receptor, 
distinguishable by their differing affinities for ILL The majority are the lower affinity 
form CKct-200-500pM), but 1-2% have a higher affinity CKd=3.8pM) and are capable of 
internalising ILl (Lowenthal and Macdonald, 1986). 
Despite the presence of ILl receptors on several T cell lines, ILl alone has little effect 
on T cells. However, ILl synergises with PHA (Hollander et al., 1987) or immobilised 
anti-T3 antibody (Scheurich et al., 1985) to activate T cells. Thus ILl secretion may be 
the "missing" effector function supplied by accessory cells in addition to receptor cross-
linking. However several lines of evidence suggest that accessory cells may also be 
. required to secrete other lymphokines. Certain T cell subsets are unresponsive to ILl 
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(Lichtmann et al., 1988; Weaver et al.,1988). The synergistic effect of monocyte culture 
supernatant on PHA-stimulated PBL proliferation can be substituted for by IL6 and is 
inhibited by anti-IL6 but not anti-IL1~ antibody (Ceuppens et al., 1988). Several murine 
T cell clones secrete and respond to IL1 (Tartak:ovsky et al., 1988). Taken together these 
data suggest accessory cells may produce several discrete lymphokines, and possibly that 
T cells can be subclassified according to their requirement for accessory cell-supplied 
lymphokines. 
1.2.4 The requirement for interleukin 2 in T3-Ti·Stimulated T cell 
proliferation 
T lymphocytes can be broadly divided into two functional classes, as mentioned 
above. Cytotoxic T cells (Tc) lyse cells presenting foreign antigen, and are therefore 
implicated in the destruction of virally infected cells. Helper T cells (TH) produce 
lymphokines, particularly interleukin 2 (IL2) and interferon-y (IFN-y), predominantly in 
response to foreign antigen presented by B lymphocytes or macrophages. Secretion of 
these lymphokines may occur only proximal to occupied antigen receptors (Janeway, 
1986; Poo ~ fil., 1988), thus facilitating specific activation of those cells interacting with 
the T cell (Malkovsky et al., 1987). 
IL2 secretion is thus a characteristic TH cell response to stimulation via the antigen 
receptor (Kronke et al., 1985), and is frequently used as a diagnostic marker for T cell 
activation. However, both immature and cytotoxic T cell populations also have the 
capacity to produce IL2, albeit a reduced capacity relative to TH cells (McGuire et al., 
1988; Lugo et aI., 1986). This suggests a more general role for interleukin 2 and this is 
confinped by the demonstration that interaction of IL2 with a T cell surface interleukin 2 
receptor (IL2r) is required for T cell proliferation (Meuer et al., 1984a). 
Two classes of IL2r have been observed, distinguishable on the basis of their affinity 
for IL2. The 55kDa human Tac antigen, cloned by two groups in 1984 (Nikaido et al., 
1984; Leonard et al., 1984), and the non-Tac 75kDa (or 70kDa) IL2-binding peptide 
(Tsudo et al. , 1987; Sharon et al.,1986) both have low affinities for IL2 (Tsudo et 
. al.,1987). However, co-existence of p55 and p75 on the same membrane results in the 
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formation of high affinity IL2 binding sites (~=10-200pM), suggesting the high affinity 
receptor to be a p55-p75 complex (Tsudo et al., 1987; Robb, 1986; Hatakeyama et al., 
1985; Dukovich et al., 1987). This conclusion is re-inforced by the fact that both p70 and 
Tac are labelled when IL2 is chemically cross-linked to the cell surface (Dukovich et al., 
1987). Furthermore, mitogenic antibodies directed against a 75kDa peptide on YT natural 
killer cells cause down-regulation of the high affinity IL2r (Nakamura et al., 1989). 
Early assays of IL2r expression employed anti-Tac antibody, and demonstrated that 
Tac expression is up-regulated by stimulation of the antigen receptor (Reem and Yeh, 
1985; Hemler et al., 1984; Meuer et al., 1984a). Increased IL2r expression, like 
increased IL2 expression, is due to transcriptional activation of the IL2r gene; 
transcription is maximal 9h after receptor stimulation (Kronke et al., 1985). In contrast, 
two reports imply that the p75 protein may be constitutively expressed. Transgenic mice 
transfected with the gene for p55 express high affinity IL2r on unstimulated splenocytes 
and thymocytes implying the prior expression of p75 on these cells (Nishi et al., 1988). 
EL4 murine thymoma cells also apparently express p75 prior to stimulation, since p55 
transfection results in the expression of high affinity IL2 receptors in EL4 cells but not 
L929 cells - a non-lymphoid lineage (Hatakeyama et al., 1985). However, the presence 
of p75 on unstimulated EL4 cells may be a phenotypic peculiarity due to their transformed 
state. Similarly, p55 transfection into developing mice may result in abnormal p75 
expression. Thus the status of p75 expression in unstimulated cells is currently unclear. 
The effect of IL2 on IL2r expression is complex. Interleukin 2 apparently stimulates 
enhanced Tac expression on IL2r-bearing T cells, but simultaneously reduces the number 
of high affinity IL2 binding sites (Depper et al., 1985; Reem and Yeh, 1985; Smith and 
Cantrell, 1985). No clear mechanistic implications can be derived from these data. 
A further level of complexity has recently been revealed by the discovery that not all 
TH cells secrete IL2; THI cells secrete IL2, IFN-y and lymphotoxiri, but TH2 cells secrete 
IL4 and IL5 (Cherwinski et al., 1987). The proportion of IL4-expressing foetal 
thymocytes declines throughout gestation and only one in 300 splenocytes express IL4 
mRNA in response to Con A, suggesting IL4 might have some role in foetal ontogeny 
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(Sideras et al., 1988). However it is currently unclear whether IL2- and IL4-expressing 
populations overlap. Harel-Bellan and colleagues (1988a) demonstrated distinct IL2- and 
IL4-dependent TH clones, antigenic activation of which was sensitive to inhibition by 
either antisense IL2 or IL4 oligonucleotides. But Pelkonen and co-workers (1987) 
describe eight Ti7expressing murine clones of which all eight respond to rIL4, but six 
also proliferate in response to IL2. Despite this apparent inconsistency, clear differences 
in effector function of the two subsets have been demonstrated, presumably using cells 
which are distinct IL2 or IIA responders. Both subsets induce B cells to secrete IgM and 
IgG3, however IgGl and IgG2a production are only stimulated by TH2 and THl cells 
respectively (Stevens et al., 1988). This may be due to differential stimulation of discrete 
B cell subsets. However such differential stimulation is apparently not mediated via 
restricted cell-cell interactions since a single B cell can bind to either THl or TH2 cells 
(Sanders et al., 1988). 
1.2.5 The role of CD4 and CDS molecules in T3~ Ti-stimulated T cell 
proliferation 
CD4 and CD8 are accessory molecules expressed on reciprocal subsets of mature 
peripheral T lymphocytes (originally designated respectively as T4 and T8 in human cells 
and L3T4 and Lyt2 in mouse). In contrast, 70-80% of thymocytes are CD4+8+ (Scollay 
et al., 1984) and four thymic phenotypes have been observed. These are generated 
sequentially in the order; CD4-8- --> CD4+8+ --> CD4+8- or CD4-8+ (Crispe et al., 
1987; Fowlkes et al., 1985; Teh et al., 1988; Tamauchi et al., 1988), possibly with an 
additional immature CD4-8+ stage intermediate between double negative and double 
positive cells (Macdonald et al., 1988; Shortman et al., 1988). Mature T3-Ti-expressing 
cells are predominantly single positive, although a small 'subset of T3-Ti+ double negative 
cells has also been identified (Ceredig et al., 1987). 
The expression of CD4 or CD8 on peripheral T cells partially correlates with the 
functional division of T lymphocytes into helper and cytotoxic subsets, but is more 
stringently associated with the class of MHC protein recognised. CD4- and CD8-
expressing T cells recognise antigen in the context of MHC class II and class I molecules 
(Sideras et al., 1988). However it is currently unclear whether IL2- and IL4-expressing 
populations overlap. Harel-Bellan and colleagues (1988a) demonstrated distinct IL2- and 
IL4-dependent TH clones, antigenic activation of which was sensitive to inhibition by 
either antisense IL2 or IL4 oligonucleotides. But Pelkonen and co-workers (1987) 
describe eight Tiy-expressing murine clones of which all eight respond to rIL4, but six 
also proliferate in response to IL2. Despite this apparent inconsistency, clear differences 
in effector function of the two subsets have been demonstrated, presumably using cells 
which are distinct IL2 or IL4 responders. Both subsets induce B cells to secrete IgM and 
IgG3, however IgGl and IgG2a production are only stimulated by TH2 and THl cells 
respectively (Stevens et al., 1988). This may be due to differential stimulation of discrete 
B cell subsets. However such differential stimulation is apparently not mediated via 
restricted cell-cell interactions since a single B cell can bind to either THl or TH2 cells 
(Sanders et al., 1988). 
1.2.S The role of CD4 and CDS molecules in T3a T1-stimulated T cell 
proliferation 
CD4 and CD8 are accessory molecules expressed on reciprocal subsets of mature 
peripheral T lymphocytes (originally designated respectively as T4 and T8 in human cells 
and L3T4 and Lyt2 in mouse). In contrast, 70-80% of thymocytes are CD4+8+ (Scollay 
et al., 1984) and four thymic phenotypes have been observed. These are generated 
sequentially in the order; CD4-8- --> CD4+8+ --> CD4+8- or CD4-8+ (Crispe et al., 
1987; Fowlkes et al., 1985; Teh et al., 1988; Tamauchi et al., 1988), possibly with an 
additional immature CD4-8+ stage intermediate between double negative and double 
positive cells (Macdonald et al., 1988; Shortman et al., 1988). Mature T3-Ti-expressing 
cells are predominantly single positive, although a small subset of TI-Ti+ double negative 
cells has also been identified (Ceredig et al., 1987). 
The expression of CD4 or CD8 on peripheral T cells partially correlates with the 
functional division of T lymphocytes into helper and cytotoxic subsets, but is more 
stringently associated with the class of MHC protein recognised. CD4- and CD8-
expressing T cells recognise antigen in the context of MHC class II and class I molecules 
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respectively. Since class Il expression is restricted to immune lineage cells this provides a 
rationale for the partial correlation of CD4 expression with the TH phenotype. Similarly, 
the ubiquitous expression of class I molecules facilitates cytolysis of infected cells by 
CDS-expressing Tc cells throughout the body. 
The strict correlation between CD4/CD8 expression and MHC protein recognition has 
lead to the theory that these molecules physically interact thereby enhancing the avidity of 
intercellular binding. Several studies have demonstrated that CD4-transfectants show 
enhanced binding (Doyle and Strominger, 1987) and physiological responsiveness (Gay 
et al., 1987) to class IT-bearing cells, and reciprocally that CD4-bearing cells respond 
more strongly to antigen co-expressed with class Il than to antigen alone (Gay et al., 
1988). T3-Ti and CD4 co-clustering has also been observed in the presence of specific 
but not non-specific antigen-presenting cells (Kupfer et al., 1987). Corresponding 
evidence for CDS/class I interaction has also been demonstrated (e.g. Gabert et al., 
1987). These data imply that physical interaction between CD4/CD8 and non-
polymorphic MHC protein determinants mediates MHC class restriction of T cells. 
However the demonstration that expression of murine Ti in human Tr cells is sufficient to 
confer murine MHC restriction (Saito et al. , 1987), combined with evidence of direct 
interaction between T cell receptor and MHC protein (Ajitkumar et al., 1988) suggests 
minimally that the TCR complex is also involved in MHC protein recognition. The 
inability of other workers to confirm the binding studies of Doyle and Strominger (Q. 
Sattentau, personal communication) further questions the involvement of the CD4 
molecule in MI-IC binding. 
Early reports of anti-CD4 antibodies capable of antagonising T cell activation evoked 
by antigen presenting cells (Dialynas et al., 1983; Greenstein et al., 1984) were 
interpreted as evidence for the importance of class WCD4 interaction. (Similar data have 
also been obtained using CDS-directed antibodies, thus to avoid repetition this account 
will be restricted to a consideration of CD4.) Subsequently, anti-CD4-mediated 
antagonism was demonstrated in systems in the absence of class II-bearing accessory 
. cells. Anti-murine CD4 (L3T4) and anti-human CD4 antibodies inhibited T cell 
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proliferation and IL2 secretion stimulated by lectins or cross-linked anti-T3 antibodies 
(Tite et al., 1986; Wassmer et al., 1985; Bank and Chess, 1985) and also stimulation via 
non T3-Ti molecules (discussed below) such as CD2 (Carrera et al., 1987), Thy 1 (Pont 
et al., 1987), Tp44 and Tp103 (Schrezenmeier and Fleischer, 1988). In contrast, the 
ability of anti-CD4 antibodies to inhibit stimulation by IL2 or by a synergistic combination 
of phorbol ester and calcium ionophore is controversial (Blue et al., 1988; Moldwin et al., 
1987; Carrera et al., 1987; Schrezenmeier and Fleischer, 1988); and anti-CD4 is 
apparently incapable of inhibiting Ly6.C-mediated T cell activation (Leo et al., 1987a). 
Nevertheless it is clear that anti-CD4 antibodies profoundly antagonise T cell activation 
induced by several ligands in the absence of class II-bearing accessory cells; and these 
findings have been taken as evidence that CD4 is capable of transmitting a negative signal. 
Consistent with this, anti-CD4 antibodies can also antagonise early metabolic responses to 
T cell activation (see below) such as increases in intracellular free calcium concentration 
([Ca2+]i) and TCA3 transcription (Rosoff et al., 1987a; Blue et al., 1988; Wilson et al., 
1988). 
More recently however the ability of CD4 to transmit positive signals has been implied 
by several lines of evidence. Co-cross-linking of CD3 and CD4 molecules on the cell 
surface by using anti-CD3 and anti-CD4 antibodies immobilised on the same Sepharose 
bead results in enhanced responses compared with those evoked by anti-CD3-Sepharose 
alone whereas these responses are inhibited by soluble anti-CD4 antibody. Enhancement 
of several responses has been demonstrated, notably proliferation (Anderson et al., 1987; 
Eichman et al., 1987), lymphokine production (Owens et al., 1987; Kelso and Owens, 
1988), and Ca2+i mobilisation (Ledbetter et al., 1988a). These results imply a 
requirement for CD4:CD3 proximity in T cell activation. Consistent with this -10% of 
surface CD4 molecules are associated with CD3 on human TH cells (Anderson et al., 
1988), and TCR triggering results in both TI-Ti and CD4 modulation (Acres et al., 1986; 
Saisawa et al., 1987; Anderson et al., 1988). Furthermore T cell activation enhances 
association between T3-Ti and CD4 (Rivas et al. , 1988). Alternatively, the enhanced 
. responses observed after CD4:CD3 co-cross-linking may be a more general phenomenon; 
since co-cross-linking of CD3 with any of CD2, CD4, CDS, CD6 or CD8 enhances T cell 
proliferation relative to stimulation by cross-linked anti-CD3 antibody alone (Walker et 
al., 1987). However, the ability of the recently described anti-CD4 antibody B66.6 to 
evoke T cell proliferation in the absence of anti-CD3 antibody (Carrel et al., 1988) does 
suggest a specific role for CD4 in T cell proliferation. This is substantiated by the recent 
demonstration of tyrosine kinase activation by anti-CD4 antibody (Veillette et al., 1989; 
discussed below) and by the ability of human immunodeficiency virus I envelope protein 
gp 120, which interacts with CD4 on human TH cells (Sattentau and Weiss, 1988), to 
stimulate increases in [Ca2+]i and IL2r expression in peripheral blood T cells (Kornfeld et 
al., 1988). Consistent with its possible role as a positive signal-transducing receptor, 
CD4 is phosphorylated in response to a variety of ligands including antigen, anti-CD3 
antibody, and anti-CD2 antibody combinations (Acres et al., 1986; Blue et al., 1987), in 
an analogous manner to various growth factor receptors. Thus, far from being merely an 
adhesion molecule involved in intercellular association, CD4 appears to be actively 
involved in the generation of mitogenic responses to ligands directed at T3-Ti and 
alternative receptors. 
The antagonistic effects of some CD4 antibodies in the absence of class II-bearing 
accessory cells may be due to their interaction with inactivating epitopes distinct from that 
recognised by B66.6. More likely however, given that the same antibody (e.g. Gkl.5) 
may have antagonistic or stimulatory effects depending on whether it is used to cross-link 
CD4 alone or to co-cross-link CD4 and CD3 (see above), is that negative effects are 
caused by destabilisation of activating receptor:CD4 complexes. This in tum suggests 
that CD4 is required to covalently modify the TCR, m<?st probably by phosphorylation. 
Finally, despite mounting evidence that CD4 is intimately involved in signal transduction, 
these results do not exclude a role for CD4 in :MHC class II protein recognition. Indeed 
given the almost total coincidence between CD4 expression and :MHC class II restriction, 
CD4 is highly likely to function as a recognition molecule for class II proteins. CDS in 
cos+ cells has substantially similar effects to CD4 in CD4+ cells, including the ability to 
· enhance T3-induced responses when co-cross-linked to T3, and a demonstrated 
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association with the tyrosine k:inase p56lck (Veillette et al., 1988). Thus CD8 probably 
interacts with MHC class I proteins, and functions as a signal transducer in a manner 
analogous to CD4. 
1.3 Mitogenic stimulation of T lymphocytes through alternative cell 
surface receptors 
T cell proliferation may be stimulated not only by T3-Ti-directed ligands, but also by 
antibodies directed against distinct extracellular receptors. Of these Thy 1 and CD2 (Tl 1) 
are the best characterised, but information is also rapidly accumulating concerning CD28 
(T44) and products of the Ly6 locus including T cell activating protein (TAP) and Ly6 
protein. While some of these have been detected only in murine or human systems, 
others occur in both species but have only been extensively characterised in one. 
Comparison of stimulation via each receptor suggests they may have differential 
requirements for accessory cells, but may all require the presence of T3-Ti. A 
dependence on T3-Ti expression would preclude the involvement of these receptors in 
immature T cell proliferation, and suggest them to be accessory molecules analogous to 
CD4/CD8 required in antigen-mediated rather than antigen-independent mitogenic 
stimulation. However, their dependence on T3-Ti is controversial (see below) and the 
widespread expression in both mature and immature T cells of such molecules as Thy 1 
suggests a function independent of antigenic stimulation. 
1.3.1 Thy 1 
The Thy 1 antigen is a 25-30.kDa glycoprotein, which may also exist as a 50.kDa dimer 
unsusceptible to reduction (Gunter et al., 1984, 1986). Human Thy 1 expression is 
restricted to immature T cells; 0.1-0.5% of bone marrow cells, and 0.2-10% of 
thymocytes, but no PBL's are Thy 1 + (McKenzie and Fabre, 1981; Ritter et al., 1983). 
In contrast, Thy 1 is widely expressed on murine T cells including thymocytes, 
splenocytes, periph~ral T cells and hybridomas and is also expressed in nervous tissue 
(Reif and Allen, 1964; Gunter et al., 1984). Thy 1 expression is not obligatory for 
murine T cell proliferation (Gunter et al., 1988; Wadsworth et al., 1989), but some anti-
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Thy 1 antibodies activate T cells to proliferate and express IL2 and IL2r in the presence of 
accessory cells (Gunter et al., 1984; MacDonald et al., 1985; Pont et al., 1985). 
Accessory cells can be substituted for by phorbol ester and a second, cross-linking 
antibody (Gunter et al., 1986). Anti-Thy I .antibodies can also induce IL2 secretion from 
Thy 1-transfected Jurkat cells (a human leukemic T cell line), implying that no murine T 
cell-specific molecules are required for Thy 1 function. However, several experiments 
suggest T3-Ti expression may be obligatory for Thy I-mediated T cell activation. The 
anti-Thy 1 antibody G7 fails to stimulate IL2 secretion from T3-Tf mutant Jurkats 
(Gunter et al., 1987) or hybridomas (Sussman et al., 1988b); but transfection of the 
missing Ti chain restores both surface T3-Ti expression and the response to G7. The 
required T3-Ti chain is clearly not Tia or Ti~, since y/o-bearing cells proliferate in 
response to anti-Thyl antibody (MacDonald et al., 1987), but may be ~. since mutants 
deficient in ~ expression do not secrete IL2 in response to anti-Thy 1 or antigen (Sussman 
et al., 1988a). 
In-contrast, Thy I-mediated [Ca2+]i increases can be observed in T3-Tr Jurkats 
(Gunter et al., 1987) and Thy 1-transfected B cells (Kroczek et al., 1986a), although not 
in a Tia- Tc clone (Schmitt-Verhulst et al., 1987) implying that Thy 1 may elevate [Ca2+]i 
independently of T3-Ti, but that [Ca2+]i elevation is not sufficient for IL2 expression and 
is therefore not a reliable indicator that a T cell will progress to DNA synthesis. Gunter 
and colleagues (1986) have provided the only clear demonstration of Thy I-mediated 
activation independent of T3-Ti using an unusual Thy 1 + Jurkat transfectant. This cell 
line secreted II...2"in response to anti-Thy 1 antibody but not T3 or Ti-directed antibodies. 
Loss of Thy 1 resulted in resumption ofT3ffi reactivity, implying Thy 1 expression had 
suppressed the ability to respond through T3-Ti. Thus it is clear that Thy 1 can generate 
signals independently of T3-Ti, but that these may or may not be sufficient to fully 
activate T cells. Consistent with this, distinct patterns of protein phosphorylation can be 
generated in response to anti-TCR or anti-Thy 1 antibodies, presumably due to 
independent early response activation (Peyron et al., 1988). It should also be noted that 
since all of these studies have been performed on TI-Tr mature cells, no conclusions can 
be drawn about the role of Thy 1 in immature T cell proliferation. 
1.3.2 Ly6 
The murine Ly6 locus encodes a family.of proteins differentially expressed in various 
T cell populations; Ly6.2A is expressed in peripheral tissues, Ly6.2B in bone marrow, 
Ly6.2C in bone marrow and peripheral cells, Ly6.2D as Ly6.2C plus thymocytes, and 
Ly6.1E in lymphoblasts (Kimura et al., 1984). Several mitogenic anti-Ly6 antibodies 
have been described, almost all of which appear to require cross-linking and co-addition 
of IT.,2 or the phorbol ester tetradecanoyl phorbol acetate (TP A). D7, which recognises a 
non-polymorphic Ly6 specificity present on Ly6.1E+ and Ly6.2A + cells, stimulates 
IL2/IL2r expression and proliferation of splenic T cells in the presence of TP A plus 
accessory cells (Malek et al., 1986). The accessory cells may be substituted by a second 
cross-linking antibody implying that IL1 and other accessory cell secretions are not 
required. Splenic T cells also proliferate in response to anti-Ly6.2C antibody 143-4-2 
plus accessory cells and IL2 or TPA (Leo et al., 1987c). Peripheral T cell mitogenesis is 
stimulated by 34-2-11 antibody combined with TP A and a cross-linking agent (Yeh et al., 
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1987). In contrast, HKl.4 antibody stimulates a Tc clone to proliferate in the absence of 
accessory cells or phorbol ester (Havran et al., 1988). Ly6 antibodies appear to 
preferentially stimulate CDS+ cells rather than CD4+ cells (Toulon et al., 1988; Leo et al., 
1987c), which may explain the failure of anti-CD4 antibody to inhibit anti-Ly6.2C-
stimulated T cell proliferation (Leo et al., 1987a). IFN-y up-regulates expression of 
Ly6.2A/E (Duniont et al., 1987; Toulon et al., 1988) suggesting a role for Ly6 receptors 
in post-antigenic or non-specific proliferation. However, Ly6 fails to mediate T cell 
activation in TI-Tr hybridomas (Sussman et al., 1988c) or TI-modulated Tc clones (Leo 
et al., 1987c) implying that Ly6-mediated activation may require TI-Ti expression. 
1.3.3 TAP 
TAP (T cell activating protein) is a 12kDa glycoprotein often found associated with a 
16kDa protein TAPa, which may be a reduced form of TAP (Rock et al., 1986; Reiser et 
al. , 1986). Although encoded in the Ly6.2 locus, TAP has a different pattern of 
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expression from any of the previously described Ly6 proteins, and is therefore assumed 
to be a distinct protein (Reiser et al., 1988). TAP is expressed on 70% of peripheral T 
lymphocytes and on 10-20% of thymocytes, predominantly mature medullary cells, but is 
not expressed on B cells or on the T cells of several mice strains, including BALB/c, C3H 
and NJ mice (Yeh et al., 1986; Rock et al., 1986). Anti-TAP antibodies plus TP A are 
mitogenic for peripheral blood cells (Yeh et al., 1987) and mature thymocytes (Yeh et al., 
1986). Splenic T cells proliferate in response to anti-TAP antibody only in the presence 
of accessory cells or IL1 implying that accessory cell secretions are required, rather than 
merely cross-linking (Rock et al., 1986). 
TAP-directed antibodies are similar to Ly6-directed antibodies in that they fail to 
induce proliferation in T3-Tr mutants or T3-Ti-modulated cells, implying a requirement 
for T3-Ti expression (Bamezai et al., 1988). Conversely, TAP expression appears to 
enhance T3-Ti-mediated T cell activation. TAP+ thymocytes are required for 
responsiveness in mixed lymphocyte reactions (i.e. antigenic stimulation) or Con A (Yeh 
et al., 1986), although this may simply reflect the correlation between TAP and T3-Ti 
expression. The demonstration that TAP- mutants are less responsive to antigen (Yeh et 
al., 1988) constitutes more powerful evidence for the involvement of TAP in antigenic 
stimulation. Similarly unresponsive mutants have also been observed which are deficient 
in the ability to make phosphatidylinositol- (Ptdlns-) linked proteins, and the effect of this 
mutation can be mimicked by treatment of cells with phosphatidylinositol-specific 
phospholipase C (Yeh et al., 1988). Since Ptdins-specific phospholipase C treatment 
releases TAP from T cells (Reiser et al., 1986), these data taken together imply that 
Ptd.Ins-linked TAP is involved in antigenic T cell activation. However since several other 
T cell antigens are also Ptd.Ins-linked (e.g. Thy 1, Homans et al., 1988; Ishihara et al. , 
1987; LFA-3 (lymphocyte function associated antigen-3), Dustin et al., 1987), the 
inhibitory effects of Ptd.Ins-phospholipase C cannot be attributed specifically to effects on 
TAP. In contrast, the ability of Ptdins-specific phospholipase C to cause cellular 
activation (Depper et al., 1984) suggests cleavage of Ptd.Ins-linked proteins might be an 
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integral component of T cell stimulation. However there is no evidence that mitogenic 
anti-Thy 1 antibodies stimulate cleavage of Thy 1 (Peyron et al., 1988). 
1.3.4 CD2 
In contrast to Thy 1, TAP and Ly6; CD2 (T11) is well characterised on human T cells 
but a murine homologue has only recently'been cloned (Sewell et al., 1987; Clayton et 
al., 1987). Human CD2 is a non-polymorphic 50kDa glycoprotein expressed on all T 
cells from the earliest T lineage precursor through thymocytes to peripheral T cells and T 
cell clones. Three epitopes are distinguishable on the basis of reactivity to antibodies; 
Tl l 1 and Tll2 are expressed on all T lymphocytes, but Tl13 is generated by 
conformational change in response to activation (Meuer et al., 1984b ). Macrophage-
depleted peripheral T cells proliferate in response to combinations of anti-Tl l 3 with anti-
T 111 or anti-Tll2 antibodies, via expression of IL2 and IL2r (Meuer et al., 1984b; 
Siciliano et al., 1985). However the ability of anti-CD2 combinations to stimulate IL2 
secretion from thymocytes and thus thymocyte proliferation is controversial (Fox et al., 
1986; Reem et al., 1987). 
O' Flynn and colleagues (1985) concluded that CD2 was responsible for the effects of 
PHA, since anti-CD2 antibodies could block [Ca2+]i elevation induced by PHA, but not 
UCH-Tl (anti-T3) or Con A. However, PHA- and CD2-mediated T cell proliferation 
differ in their requirements for macrophages (Meuer et al., 1984b) and T3-Ti expression 
(Moretta et al., 1987) implying that CD2 is not the sole PHA effector molecule. This is 
consistent with the observed interaction between PHA and T3-Ti (Chilson et al., 1984; 
Kanellopoulos et al., 1985). 
Recently, LFA-3 has been proposed as the in vivo ligand for CD2, due to the observed 
ability of CD2 to bind LFA-3 (Takai et al., 1987; Selvaraj et al., 1987). A physiological 
role for this interaction has been inferred since anti-CD2 antibodies activate T cells 
synergistically with purified LFA-3 or LFA-3-transfected cells (Bierer et al. , 1988a; 
Bockenstedt et al., 1988). CD2 stimulation during intercellular interaction may contribute 
to antigen-evoked proliferation since CD2-transfected murine T cell hybridomas show 
enhanced responses to antigen, and this augmentation is reversed by anti-CD2 or anti-
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LFA-3 antibodies (Bierer et al., 1988b). At least in mature cells, CD2 may be incapable 
of transducing signals in the absence of TI-Ti. 
Several investigators have observed the failure of CD2-directed ligands to evoke 
[Ca2+]i, IL2 or proliferative responses in T3-modulated or mutant T3-T( cell lines, but 
found that T3-Ti re-expression restores CD2-responsiveness (Meuer et al., 1984b; 
Pantaleo et al., 1987c; Bockenstedt et al., 1988; Breitmeyer et al., 1987). In contrast, 
other groups have observed CD2-stimulated [Ca2+]i and IL2 increases in apparently 
T3-T( cell lines (Pantaleo et al., 1988; Moretta et al., 1987; Alcover et al., 1986), but 
these studies may have failed to detect the low level of T3-Ti expression required for 
CD2-responsiveness (<1,000 molecules/cell; Alcover et al., 1988a). Thus it appears 
likely that T3-Ti expression is obligatory for CD2 responsiveness in cells normally 
T3-Ti+. However, in non-T3-Ti-expressing cells such as immature thymocytes and 
natural killer cells, CD2 stimuli may be sufficient to induce proliferation (Siciliano et al., 
1985; Fox et al., 1986; Toribio et al., 1989). Thus, CD2-mediated proliferation may 
have a role in human T cell maturation. 
The murine CD2 homologue is expressed in thymus and spleen (Sewell et al., 1987) 
and may also be expressed on B cells (Yagita et al., 1989). The cloned gene appears to 
encode a transmembrane protein with a large, proline-rich cytoplasmic domain, possibly 
with a cation binding site (Clayton et al., 1987). No mitogenic antibodies have so far 
been cloned. However, anti-rat CD2 antibodies are mitogenic suggesting that CD2 may 
have similar function in humans and rodents (Clark et al., 1988). 
1.3.S CD28 . 
CD28 (T44) is a glycoprotein of similar size (40-45kDa reduced or 80-85kDa non-
reduce4) but distinct from Ti, expressed on both a/~+ llD:d y/o+ human T cells (Moretta et 
al., 1985; Poggi et al., 1987; Testi and Lanier, 1989). Anti-CD28 antibodies are 
mitogenic for peripheral blood T cells in the presence of accessory cells or TP A (Moretta 
et al., 1985; June et al., 1987; Baroja et al., 1988), but T3-Ti-modulated and T3-Ti-
deficient cells are unresponsive to CD28, although CD28 does not co-modulate with 
T3-Ti or CD2 (Moretta et al., 1985, 1987). However, synergistic combinations of CD2-
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and CD28-directed ligands stimulate PBL proliferation independent of accessory cells or 
T3-Ti modulation (Van Lier et al., 1988; Pierres et al., 1988), implying that these 
receptors may enable non-specific involvement of T cells in immune reactions. 
1.3.6 Additional molecules 
An ever increasing number of additional molecules also appear to be implicated in T 
cell activation including THAM, a 110-128kDa molecule expressed on immature 
thymocytes (Naquet et al., 1988), and Tp90 and Tp45, both expressed on mature cos+ 
cells (Carrel et al., 1987a,b). CD45, a 180-220.kDa glycoprotein, may also be important, 
particularly since it has tyrosine phosphatase activity (Charbonneau et al., 1988). Anti-
CD45 antibodies may antagonise or enhance stimulation via other antigens depending on 
whether or not they are used to cross-link CD45 to the other antigen (Martorelli et al., 
1987; Bernabeu et al., 1987; Ledbetter et al., 1988a). Doubtless other molecules remain 
to be identified, many of which may function primarily during antigenic stimulation as, 
for example, lymphokine receptors and adhesion molecules, possibly with considerable 
overlap with molecules already characterised functionally but not at the molecular level. 
1.4 Early responses to receptor stimulation in T lymphocytes 
1.4.1 Phosphatidylinositol 4,5-bisphosphate metabolism 
Phosphatidylinositol 4,5-bisphosphate (PtdlnsP2) metabolism is one of the earliest 
detected events consequent on T3-Ti-mediated T lymphocyte stimulation. Receptor-
stimulated inositol phospholipid turnover, first demonstrated in the 1950s by the Hokins 
(Hokin and Hokin, 1953) and subsequently observed in response to a wide variety of 
hormones and mitogens (reviewed in Michell, 1975; Berridge and Irvine, 1984; Abdel-
Laitif, 1986), comprises several components. Synt~esis of the phosphoinositides 
(phosphatidylinositol, phosphatidylinositol 4-phosphate (PtdlnsP) and 
phosphatidylinositol 4,5-b_isphosphate) is accompanied by rapid phosphodiesteratic 
cleavage of PtdlnsP2, and possibly Ptdlns and PtdlnsP (Durell et al., 1968; Downes and 
Wusteman, 1983). Phosphoinositide breakdown has been assayed both as loss of pre-
labelled inositol-containing lipids and accumulation of inositol phosphates, but neither of 
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these techniques distinguish between hydrolysis of PtdlnsP2 and that of PtdlnsP or 
Ptdlns. Inositol mono- and bisphosphates (InsP and InsP2) may be directly generated by 
hydrolysis of Ptdlns and PtdlnsP respectively, but are also dephosphorylation products 
of inositol trisphosphate (InsP3). Conversely, decreases in Ptdlns and PtdlnsP may be 
the result of phospholipase or kinase action, since PtdlnsP2 is synthesised from Ptdlns 
via phosphorylation. Therefore, although the term "PtdlnsP2 breakdown" is used in this 
thesis to mean phospholipase C-catalysed PtdlnsP2 hydrolysis, its usage is not intended 
to imply that other phosphoinositides are not also cleaved. 
In T cells, increases in inositol phosphate accumulation and phosphoinositide 
synthesis are detectable within 1 min of Con A or PHA addition (Taylor et al., 1984, 
Grier and Mastro, 1985; Sasaki and Hasegawa-Sasaki, 1985). Inositol phosphate 
accumulation also occurs in response to T3-Ti-directed antibodies. In Jurkats, anti-T3 
antibody (OKT3) and anti-Ti antibody (C305) stimulate InsP2 and InsP3 accumulation 
within 30s, followed by a slower accumulation of InsP (Imboden and Stobo, 1985). 
More recently cloning of 145-2Cll, an antibody-producing hybridoma specific for 
murine T3-E (Leo et al.. 1987b ), has facilitated observation of similar T3-mediated 
inositol phosphate increases in murine T cells (Klausner et al., 1987). Such responses do 
. . 
not require TialJ3 expression, since anti-T3 antibody has a similar effect in y/o-expressing 
T cells (Pantaleo et al., 1987a). However, interaction of ligand with Ti is sufficient to 
induce phosphoinositide metabolism; antigen presentation to ex/~+ cells stimulates inositol 
phosphate accumulation (Klausner et al., 1987; Treves et al., 1987) and anti-Tiy antibody 
stimulates increases in Ptdlns and phosphatidic acid (PA) in a y/o+ T cell clone (Bismuth 
et al., 1988). 
These results suggest that phosphoinositide metabolism may occur during antigenic 
stimulation of T cells. However stimulation of non-T3-Ti receptors may also result in 
inositol phosphate accumulation. The anti-Thy 1 antibody G7 stimulates small inositol 
phosphate increases (relative to those induced by 145-2Cl 1) in a murine T cell hybridoma 
(Klausner et al., 1987). Anti-CD2 antibody combinations stimulate PtdlnsP2 breakdown 
in cxf~+ and y/8-bearing cells (Pantaleo et al., 1987a,b; Gardner et al., 1989). The ability 
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of purified LFA-3 plus anti-CD2 antibody to evoke an inositol phosphate response 
(Bockenstedt et al., 1988) implies that this may reflect a physiological event since LFA-3 
is thought to be the physiological ligand for CD2. The absence of this response in mutant 
T3-Tc cells has been suggested as evidence that T3-Ti is required for transduction of 
signals from non T3-Tireceptors (as discussed above), particularly since Ti~ transfection 
simultaneously restores T3-Ti surface expression and the ability to respond to LFA-3/anti-
CD2 antibody. The substantial cytoplasmic domains of several T3 components render the 
T3 complex a suitable candidate for "universal transducer" for all surface receptors. 
However only molecular characterisation of the mechanism of receptor coupling to 
phospholipase C can validate this hypothesis. 
1.4.2 Receptor coupling to PtdlnsP2 breakdown 
Several lines of evidence suggest that receptor-mediated phospholipase C activation 
involves an intermediary OTP-binding protein, or G-protein. Strategies employed to 
evaluate G-protein involvement reflect current knowledge of adenylate cyclase modulation 
by G-proteins, and can therefore be best explained by a brief review of receptor coupling 
to adenylate cyclase (reviewed in Neer and Clapham, 1988; Fain et al., 1988; Levitski, 
1988). 
Cyclase activity is regulated by two classes of G-protein, Gs (Mr 40kDa) and Gi (Mr 
41.kDa), which respectively couple cyclase to activatory and inhibitory cell surface 
receptors. Both proteins are coupled to j3y subunits when inactive, but stimulation of a 
positive (or negative) receptor by its agonist results in dissociation of j3y from Gs (or Gi) 
and exchange of GDP for GTP in the guanine nucleotide binding site. Cyclase is 
activated by the GTP-bound form of Gs (G8-GTP), and can be permanently activated by 
non-hydrolysable GTP analogues such as GTPyS and GppNHp. Conversely these 
analogues prevent cyclase inactivation by Gi, since this requires hydrolysis of Gi-bound 
GTP. Cyclase activity can also be modulated by some bacterial toxins, which covalently 
modify specific G proteins by the addition of an ADP-ribose group. ADP-ribosylation of 
Gs by cholera toxin inhibits Gs GTPase activity thereby stabilising G8-GTP and 
enhancing cyclase activation. Pertussis toxin-mediated ADP-ribosylation of Gi abrogates 
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Gi-mediated cyclase inactivation by inhibiting GTP entry into the Gi guanine nucleotide 
binding site. Adenylate cyclase activity may also be modulated independently of surface 
receptors by fluoride ions complexed with aluminium. AIF4- appears to mimic the role of 
the y phosphate of GTP and thus modulates G protein activity (Bigay et al., 1987). 
The above results for the cyclase system suggested three obvious methods for probing 
the involvement of G-proteins in receptor-mediated phospholipase C activation. 
i The effect of guanine nucleotides and analogues on PtdinsP2 breakdown in 
permeabilised cell systems 
Activation of PtdlnsP2 hydrolysis in permeabilised cells or membrane preparations by 
GTP, GTPyS, or GppNHp, first observed in mast cells transiently permeabilised with 
ATP4-. (Cockroft and Gomperts, 1985), has now been demonstrated in a wide variety of · 
cell types including rat hepatocytes (Wallace and Fain, 1985), blowfly salivary glands 
(Litosch et al., 1985), platelets (Baldassare and Fisher, 1986), rat pituitary cells (Straub 
and Gershengorn, 1986), and chinese banister lung fibroblasts (Magnaldo et al., 1987). 
Lo and Hughes (1987b) demonstrated that although similar inositol phosphate responses 
could be evoked in permeabilised human pituitary tumour cells by guanine and non-
guanine nucleotides (e.g. CTP, ATP, UTP, ATPyS) only guanine nucleotides could 
significantly enhance cholecystokinin-stimulated PtdlnsP2 breakdown. Similarly, 
guanine nucleotides and PtdlnsP2-cleaving ligands synergistically stimulate PtdlnsP2 
hydrolysis in many other systems (e.g. Rebecchi and Rosen, 1987; Hrbolich et al., 1987; 
Dunlop and Larkins, 1986), suggesting a possible ,G-protein involvement in receptor-
stimulated PtdlnsP2 hydrolysis. GTPyS-activated PtdlnsP2 hydrolysis has also been 
demonstrated in Jurkat membranes and murine thymocytes, implying that a similar 
mechanism operates in T lymphocytes, although synergistic activation with Con A or anti.-
TI antibody could not be demonstrated (Sasaki and Hasegawa-Sasaki, 1987; Zilberman et 
al., 1987). 
!! The effect of fluoride ions on PtdlnsP2 breakdown 
PtdlnsP2 breakdown stimulated by fluoride and fluoroaluminate ions has been 
demonstrated in several cell types including hepatocytes, rat brain, and T lymphocytes 
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(Blackmore et al., 1985; Litosch, 1987; Sasaki and Hasegawa-Sasaki, 1987; O'Shea et 
al. , 1987). Similarly to guanine nucleotide-evoked stimulation, AIF4- stimulation could 
be reversed by GDP~S in hepatocytes (Cockroft and Taylor, 1987), implying that both 
operate via a G-protein. However, in T3-modulated T cells AIF4- was not competent to 
induce InsP3 increases (Pantaleo et al., 1987c), implying that a component of the T3-Ti 
complex, or a TI-Ti-associated peptide, is required at a stage between A1F4- function and 
phospholipase C function. The required T3-Ti component is clearly not CD3-,, since ,-
mutants retain the capacity to accumulate InsP3 in response to anti-TI antibody (Sussman 
et al., 1988a), but may be a T3-Ti-associated G-protein (see below). Furthermore, CD3-
Tl may also be required for T3-Ti-mediated (although not AIF4--induced) PtdlnsP2 
hydrolysis. Mutants deficient in CD3-11 give poor inositol phosphate responses to anti-
CD3-£ antibody, but normal responses to AIF4- (Mercep et al., 1988). 
iii The effect of bacterial toxins on PtdlnsP2 breakdown 
Pertussis toxin-mediated inhibition of phospholipase C activation has been 
demonstrated in hamster fibroblasts (Paris and Pouyssegur, 1987), rabbit neutrophils 
(Volpi et al., 1985) and human polymorphonuclear leukocytes (Smith et al., 1985) among 
other cell types; suggesting that Gi or a Gi-like protein is involved in phospholipase C 
activation. Similar results cannot be demonstrated in T lymphocytes, since the non-ADP-
ribosylating ~ subunit of pertussis toxin is mitogenic for T cells, and stimulates similar 
early responses to T3-Tj-directed T cell mitogens (Rosoff et al. , 1987b; Strnad and 
. 
Carchman, 1988; Thom and Casnellie, 1989; Y. Zilberman and J.P. Moore, unpublished 
data). However cholera toxin pre-treatment which inhibits pituitary cell InsP3 responses 
to cholecystokinin, acetylcholine, and bradykinin via alteration of receptor-G protein 
coupling (Lo and Hughes, 1987 a) inhibits T3-Tj-mediated inositol phosphate increases in 
Jurkats via a mechanism distinct from cAMP elevation (Imboden et al., 1986). Cholera 
toxin effects imply that Gs may be involved in phospholipase C activation. 
Taken together these results imply that distinct G proteins may be responsible for 
receptor coupling to phospholipase C in different cell types, or even that distinct proteins 
couple to different receptors within the same cell. The latter situation has been suggested 
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by the demonstration that PtdlnsP2 hydrolysis stimulated via different receptors (in the 
same cell population) is differentially sensitive to inhibition by pertussis toxin (Taylor et 
al., 1988; Ashkenazi et al., 1989; Johnson and Garrison, 1987). However, the identities 
of the relevant G-proteins are unclear. Effects of cholera and pertussis toxins suggest the 
involvement of Gs and Gi (or Gs- and Gi-like proteins) respectively, but other data 
suggest the involvement of a distinct class of G-proteins, Gp, which have not yet been 
cloned. It is probable that different G-proteins including Gi and Gs may be utilised in 
different cell types. This apparent complexity contrasts sharply with the earlier 
hypothesis that mariy growth factors might couple through a single GTP-binding protein 
p21ras, the cellular homologue of transforming oncoproteins Harvey-, Kirsten- and N-
ras. Initial reports described elevated basal and stimulated amounts of inositol 
phospholipids and phosphates in cells transformed with oncogenic ras proteins, and 
suggested that the transforming potential of ras might be due to an enhancement of 
phosphoinositide metabolism (Chiarugi et al., 1985, 1986; Wakelam et al., 1986; 
Fleischman et al., 1986). However, subsequent investigations failed to find increases in 
phosphoinositide metabolism in ras-transformed cells (Seuwen et al., 1988; Huang et al., 
1988; Wolfman and Macara, 1987; Lacal et al., 1987b), and demonstrated that previously 
reported increases in phosphoinositide metabolism might be artefacts associated with cell 
density or receptor number effects (Wakelam, 1988; Downward et al., 1988). 
Furthermore, direct introduction of oncogenic p21ras into 3T3 fibroblasts by scrape-
loading does not stimulate inositol phosphate accumulation despite protein kinase C 
activation (Morris et al., 1989). Activation of protein kinase C has also been 
demonstrated in ras-transformed and ras-injected cells, and apparently precedes, rather 
than being a consequence of, phosphatidylcholine hydrolysis (Lacal et al., 1987a; 
Wolfman and Macara, 1987; Huang et al., 1988; J.D.H. Morris, personal 
communication). Therefore p21 ras is unlikely to be the G-protein responsible for 
phospholipase C activation, although it is almost certainly involved in mitogenesis. 
In murine thyniocytes, phospholipase C-receptpr coupling may be achieved by a 
25kDa G-protein recently described by Wang and colleagues (1989). This protein, 
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togeth~r with Gi, was found to have affinity to a Con A-Sepharose column, implying it to 
be associated with Con A receptor(s). Gi apparently dissociated from the cell membranes 
during Con A stimulation, since no Gi was found associated with Con A-Sepharose after 
passage of membranes prepared from Con A-stimulated thymocytes. Gi dissociation may 
reflect a role for Gi in cAMP suppression dining Con A stimulation of thymocytes. The 
other receptor-associated G protein (25kDa) was found to enhance Ptd.InsP2 hydrolysis 
by Ptd.Ins-phospholipase C, suggesting it might be the protein responsible for receptor-
phospholipase C coupling in murine thymocytes. Despite the demonstrated requirement 
for TI-Ti expression in A1F4--stimulated InsP3 accumulation (Pantaleo et al., 1987c), and 
the coincidence of molecular weight of this G-protein and the CD3-e chain, the failure to 
find a GTP-binding domain in the CD3-e protein (Clevers et al., 1988) suggests that the 
two proteins are not identical. 
1.4.3 Novel inositol polyphosphates 
In addition to inositol 1,4,5-trisphosphate (Ins(l,4,5)P3), the direct product of 
phospholipase C-catalysed PtdinsP2 breakdown, several additional inositol 
polyphosphates have now been characterised. The production of inositol 1 :2-cyclic 
phosphate from Ptdins in stimulated tissues was described in the 1970s (Michell and 
Lapetina, 1972, 1973), but more recently Majerus and colleagues have suggested that 
cyclic inositol 1:2,4,5-trisphosphate (clns(l:2,4,5)P3) may be a significant breakdown 
product of Ptd.InsP2 in platelets and sheep seminal vesicles (Wilson et al., 1985; Ishii et 
al., 1986; Connolly et al., 1986b). This contrasts with data from Hawkins and co-
workers (1987) who could find no evidence of cins(l :2,4,5)P3 accumulation in 
carbachol-stimulated parotid gland. It has been suggested independently that both the 
presence and absence of cins(l :2,4,5)P3 are artefacts of the protocols employed for 
reaction termination and inositol phosphate extraction (Hawkins et al., 1987; Majerus et 
al., 1988). However, the demonstration that Ins(l,4,5)P3 and cins(l :2,4,5)P3 
accumulate with distinctkinetics and in varying amounts relative to each other implies that 
both may be genuine products of Ptd.InsP2 hydrolysis (Dixon and Hokin, 1987; Hughes 
et al., 1988). 
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The existence of a distinct InsP3 isomer inositol 1,3,4-trisphosphate (Ins(l,3,4)P3) 
was demonstrated in carbachol-stimulated rat parotid glands in 1984 (Irvine et al., 1984). 
The identity of the precursor for Ins(l,3,4)P3 was at first unclear due to the failure to 
identify a parent lipid (i.e. Ptdlns(3,4)P2), but was apparently resolved by the isolation of 
inositol 1,3,4,5-tetrakisphosphate (lns(l,3;4,5)P4) from carbachol-stimulated rat brain 
and the subsequent demonstration of sequential Ins( 1,4,5)P3 / Ins( 1,3,4,5)P 4 / 
Ins(l,3,4)P3 conversion in parotid homogenates and Ins(l,4,5)P3-microinjected 
Xenopus oocytes (Irvine et al., 1985; Batty et al., 1985; Irvine et al., 1986a; Downes et 
al. , 1986; Hawkins ~t al., 1986). More recently, the identification of a Ptdlns 3'-kinase 
and the isolation of phosphatidylinositol 3-phosphate (Ptdlns 3-P), Ptdlns(3,4)P2, and 
phosphatidylinositol 3,4,5-trisphosphate (Ptdlns(3,4,5)P3) has suggested alternative 
mechanisms of Ins(l,3,4)P3 and Ins(l,3,4,5)P4 generation (Whitman et al., 1987, 1988; 
Traynor-Kaplan et al., 1988; Auger et al., 1989). Ptdlns(3)P has now been identified in 
human astrocytoma cells (Stephens et al. , 1989), fibroblasts (Whitman et al., 1988), and 
smooth muscle cells (Auger et al., 1989). In contrast, Ptdlns(3,4)P2 and 
Ptdlns(3,4,5)P3 have not been found in quiescent cells, but appear rapidly on agonist 
addition (Traynor-Kaplan et al., 1988; Auger et al., 1989). Ptdlns 3'-kinase associates 
with p60v-src in Rous sarcoma virus-infected chick embryo fibroblasts, and is also found 
in anti-phosphotyrosine immunoprecipitates from platelet-'derived growth factor (PDGF)-
stimull:lted smooth muscle cells, suggesting that Ptdlns 3'-kinase activity may be involved 
in mitogenesis and cell transformation (Fukui and Hanafusa, 1989; Auger et al., 1989). 
The possible origins and observed interconversions of inositol polyphosphates 
(excluding possible cyclic derivatives) are summarised in Figure 1.2. Despite the 
possibility of Ptdlns(3,4,5)P3 cleavage, it seems clear that Ins(l,4,5)P3 phosphorylation 
is a major synthetic route for Ins(l,3,4,5)P4, since a specific kinase has been identified in 
turkey erythrocytes (Morris, A.J. et al., 1987), RINm5F cells (Biden and Wollheim, 
1986), pig aortic smooth muscle (Yamaguchi et al., 1987), rat brain (Johanson et al. , 
1988), platelets (Daniel et al., 1988) and murine thymocytes (Zilberman et al., 1987). 
Cyclic Ins(l:2,4,5)P3 is not a substrate for this kinase (Connolly et al., 1987). 
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Figure 1.2 Inositol polyphosphate generation and metabolism. This reaction scheme shows both reactions which have been demonstrated 
to occur (-) and i-ossible, but as yet unreported, reactions (- -). Reactions 1-5 are discussed in the text. Reactions 3 and 6 are both 
catalysed by a Mg +-dependent Ins(l,4,5)P3 5'-phosphomonoesterase (Downes et al, 1982; Shears et al, 1985, 1987). Reactions 7 and 8 
are catalysed by inositol polyphosphate 1-phosphatase in calf brain.(lnhom and Majerus, 1987), adrenal glomerulosa cells (Balla et al, 
1988), rat pituitary tumour cells (Dean and Moyer, 1988), and rat brain (Emaux et al, 1987; Delvaux et al, 1987). Reaction 9 has been 
observed in hepatocytes, calf brain extracts, and rat basophilic leukemia 2H3 cells (Hansen et al, 1986; Bansal et al, 1987; Cunha-Melo et 
al, 1988). Reactions 10 and 11 have been demonstrated in calf brain extracts (Bansal et al, 1987; Inborn et al, 1987). All inositol 
monophosphates may be degraded to inositol and subsequently recycled to inositol phospholipids. Several of these reactions are inhibited by LiCl. 
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The demonstration that Ins(l,4,5)P3 kinase is calcium-sensitive forms part of this thesis, 
and is discussed later. Ins(l,3,4)P3, probably formed by Ins(l,3,4,5)P4 
dephosphorylation, can be rephosphorylated to Ins(l,3,4,6)P4 in adrenal glomerulosa 
cells and hepatocytes (Balla et al., 1987, 1988; Shears et al., 1987; Hansen et al., 1988). 
In rat brain, Ins(l,3,4,6)P4 can be further phosphorylated to Ins(l,3,4,5,6)P5 (Stephens 
et al., 1988), which may be the InsP5 detected in GI4 cells (Heslop et al., 1985). 
Thyrotropin-releasing hormone causes little peturbation of InsP5 and InsP6 in GI4 cells 
(Heslop et al., 1985), implying that neither has a role as a rapid second messenger. 
Indeed InsP5 and InsP6 are better known respectively as an allosteric regulator of oxygen 
binding to haemoglobin in avian erythrocytes and a major plant phosphate store (phytic 
acid). However, local infusion of InsP5 and InsP6 into a discrete brain stem nucleus 
implicated in cardiovascular regulation results in dose-dependent changes in heart rate and 
blood pressure, implying that InsPs and InsP6 may function as neurotransmitters (Vallejo 
et al., 1987). A clearer picture exists of the functional role of Ins(l,4,5)P3, and possibly 
Ins(l,3,4,5)P4. Both may be involved in the rapid agonist-induced rise in [Ca2+]i 
observed in many cell systems (see Section 1.4.5). 
1.4.4 Ligand-stimulated [Ca2+]i increases 
T cell [Ca2+]i is increased several-fold above the resting level (approximately lOOnM) 
byHgands directed against a variety of surface receptors including T3-Ti. [Ca2+]i 
increases within 30s of lectin or T3-Ti-directed antibody addition both in human and 
murine T cells, and reaches a maximum of 0.5-lµM within 60-120s (Tsien et al., 1982; 
Hesketh et al., 1983b; Weiss, M.J. et al., 1984; O' Flynn et al., 1984; Oettgen et al., 
1985). Subsequently, [Ca2+]i rapidly decreases to about 200nM then gradually declines 
to basal level over 24h (Hesketh et al., 1983a). In Ca2+-depleted medium, ligands 
stimulate [Ca2+Ji increases of identical magnitude, but only 5-10 minutes duration, 
implying that the initial increase due to mobilisation of intracellular calcium stores is 
succeeded by influx of extracellular calcium (Hesketh et al., 1985; Imboden and Stobo, 
1985). These responses have been observed predominantly in Tia;~-expressing cells 
such as Jurkats and thymocytes. However, similar increases have also been observed in 
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yo-bearing T cells in response to PHA, or antibodies directed against T3, Tio, or Tiy 
(Pantaleo et al., 1987a; Krangel et al., 1987; Wu et al., 1988; Bismuth et al., 1988). 
Similar responses have been observed in T cells challenged with antigen-presenting cells, 
implying that [Ca2+]i elevation is a physiological response to antigen-T cell receptor 
interaction (Nisbet-Brown et al., 1985; ·Treves et al., 1987; Poenie et al., 1987). 
However, [Ca2+]i elevation is also evoked by antibodies directed at receptors other than 
TI-Ti. 
Anti-CD2 antibody combinations stimulate similar [Ca2+]i responses to TI-Ti-directed 
ligands in peripheral blood lymphocytes and Jurkats (Breitmeyer et al., 1987; Pantaleo et 
al., 19.87a,b,c; Weiss, M.J. et al., 1984). The initial failure to find an intracellular 
component of the CD2 response led to the suggestion that CD2 might function as a Ca2+ _ 
channel (Alcover et al., 1986). However, despite the requirement for the cytoplasmic 
CD2 domain in CD2-mediated [Ca2+]i responses (He et al., 1988), anti-CD2 antibody 
failed to evoke [Ca2+]i elevation in CD2-transfected gut epithelial SF9 cells, implying that 
additional molecules are required to generate responses to CD2 (Alcover et al., 1988b). 
In contrast, cross-linking of anti-Thy 1 antibodies on both T cells and Thy 1-transfected B 
cells results in increased [Ca2+Ji implying that no other T cell-specific molecules are 
required (Kroczek et al., 1986a,b; Gunter et al., 1986) . 
. Cross-linking of several other surface receptors also generates [Ca2+]i responses. 
Anti-TAP and anti-Ly6 antibodies are effective in murine T cells (Malek et al., 1986; Yeh 
et al., 1987), while in human T cells small responses can be generated by cross-linking of 
any of CD4, CDS, CD6 or CDS (Ledbetter et al., 1987b; Carrel et al., 1988). The ability 
of these molecules to stimulate [Ca2+]i elevation may be important to their function as 
accessory molecules in antigenic stimulation. 
1.4.S The mechanism of ligand-stimulated [Ca2+]i increases 
The mechanism by which ligands induce calcium release from intracellular stores 
remained a mystery until the demonstration that Ins(l,4,5)P3 could release calcium from a 
non-mitochondrial intracellular calcium store in permeabilised parotid acinar cells (Streb et 
al., 1983). Subsequently Ins(l,4,5)P3-mediated Ca2+ release has been demonstrated in a 
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variety of cells including T lymphocytes (Imboden and Stobo, 1985; Eberl and Schnell, 
1987; Gukovskaya et al., 1986), neutrophils (Prentki et al., 1984), hepatocytes (Joseph 
et al., 1984), sea urchin egg homogenates (Clapper and Lee, 1985) and platelets (Wilson 
et al., 1985). Although clearly non-mitochondrial, the precise identity of the 
Ins(l,4,5)P3-sensitive calcium store is not known, although it may be an intracellular 
membrane system related to, but distinct from, the endoplasmic reticulum (Volpe et al., 
1988) .. Ins(l,4,5)P3 receptors have been characterised in microsomal fractions from 
adrenal cortex, anterior pituitary and liver (Baukal et al., 1985; Guillemette et al., 1987), 
but have also been found associated with a plasma membrane fraction (Guillemette et al., 
1988). In the brain Ins(l,4,5)P3 binding to the cerebellar receptor is antagonised by 
calcium due to the action of a Ca2+-binding protein, calmedin (Worley et al., 1987; 
Supattapore et al., 1988; Danoff et al., 1988). In contrast, Ins(l,4,5)P3-mediated 
calcium release is enhanced by OTP, via a mechanism involving OTP hydrolysis (and 
thus distinct from G-protein mediated phospholipase C activation), in a variety of 
permeabilised cell systems (Guillemette et al., 1987; Wolf et al., 1987; Gill et al., 1986; 
Ueda et al., 1986, 1988). It is not clear whether the in vivo function of GTP in this 
context is the synergistic activation of Ca2+ release with Ins(l,4,5)P3, or as a component 
required for store refilling. 
Thus there is strong evidence that intracellular Ca2+ release is mediated at least in part 
by Ins(l,4,5)P3. However the role, if any, of Ins(l,3,4,5)P4 as a mediator of [Ca2+Ji 
responses is unclear. Ins(l,3,4,5)P4 at concentrations up to 20µM is ineffective at 
releasing Ca2+ from perrneabilised Swiss 3T3 cells (Irvine et al., 1986b), but two 
Ins(l,3,4,5)P4 receptors of differing affinity (~ 4x1Q-9M and 9x1Q-8M) have been 
observed in adrenal cortical rnicrosomes (Enyedi and Williams, 1988). These may be 
involved in Ca2+ re-uptake into intracellular stores since Ins(l,3,4,5)P4 apparently causes 
Ca2+ sequestration into the Ca2+ stores of electroperrneabilised neoplastic rat liver 
epithelial cells, via a mechanism not involving binding to the Ins(l,4,5)P3 receptor (Hill 
et al., 1988b). This work contrasts with previous data suggesting that Ins(l ,3,4,5)P4 
mediates influx of extracellular Ca2+ (Ca2+ 0 ). Irvine and Moor (1986) demonstrated that 
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Ins(2,4,5)P3, a non-metabolisable but Ca2+-mobilising InsP3, was only capable of 
causing Ca2+0 entry in the presence of Ins(l,3,4,5)P,, using the raising of a fertilisation 
envelope in sea urchin eggs as a diagnostic assay for Ca2+ 0 entry. However, Crossley 
and co'..:workers (1988) were unable to find a requirement for either Ins(l,3,4,5)P4 or for 
external Ca2+ ions for the sea urchin egg fertilisation envelope to be raised by 
Ins(2,4,5)P3 and Irvine et al. (1988) subsequently reported that the validity of their earlier 
finding was restricted to a single species of sea urchin (Lytechinus variegatus) at a 
particular season. Several groups have shown synergistic effects of Ins(l,3,4,5)P4 and 
Ins(l,4,5)P3 on intracellular Ca2+ release (Spat et al., 1987; Joseph et al., 1987). 
However since Ca2+ re-uptake does not occur until Ins(l,4,5)P3 has been degraded, 
these effects may simply be due to Ins(l,3,4,5)P4-mediated inhibition of Ins(l,4,5)P3 
hydrolysis via competition for the same enzyme (Joseph et al., 1987). This explanation 
may also apply to the apparent synergistic effect of Ins(l,4,5)P3 and Ins(l,3,4,5)P4 on 
Ca2+0 influx in lacrimal acinar cells (Morris, A.P. et al., 1987). 
Consistent with this lack of hard evidence for a role for Ins( 1,3,4,5)P 4 in Ca2+ 0 entry, 
two recent pieces of work imply that Ins(l,3,4,5)P4 is neither necessary nor sufficient to 
mediate Ca2+0 entry. Substance P fails to stimulate Ins(l,3,4,5)P4 accumulation in a 
pancreatoma cell line, apparently due to a deficiency in Ins(l,4,5)P3 kinase activity, but 
nevertheless induces Ca2+0 entry (Horstman et al., 1988). In contrast Ca2+ mobilisation 
in Jurkats is accompanied by Ins(l,3,4,5)P4 accumulation (Stewart et al., 1986). 
However, examination of the decline in Ins(l,3,4,5)P4 and [Ca2+]i in Con A-treated 
Jurkats after the addition of ex-methyl mannoside (which displaces Con A from its 
receptors) shows that Ins(l,3,4,5)P4 is insufficient tq mediate Ca2+ 0 entry, since the 
onset of [Ca2+]i decline precedes that of Ins(l,3,4,5)P4 by at least 60s (Imboden and 
Weiss, 1987). These workers also examined the time course of Ins(l,4,5)P3 decline, and 
found it to be co-incident with that of [Ca2+]i, implying a possible role for Ins(l,4,5)P3 
in receptor-stimulated Ca2+0 influx. Furthermore, Kuno and Gardner (1987) have shown 
that in T cell membrane patches Ins(l,4,5)P3 increases the opening probability of a 
· voltage-insensitive Ca2+ channel, which may be identical to that activated by PHA, and 
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T3- and CD2-directed antibodies (Kuna et al., 1986; Pecht et al., 1987; Gardner et al., 
1989). Taken together, these data imply that Ins(l,4,5)P3 may be responsible for both 
components (i.e. intracellular Ca2+ release and extracellular Ca2+ entry) of the Ca2+ 
response evoked in T cells by lectins and T3-Ti- and CD2-directed antibodies. 
1.5 Receptor-mediated protein kinase activation in T lymphocytes 
1.5.1 Protein kinase C activation 
Ligand-induced PtdlnsP2 hydrolysis causes [Ca2+Ji elevation via production of Ca2+_ 
mobilising inositol phosphate(s) (see Section 1.4.5). However, PtdlnsP2 cleavage may 
also activate a Ca2+/phospholipid-dependent protein kinase, protein kinase C, via 
production of diacylglycerol (Kishimoto et al., 1980). The early measurements of protein 
kinase C activity as a calcium/phospholipid dependent increase in histone phosphorylation 
have now been extended by assaying the phosphorylation of distinct characteristic 
proteins, particularly an acidic 80kDa protein, distinct from protein kinase C (Rodriguez-
Pena and Rozengurt, 1986; Blackshear et al., 1986). In addition to the effect of 
diacylglycerol (DAG), protein kinase C is also activated by phorbol esters (Parker et al., 
1984; Castagna et al. , 1982) and possibly by PtdlnsP2 (Chauhan and Brockerhoff, 
1988). Since phorbol esters stimulate protein kinase C translocation from the cytosol to 
the plasma membrane (Kraft and Anderson, 1983), protein kinase C translocation is often 
used as a marker for protein kinase C activation. However, some mitogens apparently 
activate protein kinase C without causing translocation, implying that protein kinase C 
translocation may not be necessary for activation, and therefore that failure to observe 
translocation does not necessarily equate with an absence of protein kinase C activation 
(Halsey et al., 1987). 
Seven subspecies of protein kinase C have so far been identified; a, PI, prr, y, 8, E 
and ~ (Kikkawa et al. , 1987; Ono et al. , 1987, 1988; Ohno et al., 1988). These are 
differentially expressed; a is most widely distributed, the p subspecies are fairly 
widespread, and y expression is confined to nervous tissue in the brain and spinal cord 
(reviewed in Nishizuka, 1988); but most cell types contain more than one subspecies. 
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Investigation of the subspecies in T lymphocytes has so far revealed that human 
peripheral blood T cells contain a and~ subspecies (Shearman et al., 1988). As yet no 
specialised functions have been ascribed to individual sub-species. Attempts to identify 
the function of protein kinase C have focussed on identification of proteins which 
undergo stimulated serine or threonine phosphorylation and might be physiologically 
relevant substrates. Alternatively, the effects of phorbol esters have been determined, 
although these are unlikely to reflect accurately the effects of DAG, since DAG undergoes 
rapid metabolism and is therefore only transiently elevated, but phorbol esters are not 
significantly metabolised and thus cause irreversible protein kinase activation, succeeded 
by down-regulation, possibly via calpain-mediated cleavage (Nishizuka, 1988). 
In T lymphocytes, several serine phosphorylation events occur in response to T3-Ti 
stimulation, and these may be important for T cell activation. Lectins, antigen and T3-Ti-
directed antibcxlies all stimulate serine phosphorylation of two murine T3 components; the 
21kDa y chain, and to a lesser extent the 25kDa £ glycoprotein (Oettgen et al., 1986; 
Samelson et al., 1985, 1986a,b; Klausner et al., 1987). Analogous ligands also stimulate 
phosphorylation of human T3 components, but of they and 8, rather than y and£, chains 
(Cantrell et al., 1987; Davies et al., 1987; Nel et al., 1987). Identical phosphorylations 
are also evoked by phorbol esters, implying that T3-Ti-evoked phosphorylations may be 
due to protein kinase C activation (Davies et al., 1987; Cantrell et al., 1985; Klausner et 
al., 1987). Phorbol esters also induce phosphorylation of IL2r, CD45, CD4, CD8 and 
the ~-chain of LFA-1 (Autero and Gahmberg, 1987; Shackelford and Trowbridge, 1986; 
Chatila and Geha, 1988; Acres et al., 1986). 
Further evidence for T3-Ti-mediated protein kinase C activation is provided by 
experiments demonstrating anti-CD3 antibody-stimulated protein kinase C translocation in 
Jurkats and human peripheral blood T cells (Ledbetter et al., 1987a; Nel et al., 1987) and 
anti-CD3 antibody-evoked 80kDa protein phosphorylation in human T cell clones 
(Friedrich et ru., 1989) . . Manger et al. (1987) have observed enhanced protein kinase C 
translocation in Jurkats stimulated with immobilised compared with soluble anti-CD3 
antibody, and suggest this may provide at least a partial explanation for the requirement 
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for antibody immobilisation for proliferation (see Section 1.2.3). Consistent with this, 
Davis and Lipsky (1989) find that T cell proliferation evoked by soluble anti-CD3 
antibody plus phorbol dibutyrate (PDBu) may be reversed by removal of PDBu at any 
stage up to 24h after ligand addition. In contrast to these data demonstrating T3-Ti-
mediated protein kinase C activation in mature T cells, neither protein kinase C 
translocation nor 80kDa protein phosphorylation can be observed in Con A-stimulated 
BALB/c thymocytes (T.R. Hesketh, personal communication). This suggests that the 
antigen receptor may be in differing functional states in mature (peripheral) and immature 
(thymic) T cells. Consistent with this, Finkel and colleagues (1987) have reported 
smaller anti-Ti antibody-induced [Ca2+]i increases in thymocytes compared with lymph 
node cells, and Havran et al. (1987) have found that splenocytes but not thymocytes 
respond to anti-CD3 antibody by expressing IL2 and IL2r, although a [Ca2+]i response is 
generated in both. 
Protein kinase C may also be activated through cell surface receptors other than T3-Ti. 
Anti-CD2 antibodies stimulate phosphorylation of 80kDa protein and the CD3-y chain in 
hum~ T cells (Friedrich et al., 1989; Breitmeyer et al., 1987); and anti-Thy 1 antibody 
stimulates phosphorylation of murine CD3-y (Klausner et al., 1987). Murine CD3-y 
phosphorylation stimulated by antigen or T3- or Thy 1-directed antibodies, but not by 
AIF4-, is inhibited by cAMP or analogue elevation, implying that both T3- and Thy 1-
evoked responses channel through a common step, upstream of G protein activation by 
AIF4- (Klausner et al., 1987; O'Shea et al., 1987). 
The widespread ability of ligands to activate protein kinase C both in T lymphocytes 
and other cells suggests protein kinase C activity may be central to mitogenic stimulation. 
Furthermore, mitogens can be substituted for by the synergistic combination of calcium 
ionophore and phorbol ester (Truneh et al., 1985; Guy et al., 1985) implying that [Ca2+]i 
elevation and protein kinase C activation, the "signals" generated by the cleavage products 
of PtdinsP2, may be sufficient to trigger cellular transition from G0 to DNA synthesis 
(Dual Signal Hypothesis, e.g. Nishizuka, 1984). However, more recent demonstrations 
both of synergistic mitogen combinations which fail to elicit PtdinsP2 hydrolysis (e.g. 
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epidermal growth factor and insulin on fibroblasts; L'Allemain and Pouyssegur, 1986; 
Hesterman et al., 1986) and of an additional response evoked by both PtdlnsP2-cleaving 
and non-PtdlnsP2-hydrolysing ligands by a mechanism independent of PtdlnsP2 
hydrolysis (tyrosine kinase activation, see below) suggests the actions of DAG and 
lns(l ,4,5)P3 to be insufficient to induce mitogenesis. Despite this, the failure of T3-Ti-
directed ligands to induce mitogenesis in protein kinase C down-regulated cells (Kim et 
ru. .• 1989; Valge et al., 1988), suggest protein kinase C activation is important in T cell 
activation. Furthermore, combination of any of a variety of antibodies directed against T 
cell surface receptors with TP A synergistically stimulates T cell proliferation (see Section 
1.3). However, such synergistic combinations may stimulate proliferation via pathways 
other than those evoked by in vivo intercellular interactions. 
1.5.2 Consequences of protein kinase C activation 
In .addition to the protein phosphorylations described above, protein kinase C may 
activate a plasma membrane-associated Na+JH+ exchanger, although this may also be 
activated independently of protein kinase C (Grinstein et al., 1987). In HC03--free 
medium. both TP A and TI-Ti-directed ligands stimulate intracellular alkalinisation via 
activation of Na+JH+ exchange (Hesketh et al., 1985; Rosoff and Cantley, 1985; Rogers 
et al., 1983). However, in the presence of HC03· the overall intracellular pH (pHi) 
change evoked by ligands is an acidification (Gelfand et al., 1988; Ganz et al., 1989). 
These results are in apparent conflict with data from several groups implying a role for 
intracellular alkalinisation in the stimulation of DNA synthesis (Pouyssegur et al., 1985; 
Ober and Pardee, 1987; Perona and Serrano, 1988; Chambard and Pouyssegur, 1986); 
but are consistent with the idea, suggested by the reported failure of amiloride analogues 
to inhibit DNA synthesis at concentrations greater than or equal to those which effectively 
antagonise Na+m+ exchange, that Na+JH+ exchanger-mediated alkalinisation is not 
required for mitogenesis (Pennington et al., 1989; Mills et al., 1986). Taken together 
these data suggest that although intracellular alkalinisation may not be an obligatory step 
in mitogenesis, pHi may be required to remain within a certain permissive range for DNA 
synthesis to occur. 
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Activation of protein kinase C may also result in phosphorylation of the S6 protein, a 
component of the 40S ribosomal subunit, although S6 phosphorylation may also be 
stimulated by a variety of other agents including cAMP (Parker et al., 1985; Rance et al., 
1985; Pelech and Krebs, 1987). An apparent causal link between Na+JH+ exchange and 
S6 phosphorylation in Chinese hamster lung fibroblast cells (Pouyssegur et al., 1982) 
may actually have been an artefact due to the use of amiloride, since dimethylamiloride (a 
more specific Na+fH+ exchange inhibitor) blocks pHi increases without affecting S6 
phosphorylation in 3T3 fibroblasts (Pennington et al., 1989). Several pieces of data 
suggest a causal link between mitogen-induced S6 phosphorylation and increases in 
protein· synthesis (Thomas et al., 1982; Duncan and Mc Conkey, 1982). Thus the general 
mitogen-stimulated increase in protein synthesis may be at least partially caused by protein 
kinase C, via S6 phosphorylation. 
In contrast to these positive effects of protein kinase C, it may also have a role in both 
long and shorter term negative feedback. The ability of phorbol esters to cause down-
modulation of a variety of cell surface molecules including in T cells the TI-Ti complex 
and CD4 (Cantrell et al., 1985; Davies et al., 1985; Wang et al., 1987) may mimic a 
protein kinase C-mediated receptor down-regulation necessary to terminate response to a 
particular stimulus. Protein kinase C activation may also modulate Ins(l,4,5)P3 
accumulation, both by activating Ins(l,4,5)P3 5'-phosphomonoesterase (Connolly et al., 
1986a; Molina y Vedia and Lapetina, 1986) and by inhibiting PtdlnsP2 breakdown. 
Phorbol ester-mediated antagonism of PtdlnsP2 hydrolysis has been observed in a wide 
range of cells including platelets (Tohmatsu et al., 1986), B cells (Bijsterbosch and 
Klaus, 1987; Harnett and Klaus, 1988), fibroblasts (Jamieson Jr. and Villereal, 1985; 
Brown et al., 1987) and vascular smooth muscle cells (Brock et al., 1985; Takata et al., 
1988). Thus the early activatory effects associated with protein kinase C activation, 
which include transcriptional activation of a variety of genes (see below), may precede, or 
even occur simultaneously with, protein kinase C-mediated negative feedback control. 
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1.5.3 Tyrosine kinase activation 
In addition to serine/threonine phosphorylation, the generation of phosphotyrosine 
residues is also associated with mitogenic stimulation. Several oncoproteins have 
tyrosine kinase activity (e.g. src, abl, fes), implying a role for tyrosine phosphorylation in 
cell transformation, and receptors for sevenil growth factors (including epidermal growth 
factor (EGF), platelet-derived growth factor (PDGF), and insulin) have an intrinsic 
tyrosine kinase domain, capable of mediating phosphorylation of both themselves and 
other cellular proteins (Cooper et al., 1982; Ek et al., 1982; Zippe! et al., 1986; Kasuga et 
al., 1982; Klein et al., 1986; Yu and Czech, 1986). 
In T cells, despite the absence of intrinsic tyrosine kinase domains in any of the TI-Ti 
complex components, CD3-~ is phosphorylated on tyrosine in response to mitogenic 
stimulation via T3-Ti or Thy 1 (Baniyash et al., 1988b; Samelson et al., 1986b, 1987; 
Klausner et al., 1987; Patel et al., 1987), and IL2 stimulates tyrosine phosphorylation of 
several proteins distinct from CD3-~ (Saltzmann et al., 1988). Several tyrosine kinases 
have been identified in T cells, including a 40.kDa enzyme generated proteolytically from a 
72.kDa protein isolated from bovine thymus (Zioncheck et al., 1988), and two human 
enzymes of Mr 70-100.kDa and 35-40.kDa which may be homologous to the bovine 
proteins (Hall et al., 1987). However, pp56lck is the best characterised T cell tyrosine 
kinase, and the most likely candidate for mediator of CD3-~ phosphorylation. 
Originally identified in a murine T cell lymphoma LSTRA, pp56lck is a 56-58kDa, 
phosphotyrosine-containing, membrane-associated tyrosine kinase of T lymphoid lineage, 
expressed in both murine and human systems (Casnellie et al., 1983; Marth et al., 1985; 
Trevillyan et al., 1986). Over-expression of pp56lck in Thy19 and LSTRA cells is due to 
insertion of the murine Moloney leukemia virus upstream of the pp56lck gene (Voronova 
and Sefton, 1986; Voronova et al., 1987; Marth et al., 1988b). However, expression of 
pp56lck is insufficient to transform fibroblasts since phosphorylation of Tyr-505 down-
regulates the kinase activity of pp56lck, in a manner analogous to the down-regulation of 
pp6Qc-src by Tyr-527 phosphorylation. Therefore Tyr-505 mutation is necessary for 
pp56lck..mediated transformation of fibroblasts in vitro (Marth et al., 1988a; Amrein and 
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Sefton, 1988). However, in LSTRA cells Tyr-505 of pp56kk is intact, but 
hypophosphorylated (Marth et al., 1988a). 
In murine T cell clones, pp56lck may be physically associated with CD4 or CD8, since 
it co-modulates and co-immunoprecipitates with these molecules (Veillette et al., 1988). 
Recent data suggest that . CD4-associated pp56lck may mediate CD3-~ tyrosine 
phosphorylation, since cross-linking of CD4 causes simultaneous phosphorylation of 
pp56lck and CD3-~ (Veillette et al., 1989). In vivo, pp56lck activation may be achieved 
by interaction of CD4 with Class II MHC proteins on the surface of antigen-presenting 
cells (see Section 1.2.5). The failure of antigen-presenting cells in the absence of 
appropriate antigen to stimulate CD3-~ phosphorylation (e.g. Klausner et al., 1987) 
presumably reflects a requirement for a T3-Ti-directed ligand to stimulate association of 
CD3 with CD4 (Rivas et al., 1988), thereby bringing substrate and enzyme into close 
proximity. However, the involvement of pp56lck, and therefore CD4:class II interaction, 
in CD3-stimulated CD3-~ phosphorylation is apparently contradicted by the 
demonstration by Veillette et al. (1989) that anti-CD3-e antibody 145-2Cl 1 stimulates 
tyrosine phosphorylation of CD3-~ but not pp56lck. However, this discrepancy may be 
due to the use of different cross-linking agents in the two experiments, Rabbit anti-
hamster lg plus 145-2Cl 1 fails to stimulate pp5&ck autophosphorylation, but 145-2Cl 1 
plus B cells (presumably bearing MHC class II molecules) induces CD3-~ 
phosphorylation. Thus, these results are consistent with the idea that class II:CD4 
interaction activates CD4-associated pp56lck, which in turn phosphorylates CD3-~. 
The causal relationship, if any, between tyrosine kinase activation and PtdlnsP2 
breakdown is currently unclear. Since PtdlnsP2 is not hydrolysed in response to tyrosine 
kinase activating ligands such as EGF and insulin (Besterman et al., 1986; L'Allemain 
and Pouyssegur, 1986), activation of tyrosine kinase is clearly insufficient to trigger 
PtdlnsP2 breakdown, and conversely tyrosine kinase activation is not always a 
consequence of PtdlnsP2 hydrolysis. This latter is also suggested by the observations 
that AIF4- stimulates inositol phosphate formation, but not CD3-~ phosphorylation in 
murine T cells (O'Shea et al., 1987) and dibutyryl CAMP inhibits anti-CD3 antibody-
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stimulated inositol phosphate formation but not CD3-~ phosphorylation (Klausner et al., 
1987). However, experiments with EGF receptors deficient in tyrosine kinase activity 
due to mutation of the residue required for phosphate transfer (Lys-721) suggest that 
tyrosine kinase activity is obligatory for EGF-induced mitogenesis, Ca2+ 0 influx, and 
inositol phosphate accumulation in EGFr-transfected fibroblasts (Chen et al., 1987; 
Honnegger et al., 1987; Moolenaar et al., 1988). Furthermore, tyrosine kinase activating 
ligands enhance inositol phosphate accumulation evoked by Ptd.InsP2-hydrolysing ligands 
in Chinese hamster lung fibroblasts (Paris et al., 1988). Taken together, these results 
suggest that although tyrosine kinase activation is insufficient alone to stimulate Ptd.InsP2 
hydrolysis, activation of the latter may require tyrosine phosphorylation of an unidentified 
protein. 
The possible requirement for tyrosine kinase activity for Ptd.InsP2 hydrolysis may be 
linked to the association and phosphorylation of an 81-85kDa Ptdlns kinase with/by 
tyrosine kinases including pp6()C-src and PDGFr (Courtneidge and Heber, 1987; Kaplan et 
al., 1987). However, the relationship between this and Ptdlns(4,5)P2 breakdown or 
accumulation is not immediately obvious, since this lipid kinase is a Ptdlns 3'-kinase 
rather than a 4'- or 5'-kinase (Auger et al., 1989; Fukui and Hanafusa, 1989). 
Furthermore, experiments with mutant PDGF receptors suggest that the PDGFr-
associated Ptdlns 3'kinase mediates events distinct from Ptdlns(4,5)P2 breakdown, but 
required for mitogenesis . . Interaction of PDGF with PDGF receptors lacking the region 
necessary for association with Ptd.Ins 3' kinase induces tyrosine kinase activation, and 
Ptd.Ins(4,5)P2 hydrolysis, but fails to stimulate DNA synthesis (Escobedo and Williams, 
1988; Coughlin et al., 1989). 
1.5.4 The role of cAMP-dependent protein kinase in mitogenic 
stimulation of T cells 
Serine/threonine phosphorylation is catalysed not only by protein kinase C, but also by 
cAMP-dependent protein kinase (protein kinase A). The latter is activated by a variety of 
hormones, including ~-adrenergic agonists, via activation of adenylate cyclase, as 
described in Section 1.4.2. Activation of cAMP-dependent protein kinase may also be 
43 
required during mitogenic stimulation of some cell types (reviewed by Boynton and 
Whitfield, 1983; Dumont et al., 1989). However the role of protein kinase A in T cell 
activation is controversial. Observed increases in cAMP during the T cell cycle suggest a 
role for cAMP in mitogenic stimulation of T lymphocytes (Boynton and Whitfield, 1983) 
but cAMP analogues and agents which raise cAMP are capable of antagonising the 
proliferative response of T cells to T3-Ti-directed ligands (Ling and Kay, 1975; 
Novogrodsky et al., 1983; Nel et al., 1988) and IL2 (Knudsen et al., 1987; Farrar et al., 
1987; Beckner and Farrar, 1988; Johnson et al., 1988). Cyclic AMP-mediated inhibition 
of T3-Ti-stimulated proliferation is apparently due to an effect on early responses; cAMP 
elevation or cAMP analogues diminish or abolish stimulated increases in inositol 
phosphates, [Ca2+Ji, and protein kinase C-mediated phosphorylation (Taylor et al., 1984; 
Takayama et al., 1988; Klausner~ al., 1987; Rincon et al., 1988; Lerner et al., 1988) 
and also inhibit transcriptional activation of the IL2 and IL2r genes (Novogrodsky et al., 
1983; Yamamoto et al., 1986; Rincon et al., 1988). The event inhibited by cAMP 
presumably lies between ligand-receptor interaction and G protein activation, since AIF4--
induced responses are not sensitive to cAMP (0' Shea et al., 1987). This is consistent 
with the absence of rapid increases in cAMP in murine and porcine lymphocytes 
stimulated with mitogenic lectins (Moore et al., 1983). In contrast, Shirakawa et al. 
(1988). reported that IL1 caused transient cAMP accumulation, and that the role of IL1 in 
the synergistic proliferative response of murine thymocytes to IL1 plus PHA could be 
substituted for by cAMP elevating agents. Wickremashinge et al. (1987) have suggested 
that IL2 may also be capable of elevating cAMP, but several other reports imply that IL2 
actually inhibits both basal and stimulated adenylate cyclase activity, possibly via 
activation of protein kinase C (Knudsen et al., 1987; Beckner and Farrar, 1986, 1987, 
1988). 
Taken together these data suggest that cAMP elevation is unlikely to be a rapid 
response to T cell stimulation via T3-Ti or the IL2 receptor. However, accessory cell 
secretions such as interleukin 1 may mediate cAMP increases at discrete points in the cell 
cycle, presumably regulated by the time courses of both secretion and receptor 
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expression, and these transient increases may be an obligatory component of the T cell 
transition from quiescence to DNA synthesis. 
1.6 Receptor-mediated activation of gene transcription in T lymphocytes 
Over 60 distinct cDNA clones have been derived from immediate early mRNA species 
that are induced on addition of PHA and TP A to quiescent human peripheral blood T cells 
Zipfel et al., 1989) but only a handful of mitogen-activated genes have so far been 
characterised. Numbered among these are some key metabolic enzymes, the cellular 
homologues of some oncogenes, and the IL2 and IL2r genes, expression of which is 
confined to T cells, and possibly only to a subset thereof (see Section 1.2.4). 
Transcriptional activation of the IL2 and IL2r genes is apparently dependent on different 
antigen-induced responses. IL2r expression is stimulated by either phorbol ester alone or 
a synergistic combination of phorbol ester and calcium ionophore implying that T3-Ti-
induced IL2r expression may be achieved by a combination of protein kinase C activation 
and increased [Ca2+]i (McCrady et al., 1988; Shackelford and Trowbridge, 1984; Weiss, 
A et al., 1984b; Kumagai et al., 1988). In contrast, although phorbol ester plus 
ionomycin stimulates IL2 mRNA accumulation in resting PBLs (McCrady et al., 1988), 
events other than those consequent on Ptd.InsP2 breakdown may be sufficient to induce 
IL2 secretion since anti-Thy 1 antibody stimulates IL2 secretion from a murine T cell 
mutant in the absence of increases in [Ca2+]i or inositol phosphates (Sussman et al., 
1988b). 
The transcriptional activation of genes encoding various key metabolic enzymes may 
account in part for the enhanced metabolic activity detectable in mitogen-stimulated T 
cells. However activation of pre-existing enzymes also occurs, and some control points 
may be regulated by both modulation of existing proteins and induction of gene 
transcription. A prime example of both phenomena is ornithine decarboxylase (ODC), the 
rate limiting enzyme in polyamine biosynthesis. Rapid ODC induction occurs within 
minutes of ligand addition via a Ca2+-dependent mechanism with no requirement for de 
novo protein biosynthesis, implying activation of pre-existing enzyme (Scott et al., 1985) 
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expression. and these transient increases may be an obligatory component of the T cell 
transition from quiescence to DNA synthesis. 
1.6 Receptor-mediated activation of gene transcription in T lymphocytes 
Over 60 distinct cDNA clones have been derived from immediate early mRNA species 
that are induced on addition of PHA and TP A to quiescent human peripheral blood T cells 
Zipfel et al., 1989) but only a handful of mitogen-activated genes have so far been 
characterised. Numbered among these are some key metabolic enzymes, the cellular 
homologues of some oncogenes, and the Il..2 and IL2r genes, expression of which is 
confined to T cells, and possibly only to a subset thereof (see Section 1.2A). 
Transcriptional activation of the IL2 and IL2r genes is apparently dependent on different 
antigen-induced responses. IL2r expression is stimulated by either phorbol ester alone or 
a synergistic combination of phorbol ester and calcium ionophore implying that T3-Ti-
induced IL2r expression may be achieved by a combination of protein kinase C activation 
and increased [Ca2+]i (McCrady et al., 1988; Shackelford and Trowbridge, 1984; Weiss, 
A et al., 1984b; Kumagai et al., 1988). In contrast, although phorbol ester plus 
ionomycin stimulates Il..2 mRNA accumulation in resting PBLs (McCrady et al., 1988), 
events other than those consequent on PtdlnsP2 breakdown may be sufficient to induce 
Il..2 secretion since anti-Thy 1 antibody stimulates Il..2 secretion from a murine T cell 
mutant in the absence of increases in [Ca2+]i or inositol phosphates (Sussman et al., 
1988b). 
The transcriptional activation of genes encoding various key metabolic enzymes may 
account in part for the enhanced metabolic activity detectable in mitogen-stimulated T 
cells. However activation of pre-existing enzymes also occurs, and some control points 
may be regulated by both modulation of existing proteins and induction of gene 
transcription. A prime example of both phenomena is omithine decarboxylase (ODC), the 
rate limiting enzyme in polyamine biosynthesis. Rapid ODC induction occurs within 
minutes of ligand addition via a Ca2+-dependent mechanism with no requirement for de 
novo protein biosynthesis, implying activation of pre-existing enzyme (Scott et al., 1985) 
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and is succeeded by a slower increase in activity which may be due to transcription of the 
ODC gene (Fidelus et al., 1984). ODC activation may in turn lead to the induction of 
several glycolytic enzymes (Brand, 1987), and may also be required for induction of loci 
unrelated to metabolism, such as the proto-oncogene c-myc (Celano et al., 1988). 
Proto-oncogene transcription is a mitogen-t:?voked response common to T cells and 
many fibroblastic cell lines, with transcription of the c-myc and c-fos loci (cellular 
counterparts of the transforming genes of avian myelocytomatosis virus and FBJ murine 
osteosarcoma virus respectively) the best characterised responses. Rapid transient 
increases in c-fos mRNA precede more prolonged increases in c-myc mRNA in lectin-
stimulated T cells and growth factor-stimulated 3T3 fibroblasts (Kelly et al., 1983; Moore 
~ al., 1986; Kronke et al., 1985; Reed et al., 1985; Muller et al., 1984), and IL2-IL2r 
interaction induces a second wave of c-myc and c-fos transcription in T cells (Farrar et 
al., 1987; Depper et al., 1985; Reed et al., 1985). Increased levels of c-myb mRNA are 
also observed in activated T cells challenged with IL2 (Farrar et al., 1987; Pauza, 1987; 
Stem and Smith, 1986), but as c-myb mRNA is maximal subsequent to maximal DNA 
synthesis, c-myb expression may not be required for DNA synthesis (Lipsick and Boyle, 
1987). In contrast, experiments utilising antisense myc and fos oligonucleotides and anti-
myc and fos antibodies suggest that both c-myc and c-fos proteins are required for 
mitogenic stimulation (Holt et al., 1986, 1988; Freytag, 1988; Yokayama and Imamoto, 
1987; Wickstrom et al., 1988; Heikkila et al., 1987; Harel-Bellan et al., 1988b; Riabowol 
et al., 1988; Iguchi-Ariga et al., 1987). While the precise function of c-myc is not 
known, c-fos appears to act as a transcription factor when complexed with AP-1 (c-jun) 
(Rauscher et al., 1988; Schuermann et al., 1989; Chiu et al., 1988; Neuberg et al., 1989). 
Fos protein regulates expression of several genes, including itself and collagenase 
(Schonthal et al., 1988). However, the mechanism by which lectins or IL2 activate c-fos 
transcription in T cells is unclear. Lectin-stimulated fos transcription is independent of 
[Ca2+]i increases, protein kinase C activation, or Na+fH+ exchange (Moore et al., 1986, 
1988; Grinstein et al., 1988). Furthermore, although c-fos expression can be regulated 
by cAMP (e.g. 8BrcAMP induces c-fos expression in Swiss 3T3 fibroblasts; Tsuda et 
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al., 1986) cAMP is not an early response to T cell activation (see Section 1.5.4), and is 
therefore unlikely to be responsible for c-fos induction in T cells. Thus despite copious 
observations of mitogen-stimulated gene expression in T cells, the causal relationship 
between transcriptional activation of many of these loci and earlier biochemical responses 
remains unclear. 
1. 7 Aims of this thesis 
I have attempted to identify important events in T lymphocyte mitogenesis by 
examining the responses of two murine T cell populations to a panel of ligands. The 
study has been undertaken in two cell populations not only to allow comparisons, but also 
to facilitate identification of phenotypic peculiarities. The cells and ligands used are 
described below. 
1.7.1 Cell types 
The two cell populations used are thymocytes derived from BALB/c mice, and clone 
4, a monoclonal helper T cell line cloned from a CJ3/H. mouse by Dr. K. Tomonari 
(Clinical Research Centre, Harrow). BALB/c thymocytes are a heterogeneous cell 
population comprised of several cell types including T lymphocytes (85%), B 
lymphocytes (<5%), erythrocytes (1-3%), and monocytes and macrophages (Corps, 
1982). As described above, thymic T cells are a mixture of cells in varying stages of 
maturity, with different stages distinguishable by their array of surface-expressed 
proteins. Of these, only the more mature cells express a T cell receptor. In contrast, Thy 
1 is expressed on all T lymphocytes in the thymus. 
Thymocytes are a useful system to work on as they are easily prepared and, despite 
individual preparation for each experiment, exhibit reproducible responses. In addition, 
thymocytes are not subject to the phenotypic alterations often induced by long term cell 
culture. However, the heterogeneity of thymocytes is undesirable for several reasons; 
l Only a small proportion of thymocytes may respond to a given stimulus. 
ii Cell types other than T lymphocytes may respond to mitogenic ligands. 
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iii Mitogenic stimulation of T lymphocytes may be facilitated (for instance by accessory 
cell-secreted lymphokines) or hindered (e.g. accessory cells may adsorb/degrade ligands) 
by other cell types within the thymocyte population. 
These considerations make thymocytes a complex system in which to analyse the 
requirements for activation of DNA synthesis. 
In contrast, clone 4 is a murine monoclonal cell line which stably expresses CD4, Thy 
1, LFA 1, IL2r and a T cell receptor specific for the l\.1HC class II molecule Ek. Clone 4 
may be mitogenically stimulated by cells bearing Ek antigen in the context of MHC class 
II proteins, or specific anti-Ti antibodies 103 and 2Hll (Tomonari, 1985). The 
homogeneity of clone 4 should result in similar responses to a particular ligand in every 
individual cell. Thus the problems associated with heterogeneous cell populations do not 
arise. However, there are problems associated with the use of monoclonal cell lines for 
analysis of the mitogenic pathway. Many such cell lines have phenotypic abnormalities 
which prevent them from generating "normal" responses to ligands. For example, the 
interaction of EGF with receptors on 3T3 fibroblasts results in no inositol phosphate 
accumulation (Besterman et al., 1986), but inositol phosphates are generated by the 
abnormal cell line A431 in response to EGF (Pike and Eakes, 1987; Hepler et al., 1987). 
By study and comparison of the responses to ligands of two cell types, one a partially 
activated (i.e. IL2r-expressing) monoclonal cell line and the other a heterogeneous 
primary cell population, it should be possible to avoid some of the difficulties associated 
with study of a single cell population. 
1.7.2 Ligands 
Four potentially mitogenic ligands have been used in this work; Con A, anti-Thyl 
antibody (KT16; Tomonari, 1988), anti-T3 antibody (145-2Cll; Leo et al., 1987b), and 
recombinant IL2. The effect of a novel anti-CD4 antibody KT6 has also been determined. 
KT6, raised by Dr. K. Tomonari, antagonises stimulation of clone 4 through the T cell 
receptor (K. Tomonari, personal communication), and may also be expected to have some 
effect on thymocyte mitogenesis as 80-90% of thymocytes bear CD4. Therefore it is of 
interest to determine the effect of K.T6 on ligand-stimulated mitogenesis of both cell types. 
r 
I 
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1.7.3 Experimental Programme 
Using the described ligands, the following programme of research has been 
undertaken: 
1 Characterisation of the effects of the described panel of ligands on mitogenesis in the 
two cell types, and definition of interactive effects of the ligands (particularly anti-CD4 
antibody) on mitogenesis. 
2. Characterisation of some early responses of the two cell types to each of these ligands. 
Effects of the ligands on [Ca2+]i, inositol phosphates, and c-myc mRNA have been 
determined. 
1 Investigation of the effect on early responses to mitogens of the antagonistic receptor 
interactions identified in 1. 
The results of these experiments are described in Chapters 3-5. These results have 
been analysed to assess the importance of these responses for mitogenesis Questions of 
particular interest include: 
i. Are there differences in early responses to the same ligand in two different cell 
populations, and do any differences correlate with mitogenic stimulation? 
ii Do mitogenic and non-mitogenic ligands evoke the same early responses in a single cell 
type? 
iii Can ligands stimulate mitogenesis in a single cell type by evoking different sets of 
early responses? 
iv Are early responses to mitogenic ligands inhibited by ligands which antagonise 
mitogenesis? 
Such analysis may facilitate identification of responses obligatory for the transition of 
lymphocytes from quiescence to DNA synthesis. To explain the sequence of experiments 
it is necessary to discuss results as they arise. Therefore all discussion and analysis of 
results is included within the results chapters, rather than being presented in separate 
sections. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals 
AMP, Anti.foam A, cyclic AMP (cAMP), dextran sulphate, EGTA, forskolin, herring 
sperm DNA, 3-isobutyl-1-methyl-xanthine (IBMX), N-lauroyl sarcosine, octanoic acid, 
mannitol, sodium azide, streptomycin sulphate (750U/mg), 12-0-tetradecanoyl 13-
phorbol acetate (TPA), and tris[hydroxymethyl]aminoethane (Trizma base) were 
purchased from Sigma Chemical Company Ltd. ADP (disodium salt), ATP (disodium 
salt), DNAse I, and tRNA, were obtained from Boehringer Mannheim. Agarose, DNA 
polymerase I (125U/ml), and restriction endonucleases were supplied by Pharmacia. 
Guanidinium isothiocyanate was obtained from Bethesda Research Laboratories, USA. 
Triton X-100 and 2,5-diphenyloxazole (PPO) were purchased from Koch-Light. Safe 
fluor S scintillant was obtained from May and Baker. Concanavalin A was from Miles-
Yecla. The calmodulin antagonist CGS9343B was a gift of Dr. A.M. Tolkovsky but was 
originally obtained from Ciba-Geigy. Interleukin 2 was generously provided by Dr. E. 
Simpson (Clinical Research Centre, Harrow). All other chemicals used were obtained 
from British Drug Houses, Fisons Scientific Apparatus, May & Baker or Merck. 
2.1.2 Radiocbemicals 
Myo-[2-3H]inositol (10-20Ci/mmol, lmCi/ml), D-myo-[2-3H]inositol 1,4,5-
trisphosphate (l.OCi/mmol, lOmCi/ml), [6-3H]thymidine_ (5.0Ci/mmol, lmCi/ml), [2,8-
3H]adenosine 3',5'-cyclic phosphate (30-50Ci/mmol, lmCi/ml), and [a-32P]dATP 
· (-3,000Ci/mmol, lOmCi/ml) were purchased from Amersham International. 
[3H]inositol 1,3,4,5-tetrakisphosphate was kindly supplied by Dr. R.F. Irvine, AFRC 
Institute of Animal Physiology and Genetics Research, Babraham, Cambridge. [3H]quin 
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2-acetoxymethyl ester (5.4 Ci/mol) was synthesised by Dr. G.A.Smith (Hesketh et al., 
1983b). 
2.1.3 Tissue culture equipment and reagents 
Falcon 96 well microtitre plates were purchased from Becton Dickinson. L-glutamine 
(200mM), 2-mercaptoethanol (50mM), Penicillin G (sodium salt, 1,625U/mg), and 
RPM! 1640 were obtained from Gibco Ltd (Scotland). Flow Laboratories (Scotland) 
supplied gentamycin (lOmg/ml), Linbro 24 well culture plates and Basal Medium Eagle 
(BME) Diploid. Mycoplasma-free foetal calf serum (FCS) was obtained from Biological 
Industries (Scotland), and was heat-inactivated by incubation at 600C for lh. 
2.1.4 Chromatography equipment and reagents 
HPLC columns, guard columns and packing materials were all obtained from HPLC 
Technology. AG1-X8 anion exchange resin (200-400mesh, formate form) was supplied 
by Bio-rad -(USA). Sephacryl HR400 gel and Protein A-Sepharose (CL-4B) were 
obtained from Pharmacia, as were the FPLC equipment and Phast microgel 
electrophoresis apparatus used in antibody purifications. The FPLC and Phast equipment 
employed were the property of the Ludwig Institute for Cancer Research, Cambridge and 
were used with the kind permission of Dr. G.I. Evan. 
2.1.S Additional material 
Phytic acid hydrolysate (Wreggett et al., 1987) was a gift from Dr. R.F.Irvine. 
Nitrocellulose membrane was obtained from Schleicher and Schuell. X-omat x-ray film 
and Tri-X pan black and white film were from Kodak. A pUC8 plasmid containing 
exons 2 and 3 of the mouse c-myc gene was provided by Dr. M.S. Neuberger, Medical 
Research Council Laboratory of Molecular Biology, Cambridge. All water used was 
purified first by distillation, and subsequently by pass~ge through a Milli Q water 
purification system (Millipore Corporation). 
2.2 Antibodies and antibody purification 
All antibodies used were obtained from Dr.K.Tomonari, Clinical Research Centre, 
Harrow. Table 2.1 shows the source and isotype of the antibodies used. Of these, 
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KT16, KT6 and 15D5 were established by Dr.K.Tomonari (1988) from a fusion of NSO 
myeloma cells with Sprague-Dawley rat splenocytes, after immunisation of the rats with 
clone 4 (KT16, KT6) or clone C6 (15D5). PC61-53 (Lowenthal et al., 1985) and 145-
2Cl 1 (Leo et al., 1985) were originally obtained from Dr. H.R. MacDonald, and Dr. J. 
Bluestone respectively. 
Antibody Target Source/lsotype Method of purification 
KT6 CD4 Rat IgG2a } Octanoic acid, then Mono Q 
15D5 CDS Rat IgG2a } FPLC 
KT16 Thyl RatlgG2c Protein A or Hypotonic Pptn 
PC61-53 IL2 receptor Rat lgGl Octanoic acid 
145-2Cll T3 HamsterlgM Gel filtration 
TABLE2.l Antibody source, type, and purification 
All antibodies were purified from serum or ascites to apparent homogeneity, as 
assayed by SDS microgel electrophoresis (see section 2.2.7). The choice of purification 
method depended on the antibody source and isotype (see Table 2.1). Some antibodies 
were treated with octanoic acid as described below. 
2.2.1 Octanoic acid treatment 
Ascites fluid or serum was placed in a Corex tube, to minimise antibody adsorption 
(G.I.Evan, personal communication), and pH adjusted to 5.0 with 3M acetic acid/lM 
sodium citrate pH 5.2. Octanoic acid was then added (5% volume). Lipids were 
precipitated by stirring for 30 mins at 250c, then pelleted by centrifugation (15 mins, 
25°C, 12,000xg). Antibody was precipitated from the supernatant by addition of an 
equal volume of saturated ammonium sulphate, then resuspended in approximately lfioth 
the original volume in inorganic salts solution (125mM NaCl, 5.2mM KCl, lmM 
N a2HP0 4 , 0.5mM MgCl2 , 0.43mM CaCl2 , lOmM HEPES; llmM glucose, at pH 
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7 .2). Ammonium sulphate traces were removed by dialysis against 2x500ml of salts 
solution. 
This protocol substantially depleted the sera of lipids, and was therefore useful for 
cleaning up sera before subjecting them to ion-exchange FPLC. In this case, ammonium 
sulphate-precipitated protein was resuspended in the FPLC starting buffer; 20mM 
triethanolamine (TEN) HCL, pH 7.5. 
One antibody, PC61-53, appeared as a single band after octanoic acid treatment, and 
was therefore not further purified. 
2.2.2 Anion exchange FPLC 
Rat IgG2a antibodies were separated from contaminating albumin and transferrin by 
anion exchange FPLC. After octanoic acid treatment, aliquots containing 50-500µg 
protein were centrifuged (1 min, 13,000xg) to remove large particles, then loaded onto a 
Mono Q column. This was protected by 2-3 in-line prefilters, changed whenever 
increasing back-pressure could not be reversed by thorough column washing. Proteins 
were eluted by increasing the sodium chloride concentration from O to IM, using a flow 
rate of between 0.5 and l.Oml/min (all eluents contained 20mM TEN HCl, pH 7.5). A 
typical solvent regime was: 5ml of OM NaCl, pH7 .5, to load and equilibrate the column; 
linear increase over 1ml to lOOmM NaCl; linear increase over 15ml to 300mM NaCl; 
rapid linear increase (in 3 ml) to, and maintenance (for 3ml) at, IM NaCl; return over 3ml 
to OM NaCl; and finally 5ml of OM NaCl to re-equilibrate the column. Protein was 
detected by measuring A2so of the eluate. Protein peaks were collected as 1ml fractions, 
and subsequently analysed by microgel electrophoresis (see Section 2.2.7, below). 
Antibody eluted between 140 and 160 mM NaCl. Relevant fractions were pooled, 
ammonium sulphate precipitated, resuspended in and dialysed against inorganic salts 
solution. 
2.2.3 Protein A affinity chromatography 
Octanoic acid treatment was apparently unsuitable for rat IgG2c antibodies, since no 
antibody could be recovered from portions of KT16 serum thus treated. Nor was 
untreated KT16 serum amenable to Mono Q (anion exchange) or Mono S (cation 
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exchange) FPLC. Therefore, KT16 (rat IgG2c) was purified on a Protein A-Sepharose 
affinity column, or by hypotonic precipitation. Prior to column preparation, Protein A-
Sepharose was swelled by shaking gently in 20mM Tris-HCl, pH 8.0, for 10 mins, then 
washed 3-4 times to remove fines and preservative (sodium azide). Antibody serum was 
dialysed against 20mM Tris-HCl / 5mM NaCl, pH 8.0, to reduce the salt concentration 
and thereby facilitate interaction of the immunoglobulin with Protein A, and then loaded 
onto the column. The column was washed twice with 10ml of 20mM Tris-HCl, pH 8.0, 
reversing it between washes. Antibody was eluted with 10ml of O. lM sodium acetate, 
pH 4.5, and the column washed into 20mM Tris-HCl, pH 8.0, containing 0.1% sodium 
azide as preservative. The antibody fraction was concentrated by ammonium sulphate 
precipitation and resuspension/dialysis in inorganic salt solution. 
2.2.4 Hypotonic Precipitation 
Rat IgG2c antibodies tend to precipitate at low salt concentrations (Steve Cobbold, 
personal communication). The necessity for dialysis against low salt concentrations prior 
to Protein A purification therefore resulted in a low KT16 yield due to loss by 
precipitation. Higher yields were achieved simply by hypotonically precipitating the 
antibody and resuspending it in the desired buffer. In practice this . was achieved by 
dialysing KT16 serum against water, collecting both precipitate and supernatant, and 
washing the precipitate by repeated centrifugation and suspension in water. After 5-6 
centrifugations, the supernatant was then resuspended/dialysed in inorganic salts solution. 
2.2.5 Gel Filtration 
IgM serum contains large, multivalent molecules not amenable to purification by 
similar techniques to IgG molecules. Therefore 145-2Cl 1 was purified by gel filtration 
using Sephacryl S-400 HR resin. An FPLC column with bed volume 100ml was 
prepared, and the void volume determined to be 30ml by eluting dextran blue with 20mM 
Tris HCl / lOOmMNaCl, pH 7.5. 145-2Cll serum was diluted with eluent, and run on 
the Sephacryl column. Protein elution was observed by monitoring A2so , and fractions 
were collected between 26 and 130 mins. Three peaks eluted at 55mins, 63mins, and 
82mins. The firs t and second peaks were identified as albumin and immunoglobulin 
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respectively by microgel-electrophoresis (Section 2.2.7). The relevant fractions were 
pooled, ammonium sulphate precipitated, and resuspended/dialysed in inorganic salts 
solution. 
2.2.6 Protein assay 
After resuspension in and dialysis against inorganic salts solution, protein 
concentration was assayed using a microbiuret assay as described by Goa (1953). A 
standard curve was constructed using bovine serum albumin (BSA; 0-500µg), and small 
aliquots (10-100µ1) of antibody solutions were spiked with 150µg BSA. Protein was 
precipitated from each sample by addition of 1ml of 10% trichloroacetic acid and 
incubation for 5-10 mins at 250c. Protein was pelletted by centrifugation (3s, 
13,000xg), the supernatant aspirated, and the protein resuspended in 950µ13% sodium 
hydroxide by incubation at 37°C for 3-12h. After resuspension, tubes were incubated for 
a further 15-30mins at 370c with 50µ1 of Benedicts reagent (1.73% copper (II) sulphate, 
10% sodium carbonate, 17 .3% sodium citrate). A330 was measured 
spectrophotometrically against a water blank, and protein concentrations calculated from 
the standard curve. Concentrations were found to be between 1 and 5mg/ml. 
2.2. 7 Microgel electrophoresis 
Electrophoresis was used at several stages to confirm the presence and ultimately the 
purity of immunoglobulin. Fractions from the FPLC were fractionated electrophoretically 
to identify those containing immunoglobulin, and thereby facilitate selection of the 
relevant fractions. After ammonium sulphate precipitation and resuspension in salts 
solution, antibody stocks were once more fractionated to assess their purity. SDS 
microgels were run on a Phast system, and stained in the Phast staining chamber. Gels 
were stained either using Coomassie or silver stain depending on the sensitivity required. 
Both staining protocols were as described in the Phast User Handbook. 
2.3 Cell culture and preparation 
2.3.1 Thymocyte preparation 
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Thymocytes were prepared by the method of Hesketh et al. (1983b).Thymi were 
isolated from 4-6 week old BALB/c mice after killing by cervical dislocation. The thymi 
were teased into RPMI 1640, supplemented with 20mM Tris, 24mM NaHC03, 2mM 
glutamine, and 20µg/ml gentamycin, pH 7.2. Connective tissue was pelleted by gravity, 
and the supernatant suspension decanted to a fresh tube, washed once by centrifugation (3 
mins, 250xg), and resuspended at a density of lxl07 cells/ml. Cell number was 
determined by viewing an aliquot of the final cell preparation on a haemocytometer under 
a Nikon binocular microscope, and viability, assayed by exclusion of 0.05% sodium 
eosin, was found to be greater than 95%. Cells were used immediately for proliferation 
assays, but stirred in a siliconised vial in a humidified gassed incubator (95% air, 5% 
COi, 370 C) for 2-4h to allow endogenous cAMP levels to fall (J.P. Moore et al., 1983) 
before use in [Ca2+]i assays. 
2.3.2 Clone 4 culture 
Clone 4, a TH cell line, was obtained from Dr. K. Tomonari, Clinical Research 
Centre, Harrow. Clone 4 stably expresses a variety of surface proteins which include a T 
cell receptor, IL2 receptors, CD4, LF A 1, and Thy 1. The TCR recognises the Ek 
antigen, and clone 4 division is stimulated by cells bearing Ek in the context of class II 
MHC proteins (Tomonari, 1985). Clone 4 was therefore stimulated using irradiated Ek.. 
bearing splenocytes from CBA mice combined with recombinant IL2 (Tomonari, 1985). 
Cultures were grown in RPMI 1640 supplemented with lOmM HEPES, 24mM NaHC03 
,10% FCS, 5x10-·s M 2-mercaptoethanol, 12µg/ml Penicillin G and lOOµg/ml 
Streptomycin, pH 7 .2. Cells were restimulated every 2-4 weeks by washing into fresh 
medium containing 50U/ml IL2, and replating in Linbro 24 well plates (2ml/well) at 1-
2.5xI04 cells per well, with 4xI06 irradiated splenocytes per well. Splenocytes were 
obtained from 3-16 CBA mice, and prepared as follows. Cells were teased into RPMI 
1640 supplemented with HEPES, NaHC03 and antibiotics; and pelletted by 
centrifugation (3 mins, 250xg). The cell pellet was resuspended in 400-800µ1 0.83% 
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NH4Cl, and incubated for 9 mins. The incubation was terminated by re-addition of 
medium, and the cells were washed into fresh medium. This Nli4Cl "shock" destroyed 
erythrocytes without significantly affecting lymphocyte viability (Agostini and Ideo, 
1965; Ling and Kay, 1975). The splenocytes were exposed to 3,500 rads y-irradiation 
using the irradiation facilities of the Radiotherapy Department, Addenbrookes Hospital, 
Cambridge (with the assistance of D. Adams). 
Antigen alone stimulated little DNA synthesis, but in combination with IL2 was a 
potent stimulus (Fig. 2.1, assayed using the protocol described in Section 2.4.2). IL2 
plus antigen caused maximal [3H]thymidine incorporation at 96h and no incorporation 
was seen on or after day 6. The response to IL2 alone, at 96h, was -50% of that 
stimulated by antigen plus IL2 (37,786+/-855 and 82,682+/-2,277 cpm respectively). 
However, long term culture with IL2 alone was not used, to avoid possible alterations in 
surface phenotype (K. Tomonari, personal communication). Single cultures using IL2 
alone were, however, used to grow cells for [Ca2+]i measurements (see Section 2.6.2, 
below). 
The maximal cell number reached was 1-2x106 per well, suggesting 5-6 cycles of 
division had occurred, and that the time taken for one cycle was approximately 20h. 
Cells were used a fixed number of days after stimulation in order to obtain optimal 
responses; 7-9 days for assays of KT16-induced proliferation, 11-16 days for all other 
experiments (K. Tomonari, personal communication). 
2.4 Proliferation assays 
The ability of various ligands to stimulate lymphocyte proliferation was examined by 
determining the ability of each ligand to stimulate incorporation of [3H]thymidine into 
DNA. Lymphocyte cultures were established in Falcon flat-bottomed 96 well plates (final 
volume 200µ1/well), and incubated in a gassed incubator (as above). The peripheral wells 
of the plate were not used for lymphocyte culture but were filled with medium to reduce 
evaporation from the central wells (Ling and Kay, 1975). Cultures were exposed to a 
brief [3H]thymidine pulse prior to termination of the reaction. 
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FIGURE 2.1 Time course of clone 4 proliferation stimulated by antigen-presenting cells and/orIL2. 
· Clone 4 cells were cultured in flat-bottomed microtitre wells as described in Section 2.4 
with medium(~). 8x1Q5 CBA splenocytes/well (•), 50U/ml IL2 (D), or CBA splenocytes plus IL2 (•). Cultures were harvested at 24h intervals up to 10 days, but data are only 
shown up to 144h, as there was no [3H]thymidine incorporation after 144h. They axis 
shows cpm of [3H]thymidine incorporated. 
1 I 
60 
Incubation time was chosen such that thymidine pulses were administered at the time of 
maximal DNA synthesis. Incubations were terminated by cell disruption and 
macromolecules were collected on glass microfibre filters (Whatman) using a Titertek Cell 
Harvester (Skatron A.S., Norway). Filters were dried and counted for 3H in 5ml of 
scintillant (see Section 2.8). 
2.4.1 Assay of thymocyte proliferation 
Thymocyte proliferation was assayed using a similar protocol to Hesketh et al. 
(1983b). Thymocytes were prepared as described above (Section 2.3.1). l.4xl06 cells 
per well were incubated for 48h, and pulsed for the final 6h with 0.3µ Ci 
[3H]thymidine/well . Longer incubations resulted in progressively lower indices of 
stimulation correlating with decreases in cell viability (L. Kean, personal communication). 
2.4.2 Assay of clone 4 proliferation 
Stimulated clone 4 proliferation was assayed using a protocol similar to that of 
Tomonari (1985). Clone 4 cells were harvested and washed into medium identical to the 
culture medium above, except for the FCS concentration which was increased to 15%. 
lx104 cells per well were incubated for 96h, to observe maximal stimulation (Fig. 2.1), 
or at 24h intervals up to 10 days to investigate time courses of stimulation. In all 
experiments, cultures were exposed to a [3H]thymidine pulse of 0.5µCi/well for the final 
12h. 
Both for clone 4 and thymocyte assays, all ligands were added to the wells prior to cell 
addition. Ligand combinations were therefore added simultaneously to the cells. 
2.5 Photomicrography 
Incubations of lymphocytes with different ligands cause~ markedly different patterns 
of cell aggregation. These were recorded by photomicrography using a Combiphot 
automatic camera system (Leitz). A Leicaflex camera was mounted on a Diavert Inverted 
Microscope, and pictures taken of cell cultures, established in 96 well microtitre plates for 
proliferation assays, immediately prior to cell harvesting. Photographs were taken of 
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thymocytes and 48 after stimulation. Exposed films (Kodak Tri-X Pan, black and white) 
were processed by the photographic department, Biochemistry Department 
2.6 Measurement of intracellular free calcium concentration 
Intracellular free calcium concentration ([Ca2+]i) was measured using the fluorescent 
Ca2+ indicator quin 2. The protocol used was similar to that described by Hesketh et al. 
(1985). 
2.6.1 Thymocyte loading 
Thymocytes were prepared as described above (Section 2.3.1), and aliquots (2x107 
cells) washed into salts solution immediately prior to loading with indicator. Thymocytes (4ml) were incubated with 1.5µM quin 2-acetoxymethylester (AME) for 40 mins at 
370 C, with regular inversion, then washed into 4.1ml of salts solution and divided 
between two 3ml quartz cuvettes to allow simultaneous [Ca2+Ji measurements in two 
fluorimeters. 0.1ml was retained to count for 3H. Aliquots thus counted showed the 
intracellular quin 2 concentration to be arou~d lmM, taking 104fl as the intracellular 
volume of a thymocyte (Hesketh et al., 1983b). The final cell density was 2.5-5x106 
cells/ml. 
2.6.2 Clone 4 loading 
Clone 4 cells (0.5-lxl07) were loaded by incubation under identical conditions to 
thymocytes, but for only 30 mins, then washed as thymocytes (final cell density: 1-2x106 
cells/ml). 
After incubation with quin 2-AME, cells cultured with both antigen and Il.,2 exhibited 
large fluorescence intensities (FI) but poor responses to ligands, with an emission 
maximum around 450nm. This suggested quin 2-AME was partitioning into the feeder 
cell membranes during loading, but not being hydrolysed due to the lack of viable 
esterase. This ester was not removed by cell washing, and its fluorescence masked the 
signal due to hydrolysed quin 2 in the clone cells. To avoid this clone cells for [Ca2+Ji 
measurements were grown with Il.,2 alone. 
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To control for effects of growing cells differently for Ca2+ and inositol phosphate 
experiments, inositol phosphate responses to anti-Thy 1 and Con A were compared in 
cells grown both with and without CBA cells. The index of stimulation (relative to 
control) evoked by anti-Thy 1 was very similar in the two cell populations (Table 2.2). 
Inositol phosphate fraction 
InsP InsP2 InsP3 InsP4 Growth stimulus 
IL2 alone 1.6 2.4 1.7 2.1 
CBA+IL2 1.7 2.1 1.5 1.8 
TABLE 2.2 Stimulation index of inositol phosphate fractions with KT16 
Clone 4 cells cultured by stimulation with IL2+/-CBA splenocytes were labelled with [3H]inositol, washed and pre-incubated as described in Section 2.7.1. Cells were 
challenged with anti-Thy 1 (20µg/ml) for 10 minutes. The reactions were quenched, and 
samples processed as described in Section 2.7.3. Inositol phosphate fractions were 
separated, dried and counted for 3H (Section 2.8). The stimulation index is the ratio cpm in stimulated cells / cpm in unstimulated cells. 
Con A caused massive increases in cpm in inositol phosphates in IL2-grown cells, 
similar to those seen in other experiments in CBA-grown cells. These results suggest that 
both Con A and anti-Thy 1 evoke responses of similar magnitude in cell~ grown+/- CBA 
cells, and therefore that comparisons between Ca2+ and inositol phosphate responses to 
anti-Thy 1 and Con A_~ valid. 
In some experiments, clone 4 cells were washed into RPMI 1640 
([inositol] = 0.19mM) or the inositol-free medium, BME Diploid (supplemented with 
2.4µM inositol) used for labelling with [3H]-inositol (see Section 2.7.1, below), and 
incubated for 7h prior to use in [Ca2+]i measurement experiments. The responses to anti-
Thy 1 were identical in cells pre-incubated in either medium, suggesting that incubation at 
low [inositol] does not modify responses to KT16. 
2.6.3 [Ca2+Ji measurement 
Quin 2 fluorescence was continuously recorded using Perkin Elmer MPF 44B and 44E 
fluorescence spectrophotometers (A.ex= 339nm, A.em= 492nm). Cells were maintained in 
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suspension using a magnetic stirring and heating block. Cells were incubated in the 
fluorimeter for 10 mins prior to ligand addition to allow temperature equilibration. Anti-
CD4 (KT6) and isotype control antibody (15D5) were added 5 mins prior to Con A/ 
KT16 to check their lack of effect on [Ca2+]i. In some experiments, the extracellular free 
Ca2+ concentration, ([Ca2+]o), was reduced to 0.lµM (i.e. equal to [Ca2+]i) by 5 min 
preincubation with lmM EGTA. EGTA was added from a lOOmM stock, pH adjusted 
such that addition to salts solution changed the pH less than 0.02 units. By reducing 
Ca2+ 0 entry this permitted measurement of Ca2+ release from intracellular stores. 
Ca2+ responses were calibrated as described by Hesketh et al., (1983b). The 
fluorescence intensities (FI) of 100% saturated quin 2 and 0% saturated quin 2 were 
determined by lysing the cells with 0.02% Triton X-100 (thereby exposing the quin 2 to 
0.43mM Ca2+) then displacing Ca2+ from quin 2 by addition of 0.25mM Mn Cl 2. Using 
these values, the FI values observed at 60s intervals were converted to percentage quin 
saturation using the formula: 
(a-c) - 0.16(b-c) 
%Ca-quin 2 = -------------------
where; a = fluorescence intensity of intact cells 
b = fluorescence intensity at 100% saturation 
c = fluorescence intensity at 0% saturation 
This formula corrects for the effect of Mg2+-binding to quin 2 (Hesketh et al., 1983b). 
[Ca2+]i was then calculated from %Ca-quin 2 using the relation: 
%Ca-quin 2 100 
[Ca2+]i = ---------------- x ------ nM 
100-%Ca-quin 2 1.122 
Data are presented as intracellular free calcium concentration (nM) against time, plotted 
at 1 min intervals. Data are the means of duplicate or triplicate determinations. Where the 
effects of inhibitors were determined, control and inhibited responses were measured 
simultaneously in two fluorimeters with cells from a single loading. 
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2. 7 lnositol phosphate assays 
Ligand-stimulated inositol phosphate accumulation was measured in lymphocytes pre-
labelled with [3H]inositol, using an assay derived from that of Taylor et al. (1984). 
Reactions were performed in salts solution. Inositol phospholipids were separated from 
inositol phosphates in the reaction mixture by extraction into an organic phase. Individual 
inositol phosphate fractions were separated by anion exchange chromatography on Partisil 
10 SAX (HPLC) or AG1-X8 resin, and quantitated by counting for 3H. 
2.7.1 Labelling of lymphocytes with [3H]inositol 
Thymocytes from 2-3 BALB/c mice were prepared in BME Diploid medium, 
supplemented with 20mM Tris, 24mM NaHC03, 2mM glutamine, penicillin and 
streptomycin, pH 7.3. Cells (2-3xl08) were continuously stirred for 16-18h with 
20µCi/ml [3H]-inositol (or 23µCi/ml for HPLC experiments), then washed twice by 
centrifugation into salts solution. Cells were resuspended to give different densities for 
different experimental procedures; 2-3xl07 cells/ml for HPLC experiments (0.6ml 
aliquots), and 5-10xl06 cells/ml for non-HPLC experiments (0.5ml aliquots) and 
incubated 20-30 mins at 370c. 
A permeabilised thymocyte system, developed by Dr. Y. Zilberman, was employed to 
investigate the [Ca2+] dependence of inositol 1,4,5 trisphosphate phosphorylation. Cells 
for these experiments were not labelled with [3H]inositol but were prepared in RPMI 
1640 as described (Section 2.3.1), washed twice into salts solution , and resuspended at 
5-10x107 cells/ml. 
Clone 4 cells were labelled by incubation with 40µCi/ml [3H]inositol for 8-9h in B:ME 
Diploid, supplemented with l OmM HEPES, 24mM NaHC03, Penicillin and 
Streptomycin, pH 7.3. Cells were washed twice into salts solution, and 0.5ml aliquots 
incubated 15-30 mins at 370c (4-9x106 cells/ml). 
2.7.2 Cell experiments 
Intact cell reactions were initiated, after 10 mins preincubation with 5mM LiCl, by 
addition of ligand. To avoid possible u +-mediated alterations of inositol phosphate 
interconversions, samples for HPLC analysis were not pre-incubated with LiCL Where 
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the effects of anti-CD4 or isotype control 15D5 were examined, anti-CD4 or 15D5 was 
added either simultaneously (time course experiments) or 5 mins prior to ligand addition 
(titration experiments). Addition at either time gave equivalent effects on ligand-
stimulated inositol phosphate accumulation. Other additions were as described in the 
Figure legends. 
Permeabilised cell reactions were initiated by dilution of 40µ1 of cells into 380µ1 of a 
hypo-osmotic medium containing 5.5mM MgCI2, 5.5mM Na2ATP, 1.3mM EGTA, 
O.lmM CaCli and 12.SnM [3H]inositol l,4,5-trisphosphate, pH 7.1. At 2 mins, 80µ1 of 
buffer solution containing 5.5mM MgCl2, 5.5mM Na2ATP, 1.3mM EGTA, 188mM 
KCl, 375mM Tris and a range of calcium concentrations was added. Cell lysis was 
greater than 95% as determined by lactate dehydrogenase (LDH) activity assays (taking 
the activity after Triton X-100 lysis to be 100%), and was unaffected by addition of KCl 
and Tris at 2 mins (Y. Zilberman, personal communication). Calcium chloride was added 
to give a range of free calcium concentrations from 0.04 to 50µM, as calculated using a 
computer programme developed by Dr. A.N. Corps from one described by Fabiato and 
Fabiato (1979). 
All reactions were terminated by addition of 3.75 volumes of chloroform/methanol 
(1:2). 
2.7.3 Inositol phosphate extraction 
After reaction termination, phases were separated by addition of 0.62ml each of 
chloroform and water (0.8ml to intact cell HPLC samples). After removal of the upper, 
aqueous phase to a fresh vial, the organic phase was washed twice with 200µ1 of a 
CDTA-containing upper phase (250µ1 to intact cell HPLC samples) prepared by shaking 
together lOOmM Na2CDTA, methanol and chloroform (5 : 8 :16) and collecting the upper 
phase, as described by Berridge et al. (1983). The washings were combined with the 
upper phase. Samples for HPLC analysis were freeze-dried after addition of 100µ1 of 
50mM mannitol (to aid inositol phosphate recovery), and removal of methanol by 
evaporation under a nitrogen stream, then stored at -2ooc. Samples for non-HPLC 
analysis were processed as described below (Section 2.7.4). 
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The lower phase was evaporated to dryness and counted in 5ml of scintillant to 
determine [3H]inositol-labelled phospholipids. 
2. 7.4 Inositol phosphate separations on AG 1-XS resin 
The combined aqueous phases were loaded onto anion exchange columns containing 
AG1-X8 resin. The columns were washed with 10ml of water and 1.2ml of 5mM 
disodium tetraborate/0.2M ammonium formate; then inositol phosphates were eluted 
sequentially using 9ml of each of the following buffers: 0.2M ammonium formate/0.lM 
formic acid (InsP); 0.4M ammonium formate/0.lM formic acid (InsP2); 0.7M ammonium 
formate/0.lM formic acid (lnsP3); 1.2M ammonium formate/0.lM formic acid (InsP4). 
Eluted fractions were oven-dried (800C), then resuspended in 15ml of scintillant and 
counted for 3H (Section 2.8). 
This elution regime is a modified version of that used by Downes et al. (1986), but 
with a reduced formate concentration of 0.7M, rather than 0.8M, for InsP3 elution, as 
0.8M formate partially eluted InsP4. Recoveries of InsP3 and InsP4 from AG1-X8 
coluIIll.lS were 93% and 87% respectively (Table 2.3) 
Addition to column dpm eluted by formate concentration 
0.2M 0.4M 0.7M 1.ZM Total 
[3H]Ins(l,4,5)P3 
[3H]InsP4 
10 
20 
27 
5 
2,054 
103 
TABLE 2.3 InsP3 and InsP4 recovery from AG1-X8 columns 
18 
847 
2,109 
975 
Duplicate aliquots (100µ1) of [3H]Ins(l,4,5)P3 (2,256 dpm) or [3H]InsP4 (1,118 dpm) 
were mixed with 400µ1 of salts solution and 2µ1 of phytic acid hydrolysate, then loaded 
onto AG1-X8 columns. Columns were eluted as described above. Fractions were 
collected, dried, and counted for 3H as described below (Section 2.8). 
97% of InsP3 counts recovered eluted in the 0.7M formate fraction, and 87% of InsP4 
counts recovered eluted in the 1.2M formate fraction. 
I, 
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2.7.S HPLC analysis of inositol phosphates 
Freeze dried samples were dissolved in 0.4ml of water spiked with approx. 200µM 
AMP, ADP, and A1P, filtered through cellulose acetate filters, and loaded onto a Partisil 
10 SAX column (250 x 4.6mm). This was protected by a guard column (50 x 4.6mm) of 
pellicular SAX, changed after every 10 runs. A flow rate of lml/min was used, and 
inositol phosphates were eluted by increasing concentrations of ammonium formate 
(buffered to pH 3.7 with orthophosphoric acid). Two protocols were used; one 
developed from Batty et al. (1985) to separate the two major inositol trisphosphate 
isomers, Ins(l,3,4)P3 and Ins(l,4,5)P3, and inositol tetrakisphosphate, and the other an 
adaptation of the method described by Heslop et al. (1985) to collect inositol pen ta- and 
hexakisphosphates in addition to the InsP3 isomers and InsP 4. 
2. 7 .Sa· · InsP3 and InsP 4 assay 
lnositol, InsP and lnsP2 were eluted over 9 mins by increasing formate concentration 
from 2mM to 750mM in a non-linear gradient (convex no. 0.3 on a Perkin-Elmer gradient 
former). lns(l,3,4)P3 and Ins(l,4,5)P3 were then eluted by a linear increase over 8 mins 
to I.OM ammonium formate, and the buffer was held at this concentration for a further 6 
mins. InsP 4 was eluted by a linear concentration increase to 1. 7M over 10 mins and 
subsequent maintenance for 20 mins. ·The column was washed for 5 mins with a 5ml/min 
1. 7M formate purge before returning to 2mM ammonium formate over 10 mins. The 
eluent was routinely collected as 0.2ml fractions between 24 and 34 mins and from 40 to 
48 mins, and counted for 3H in 5 ml scintillation fluid. 
Fig 2.2 shows a typical elution profile obtained using a standard sample generated by 
stimulating intact thymocytes with lOµg/ml Con A for 2 minutes. Fractions were 
continuously collected throughout the run. The first four peaks have not been identified 
relative to standards, but are likely to be inositol, glycerophosphoinositol, inositol 
monophosphate and inositol bisphosphate by comparison with data presented in Heslop 
et al. (1985). The split nature of the putative inositol bisphosphate peak may represent 
the incomplete separation of two inositol bisphosphate isomers, Ins(l,4)P2 and 
lns(3,4)P2 formed by degradation of Ins(l,4,5)P3 and lns(l,3,4)P3 respectively. 
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FIGURE 2.2 Elution profile of inositol phosphates extracted from Con A-stimulated thymocytes. 
[3H]inositol-labelled BALB/c thymocytes were stimulated for 2 mins with lOµg/ml Con A (Section 2.7.2), then reaction quenched and inositol phosphates extracted as described in Section 2.7.3. Ip.ositol phosphates were separated on a Partisil 10-SAX HPLC column by a modified version of the method of Batty et al. (1985) described in Section 2.7.5a, and the eluate collected as 0.5ml fractions between O and 20 mins and as 0.2ml fractions from 20 to 50 mins. Fractions were counted in 4.5ml of scintillation fluid (Section 2.8). Peale identities were assigned as described in the text; The dashed line shows the ammonium formate concentration. 
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Three further peaks eluted between 20 and 30 mins. Of the two major peaks, the earlier 
co-eluted with ATP and is therefore assumed to be Ins(l,3,4)P3 (Irvine et al., 1985), 
while the later co-eluted with myo[2-3H]inositol 1,4,5 trisphosphate. The minor peak 
eluting after Ins(l,4,5)P3 was too small for accurate quantitation, but may be inositol 
2,4,5-trisphosphate. A minor peak eluting just before Ins(l,3,4)P3 was sometimes 
detected, which may be cyclic inositol 1,4,5 trisphosphate, as described by Connolly et 
al. (1986a), but was too small to quantitate. The peak at 42 mins co-eluted with 
[3H]inositol l,3,4,5 tetrak:isphosphate, and thus is assumed to be InsP4. 
2.7.Sb InsP3, lnsP4, InsPs and InsP6 assay 
To elute InsPs and InsP6, the ammonium formate concentration was increased to 
3.4M. Gradient details were as follows: 15 mins at 2mM formate to elute inositol, linear 
increase over 60 mins to 750mM to elute InsP and InsP2, linear increase over 30 mins to 
3.4M formate and subsequent maintenance at this concentration for 15 mins to elute InsP3 
isomers, InsP4, InsP5 and InsP6. The concentration was then returned to 2mM formate 
over 15 mins. The eluent was collected as 0.5ml fractions between 72 and 86 mins, and 
as 1ml fractions between 90 and 116 mins. 0.2ml aliquots were removed from the 
fractions and counted in 15ml of scintillant. 
This protocol resulted in similar count recovery of InsP3 and InsP 4 from a standard 
sample as was obtained using the previous assay (2.7.5.a). An additional, more strongly 
retained peak eluted at approx. 2.lM ammonium formate. The InsP5 peak described by 
Heslop et al. (1985) eluted at a similar formate concentration (Table 2.4) suggesting that 
the peak eluted by 2. lM formate is InsP5. No more polar peak analogous to InsP6 was 
observed. 
Interestingly, the ratio of InsP4 to Ins(l,4,5)P3 apperu::ed to be far greater in Con A-
stimulated thymocytes than in 5-hydroxytryptamine-stimulated blowfly salivary gland 
(Table 2.5 and Heslop et al. , 1985), carbachol-stimulated brain slices (Batty et al., 1985) 
or Jurkat cells stimulated with anti-TI antibody (Stewart et al. 1986). 
Inositol phosphate 
Ins(l,3,4)P3 
Ins(l,4,5)P3 
InsP4 
InsP5 
InsP6 
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Eluting formate concentration (M) 
a) Heslop et al. (1985) b) This work 
0.63 0.69 
0.68 
1.39 
2.02 
2.66 
0.71 
1.53 
2.12 
Not found 
TABLE 2.4 Comparison of formate concentrations required for inositol phosphate elution Eluting concentrations were calculated by comparison of elution time and elution regime. 
Inositol phosphate dpm in standard Ratio to dpm in Ratio from 
sample Ins(l,4,5)P3 Heslop et al. Ins(l ,3,4)P3 4,452 2.1 0.20 Ins(l,4,5)P3 2,120 1.0 1.0 
InsP4 18,325 8.6 0.26 
InsP5. 3,810 1.8 0.02 
InsP6 Not found 0.06 
TABLE 2.5 Relative radioactivity in Ins(l,3,4)P3, Ins(l,4,5)P3, InsP4 and InsP5 The dpm are shown for inositol polyphosphates in a 2 min standard sample, separated and quantitated as described in Section 2.7.5.b. Ratios are calculated relative to dpm in Ins(l,4,5)P3, and compared with ratios for 5-hydroxytryptamine-stimulated blowfly salivary gland calculated from Heslop et al. (1985). 
This difference may be attributable, in part, to the method of extraction employed by 
the groups cited which involves the use of trichloroacetic acid. Trichloroacetic acid 
extraction of inositol phosphates (as described below, Section 2.7.6) from thymocytes 
stimulated for 2 mins with Con A resulted in an InsP4: Ins(l,4,5)P3 ratio 16-fold smaller 
than that seen when inositol phosphates were extracted using chloroform/methanol (as 
described in section 2.7.3). To investigate this change in ratio, a comparison of 
[3H] Ins( 1,4,5)P3 and [3H] InsP 4 recoveries using trichloroacetic acid and 
chloroform/methanol protocols for reaction termination and inositol phosphate extraction 
was effected. [3H]Ins(l,4,5)P3 and [3H]InsP4 were extracted from media with or 
without cells using both protocols and the recoveries examined by HPLC separation and 
quantitation as described (Section 2. 7 .5a). Trichloroacetic acid had little effect on the 
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recovery of Ins(l,4,5)P3 either from salts solution or from a cell suspension (Table 
2.6.a), but InsP4 recovery from trichloroacetic acid-treated samples was only 43% from 
salts solution, and 5% in the presence of cells, of that from chloroform/methanol-
extracted samples (Table 2.6.b). In the absence of cells, low recovery was due to 
adsorption onto the cellulose. acetate filters. However, in the presence of cells only 50% 
of the unrecovered counts were filter associated. Residual unrecovered counts could not 
be accounted for by precipitation with protein or dephosphorylation to give lower inositol 
phosphates, since no counts were found to be associated with the protein precipitate, and 
no counts eluted earlier than InsP 4 from the HPLC column. 
i) Sample . dpm in Ins(l,4,5)P3 
Control 12,424 +1- 438 
a 11,171 +1- 508 
b 11,090 +1- 1,427 
C 12,018 +1- 16 
d 10,910 +1- 230 
ii) Sample dpm in InsP4 dpm on filter Total 
Control 1,328 +1- 58 104 +/- 46 1,432 
a 1,163 +1- 42 244 +1- 9 1,407 
b 1,083 +1- 9 33 +1- 12 1,116 
C 498 +1- 35 847 +/- 33 1,345 
d 58 +1- 20 691 +1- 153 749 
TABLE 2.6 Effect of extraction method on [3H]Ins(l,4,5)P3 and [3H]InsP4 recovery 100µ1 aliquots of a_ [3H]Ins(l,4,5)P3 solution (1.2x104 dpm / 100µ1; i) or a [3H]InsP4 
solution (1.3x103 dpm / 100µ1; ii) were added to 0.5ml of salts solution (Control, a, c) or thymocyte suspension (b, d). The con_trol sample was freeze-dried, and the other samples were extracted using a neutral chloroform/ methanol metliod (a, b) or a trichloroacetic acid protocol (c, d). Duplicate samples were assayed for InsP3 and InsP4 by HPLC, as described in Section 2.7.5.a. InsP and InsP2 fractions were also collected but contained no radioactivity. (ii) Cellulose acetate filters were also counted, after drying, in 5ml of scin tillant. 
InsP4 loss could be substantially reduced by spiking samples with 2µ1 phytic acid 
hydrolysate (13mg phosphate/ml, Wregget et al., 1987). However, chloroform / 
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methanol extraction was the preferred procedure, since it was a quicker procedure, and 
was reliable without the need for phytic acid supplements. 
2.7.6 Trichloroacetic acid extraction of inositol phosphates 
Trichloroacetic acid extraction was according to the method of Batty et al., (1985). 
Reactions were quenched by the addition of an equal volume of ice-cold 15% w/v 
trichloroacetic. Tubes were vortexed and incubated at ooc for 10-15 mins. Precipitated 
protein was sedimented by centrifugation for 5 mins, and the supernatant removed to a 
fresh tube and washed five times with 2 volumes of water-saturated diethyl ether to 
remove trichloroacetic acid. Sample pH was adjusted to 7-8 with lM NaHC03, and 
samples were stored at -2ooc. For HPLC analysis, samples were spiked with adenine 
nucleotides (200µM), filtered, and assayed for InsP3 and InsP 4 as described in Section 
2.7.5.a. 
2.8 Liquid Scintillation counting 
Tritium was counted using a Packard Tri-Carb 460C scintillation counter. Filters 
bearing 3H-DNA (Section 2.4) and fractions from the HPLC (Section 2.7.5) were 
counted in 5ml plastic scintillation vial inserts containing 4.5ml of scintillation fluid. 
Inositol phosphate fractions separated on AG1-X8 resin (Section 2.7.4) were eluted into 
15ml plastic scintillation vials, and oven dried at 800C. Inositol phosphate fractions were 
resuspended by vigorously vortexing for 60s in 15ml scintillant 2-3 times, and counted 
in these vials. 
Two types of scintillant were used during the course of this work. The first, a cocktail 
consisting of; toluene : Triton X-100 : water (8 : 4 : 1) containing 2.5% w/v PPO 
(scintillant a) was used to count all HPLC-generated samples and some of the 
proliferation assays and AG1-X8-generated inositol phosphate fractions. A switch was 
made to the second, commercially-produced scintillant, Safe Fluor S (scintillant b), to 
comply with regulations introduced in 1988 concerning the biodegradability of 
scintillation fluids. This particular biodegradable scintillant was selected for its ability to 
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solubilise inositol phosphate fractions. It was however necessary to add 6.6% (v/v) 
water to Safe Fluor S before it was effective at solubilising inositol phosphates. 
Counting efficiency was determined using the internal standard of the counter, 
calibrated by comparison with standard samples of known quenching provided by the 
manufacturer. The counting efficiency within most experiments only varied approx. 3-
5%, and results are therefore expressed as cpm. However the efficiency of counting of 
HPLC fractions was found to significantly decrease as the formate concentration of the 
eluent increased. Therefore data for HPLC fractions were converted to dpm and 
expressed as a percentage of dpm in 3H-labelled lipids to allow comparison between 
experiments. Counting efficiency was greater with Safe Fluor S (approx. 120% of 
scintillant a), but the ratio 
cpm in inositol phosphate fraction/ cpm in lipids (i) 
was very similar in both scintillants for all four inositol phosphate fractions (Table 2.3); 
and the scintillants had very similar counting efficiency calibrations. 
Scintillant InsP InsP2 InsP3 InsP4 
a cpm 1,866+/-27 358+/-66 296+/-49 378+/-7 
ratio (i) 2.42 0.46 0.38 0.49 
b cpm 2,246+/-15 505+/-63 346+/-38 505+;_43 
ratio (i) 2.43 0.55 0.37 0.55 
TABLE 2.7 Comparison of inositol phosphates counts visualised using two scintillation fluids 
[3H]inositol-labelled thymocytes were challenged with lOµg/ml Con A for 10 mins, as described in Section 2. 7 .1. The reaction was terminated, and inositol phosphates extracted, processed and separated as described (Section 2.7.2-4). Fractions were oven dried, resuspended in 15 ml of scintillant, and repeatedly vortexed and counted until 
counts were stable. Data shown as 'cpm' are the mean cpm +/- s.d. of duplicate determinations. Ratio (i) was calculated using the following values for cpm in lipids: 77,078+/-4,523 (scintillant a) and 92,523+/-800 (scintillant b). 
Samples were always counted for sufficient time to ensure that the counting error was 
considerably less than errors likely to arise elsewhere in the experiment. 
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2.9 cAMP assay 
Clone 4 cells were washed once into salts solution and incubated as 1.0ml aliquots 
(0.9-2xl07 cells/ml) at 370c for 20-30 mins. The reaction was started by reagent 
addition and quenched by a 3s microfuge spin (13,000xg), rapid removal of the 
supernatant, cell pellet lysis with 100µ1 Milli Q water, and boiling for 5 mins. Samples 
were then frozen at -2ooc. 
The samples were assayed for cAMP by Dr. S.R.Pennington (Liverpool University) 
using a competitive binding assay, as described by Brown et al. (1971). 50µ1 of sample 
or cAMP standards (containing 0.031-16 pmol cAMP / 50µ1 in 50mM Tris-HCI, 4mM 
EDT A, pH7 .5) were incubated for 2 hours at ooc with 50µ1 of [3H]cAMP (34nCi) and 
100µ1 of cAMP binding protein (prepared by Dr. R. Farndale from bovine adrenal 
glands). A blank was created by incubating 150µ1 of buffer (50mM Tris-HCI, 4mM 
EDTA, pH 7.5) with 50µ1 of [3H]cAMP. 100µ1 of 40mg/ml charcoal/0.5mg/ml BSA 
suspension (in buffer) was added to each sample to absorb unbound cAMP, then samples 
were centrifuged (2 mins, 13,000xg, 4°C) to pellet the charcoal, and 200µ1 aliquots of 
supernatant were counted for 3H. A standard curve was constructed by plotting: 
cpm in standard tube - cpm in blank 
total cpm (34nCi) 
versus [ cAMP], and the cAMP content of samples was then calculated using the standard 
curve. 
2.10 c-~ mRNA assay 
Thymocytes were prepared in RPM! 1640 as described above, and incubated at lxl07 
cells/ml for 5h. Clone 4 cells were washed into RPMI 1640 containing HEPES, 
NaHC03, and penicillin/su·eptomycin, and incubated at 2-5 x106 cells/ml for lh. 
Reaction was started by ligand addition and terminated by rapid centrifugation (30s , 
1000g), and resuspension in 1ml of guanidinium isothiocyanate solution ( 4M GITC, 
25mM sodium citrate, lOOmM 2-mercaptoethanol, 0.5% N-lauroyl sarcosine, 0.1 % 
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antifoam, pH 7.0). RNA was prepared and analysed as previously described (Moore et 
al., 1988). 
2.10.1 RN A isolation 
RNA was isolated by centrifugation through CsCl using a method based on that of 
Chirgwin et al. (1979): Samples were mixed with 400mg CsCl and loaded onto a 
cushion of 1.2ml of 5.7M CsCl, lOOmM EDTA, pH 7.0 in polyallomer centrifuge tubes. 
RNA was pelletted by centrifugation (35,000xg, 12-16h), and the pellet resuspended in 
200µ1 of 5mM Na2EDTA, 1 % lithium dodecyl sulphate (LiDS), lOmM HEPES, pH 7 .0. 
Fats and proteins were extracted into an organic phase generated by addition of 100µ1 of 
chloroform/butan-1-ol (4: 1) and centrifugation (2 mins, 14,000xg). The upper phase 
was removed to a fresh tube, the lower phase washed with 100µ1 of EDT A / LiDS / 
HEPES solution, and washing and upper phase combined. 
RNA was precipitated by incubation at -700C for 30 mins with lfioth volume of 3M 
sodium acetate, pH 5.6, and 2.5 volumes of absolute alcohol, as described by Maniatis et 
al. (1982). RNA was pelleted by centrifugation (10 mins, 15,000xg, -10°C), vacuum 
dried, resuspended in 20 µl of sterile water, and quantitated by measuring A260· 107 
thymocytes typically yielded 4-5µg total RNA. 106 clone 4 cells typically yielded 2-3µg 
totalRNA. 
2.10.2 RNA fractionation 
RNA was fractionated by gel electrophoresis as described by Rave et al. (1979). Total 
cellular RNA was denatured by incubation for 15 mins at 580C in electrophoresis buffer 
(20mM MOPS, 5mM sodium acetate, lmM Na2EDTA, pH 6.8) supplemented with 6.6% 
formaldehyde and 50% de-ionised formamide, and fractionated on a 0.8% agarose / 7% 
formaldehyde gel. The loading of equal amounts of t9tal RNA in each lane was 
confirmed by ethidium bromide staining, and gels photographed on an ultraviolet 
transilluminator (254nm) after destaining in sterile water. 
2.10.3 Transfer of RNA to nitrocellulose membrane 
RNA was transferred from the gel to nitrocellulose membrane using a modified 
version of the protocol described by Thomas (1980). The gel was sandwiched between 
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buffer-saturated filter paper (extending into a buffer reservoir) and a sheet of 
nitrocellulose, covered by 30-40 sheets of filter paper and a 1 kilogram weight. Transfer 
was complete after 4h. The buffer used was 1.5M sodium chloride, 0.15M tri-sodium 
citrate, pH 7.0 (lOxSSC). RNA was fixed by baking in vacuo for 3h at 80°C. The 
location of 18S and 23S rRNA in the filters was determined by staining selected lanes 
with methylene blue dye (0.04% in 500mM sodium acetate, pH 6.0), at regular intervals 
to confirm band assignations. 
2.10.4 Hybridisation with c-JD.li. cDNA probe 
Purified c-myc cDNA (complementary to exons 2 and 3 of the mouse c-myc gene; 
Neuberger and Calabi, 1983) was labelled with [a-32P]dATP by nick translation (Rigby 
et al., .1977), and isolated from the reaction mixture by alcohol precipitation and 
resuspension in sterile water. 
[32P]-labelled c-myc probe was hybridised to nitrocellulose membranes using a 
protocol based on that of Wahl et al. (1979). Nitrocellulose membranes were soaked for 
2-3 mins in hybridisation solution (50% formamide, 10% dextran sulphate, 0.6M sodium 
chloride, 0.06M trisodium citrate, 20µg/ml sonicated herring sperm DNA and lx 
Denhardts reagent), then incubated at 42°C for 16-24h with denatured 32P-labelled c-myc 
probe (0.4-1.0x.107 dpm) in 10ml of hybridisation solution in a sealed plastic bag. 
Nitrocellulose membranes were washed twice for 30 mins in 500ml of 2x SSC, 0.1 % 
SDS at room temperature, twice for 30 mins in O.lxSSC, 0.05% SDS at 550c (Shank et 
al., 1978), then exposed to preflashed Kodak X-omat x-ray film for 1-14 days at -1ooc 
with a single intensifying screen. The intensities of the major bands were determined by 
scanning densitometry. 
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CHAPTER 3 
MITOGENIC STIMULATION OF T LYMPHOCYTES 
3.1 Mitogenic stimulation of clone 4 
3.1.1 Stimulation of clone 4 by interleukin 2 
Clone 4, a helper T cell clone, expresses antigen receptors directed against Ek antigen, 
and cultures were therefore stimulated with a combination of Ek..bearing cells and IL2 
(Tomonari, 1985; and see Fig. 2.1). Stable expression of IL2r enables clone 4 also to 
respond to IL2 alone (Fig. 3.la). IL2 was mitogenic at concentrations greater than 2 
U/ml with maximal [3H]thymidine incorporation at 50 U/ml IL2, and supobtimal 
responses at concentrations above 50 U/ml (e.g. 80% with 200 U/ml). IL2-stimulated 
clone 4 mitogenesis was inhibited by the anti-IL2 receptor (IL2r) antibody PC61-53. 
PC61-53 alone did not stimulate DNA synthesis, but was a potent antagonist of 
stimulation by 50 U/ml IL2 (Fig 3.lb). Ki was approximately equal to 0.35µg/ml, and 
12.5µg/ml PC61-53 caused greater than 98% inhibition. The ability of PC61-53 to 
antagonise IL2-stimulated mitogenesis despite its failure to stimulate mitogenesis suggests 
that PC61-53 does not recognise an activating epitope of the IL2 receptor, but either 
evokes responses antagonistic to those evoked by IL2, or more probably impairs binding 
of IL2 to IL2r, possibly by steric hindrance due to recognition of an overlapping epitope. 
The presumed ability of PC61-53 to inhibit productive interaction of IL2 with IL2r makes 
it a useful tool for establishing which mitogens operate via an IL2-IL2r interaction. The 
involvement of such an interaction in mitogenic stimulation through Thy 1 was examined, 
using the anti-Thy 1 antibody KT16. 
3.1.2 Stimulation of clone 4 by anti-Thy 1 antibody 
KT16 stimulated DNA synthesis maximally in clone 4 over a narrow concentration 
range between 100 and 200 ng/ml (Fig. 3.2a). Maximal KT16 responses were 10-20% 
of those with 50 U/ml IL2. 
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FIGURE 3.1 A. Mitogenic stimulation of clone 4 by IL2. Clone 4 cells were cultured with the indicated IL2 concentrations for 96h, and DNA synthesis assayed by [3H]thymidine incorporation as described in Section 2.4. B. Effect of anti-IL2r antibody on IL2-stimulated clone _4 proliferation. Clone 4 cells were cultured with 50U/ml and the indicated concentrations of anti-IL2r antibody PC61-53 for 96h and DNA synthesis measured as in a. The ordinate in this and all subsequent figures depicting DNA synthesis data shows cpm of [3H]thymidine incorporated. Each point is the mean(+/- standard deviation) of duplicate determinations. 
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FIGURE 3.2 A. Mitogenic stimulation of clone 4 by anti-Thy 1 antibody. 
Clone 4 cells were cultured with the indicated concentrations of anti-Thy 1 antibody KTl 6 
for 96h and DNA synthesis assayed as descibed in the legend to Fig. 3.1. 
B. Effect of anti IL2r antibody on KT16-stimulated clone 4 proliferation. Clone 4 cells 
were cultured with 125ng/ml KT16 and the indicated conc~ntrations of anti-IL2r antibody 
PC61-53 for 96h and DNA synthesis assayed. Each point is the mean (+/- standard 
deviation) of duplicate determinations. 
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Mitogenic stimulation of clone 4 by 150ng/ml KT16 was inhibited by PC61-53 (Fig. 
3.2b), suggesting IL2-IL2r interaction to be essential for mitogenic stimulation through 
Thy 1. KT16-mediated mitogenesis was inhibited by greater than 98% by O.lµg/ml 
PC61-53, compared with a Ki of 0.35µg/ml for inhibition of IL2-stimulated mitogenesis, 
possibly indicating that significantly less than 50U/ml IL2 was secreted by clone 4 in 
response to KT16 doses optimal for mitogenesis. In this context, it is interesting to note 
that KT16-stimulated clone 4 proliferation was inhibited by 50U/ml IL2 (see below). 
3.1.3 Responses to mitogen combinations 
KT16 and IL2 both activated DNA synthesis individually, but when combined were 
mutually antagonistic. Titration of KT16 against an optimal mitogenic IL2 concentration 
showed concentration dependent inhibition of IL2-stimulated mitogenesis by KT16 (Fig. 
3.3a). Combination of optimal concentrations of KT16 and IL2 stimulated virtually no 
DNA synthesis. Thus although IL2-IL2r interaction was essential for KT16 to stimulate 
proliferation, exogenous IL2 was antagonistic to KTl 6. This apparent paradox may be 
resolved by postulating that optimal KT16 concentrations stimulate secretion of less than 
SOU/ml IL2 (as suggested above). Furthermore, since supraoptimal KT16 concentrations 
presumably stimulate sufficient IL2 production to antagonise stimulation through Thy 1, 
IL2-KT16 antagonism may explain the narrow concentration range over which KT16 is 
mitogenic. 
IL2-activated DNA synthesis in clone 4 was also antagonised by the polyvalent lectin 
Con A (Fig. 3.3b), although Con A was not mitogenic alone. The failure of Con A to 
stimulate clone 4 proliferation may reflect its inability to elicit IL2 secretion from clone 4, 
or conversely may indicate that Con A induces secretion of antagonistic concentrations of 
Il...2. 
The anti-T3 antibody 145-2Cl 1 was also ineffective as a mitogen for clone 4. This 
result is surprising because 145-2Cl 1 is a potent mitogen for purified T3-T/ T cells (Leo 
et al., 1987b) and clone 4 expresses T3-Ti. 
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FIGURE 3.3 Inhibition of IL2-stimulated clone 4 proliferation by KTl 6 and Con A. Clone 4 cells were cultured with 50U/ml IL2 and the indicated concentrations of KTl 6 (A) or Con A (B) for 96h. DNA synthesis was assayed as described in the legend to Fig. 3.1. Each point is the mean (+ /- standard deviation) of dupli~ate determinations. 
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However, the failure of 145-2Cll as a mitogen for clone 4 may reflect the absence of 
agents capable of cross-linking 145-2Cl 1 on the surface of clone 4, since ligand cross-
linking appears to be an important component of the T3-Ti-mediated mitogenic signal (see 
Section 1.2.3). Cross-linking could be achieved by interaction of the Fe portion of 
145-2Cl 1 with Fe receptors on the surface of accessory cells (as used by Leo et al., 
1987b ), or on the T cell surface. Therefore these results suggest that clone 4 lacks an Fe 
receptor specific for hamster IgM. Alternatively, 145-2Cl 1 may simply stimulate 
secretion of either insufficient or antagonistic amounts of IL2 from clone 4. 
3.2 Mitogenic stimulation of BALB/c thymocytes 
3.2.1 Stimulation of thymocytes by Con A 
In contrast to clone 4, only a very small proportion of thymocytes derived from 
BALB/c mice can respond to a single antigen since each individual thymocyte expresses a 
unique Ti. However, BALB/c thymocytes were mitogenically stimulated by Con A (Fig 
3.4a), presumably due to interaction with T3, or non-polymorphic determinants of Ti (see 
Section 1.2.2). Maximal incorporation was stimulated by 0.75-1.0µg/ml Con A. 
Supraoptimal concentrations evoked diminished responses, and no incorporation was 
stimulated by concentrations greater than 2.5µg/ml. IL2 synergised with 0.8µg/ml Con 
A, with maximal stimulation at 20U/ml IL2 (Fig. 3.4b), but was ineffective alone, 
presumably due to the virtual absence of IL2r from resting thymocytes. IL2 increased 
maximum Con A-induced [3H]thymidine incorporation 2-3 fold. 
The phorbol ester 12-0-tetradecanoyl phorbol 13-acetate (TPA), like IL2, synergised 
with Con A, but was ineffective alone. lOnM TPA increased maximum incorporation 4-
fold, and shifted the optimum Con A concentration to 0.5µg/ml (Fig. 3.4a). Although 
both TPA and IL2 singly were ineffective, together they stimulated [3H]thymidine 
incorporation into BALB/c thymocytes (data not shown). This suggests that protein 
kinase C activation may . be sufficient to stimulate IL2r expression, as TPA activates 
protein kinase C (Castagna et al. , 1982). 
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FIGURE 3.4 Mitogenic stimulation of BALB/c thymocytes by Con A. 
A. Thymocytes w~re cultured with the indicated Con A concentrations plus medium (.A), 
20U/ml IL2 (•) or lOnM TPA (D) for 48h, and DNA synthesis assayed as described in 
Section 2.4. Each point is the mean of duplicate determinations. Standard deviations are 
omitted for the sake of clarity. 
B. Thymocytes were cultured with 0.8µg/ml Con A plus the indicated IL2 concentrations 
for 48h, and DNA synthesis assayed. Each point is a single determination. 
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However, as resting thymocytes may express a low level of IL2r (Jenkinson et al., 
1987), IL2-IL2r interaction may also have positive feedback effects on IL2r expression. 
3.2.2 Stimulation of thymocytes by anti-Thy 1 and anti-T3 antibodies 
Thymocyte DNA synthesis was also stimulated by anti-Thy 1 antibody, KT16, and 
anti-T3 antibody, 145.;2Cll (Fig. 3.5a&b respectively). Both antibodies were only 
weakly mitogenic alone. KT16 and 145-2Cl 1 stimulated 29% and 23% respectively of 
the incorporation stimulated by 0.8µg/ml Con A. However the potencies of both KT16 
and 145-2Cl 1 were enhanced 3-4 fold by IL2 (20U/ml) suggesting that the low potencies 
of the antibodies alone relative to Con A were due to their inability to stimulate significant 
IL2 production. Since, TP A also enhanced Thy 1- and T3-induced thymocyte 
proliferation (TPA increased KT16 and 145-2Cll stimulation 7-8 fold and 12 fold 
respectively), these data reinforce the idea that activation of protein kinase C is required 
for stimulated IL2 secretion, and suggest that neither KT16 nor 145-2Cl 1 stimulate 
appreciable protein kinase C activation in BALB/c thymocytes (however see Section 
3.2.3). 
The relationship between [3H]thymidine incorporation (as a percentage of maximal 
stimulation) and KT16 concentration was similar in cells co-stimulated with KT16 plus 
either TPA or IL2. Proliferation increased sharply between 3 and 6 µg/ml KT16, was 
maximal by 12µg/ml, and did not significantly decrease at concentrations up to 200µg/ml 
(Fig. 3.5a; and additional experiments). This concentration dependence profile differed 
from that seen with Con A since [3H]thymidine incorporation declined at supraoptimal 
Con A concentrations. The profile of 145-2Cll concentration dependence was more 
similar to that seen with Con A. Maximum [3H]thymidine incorporation was stimulated 
by 145-2Cl 1 concentrations between 1 and 25 µg/ml. C~ncentrations below 0.2µg/ml 
and above lOOµg/ml stimulated less than 8% of maximal incorporation. 
The profiles exhibited by Con A and 145-2Cl 1 demonstrate inhibition of mitogenesis 
by supramitogenic concentrations of these ligands. High ligand concentrations may cause 
increased receptor modulation (e.g. capping), resulting in signals of insufficient duration 
to activate DNA synthesis. 
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FIGURE 3.5 Mitogenic stimulation of BALB/c thymocytes by KTl 6 and 145-2Cl 1. 
Thymocytes were stimulated with the indicated concentrations of KT16 (A) or 145-2Cl 1 (B) plus medium(~), 20U/ml IL2 (a) or lOnM TPA (D), and DNA synthesis assayed as 
described in Section 4.2. Each point is a single determination. Similar results were 
obtained in several experiments. 
87 
In support of this, Pozzan et al. (1981) demonstrated that addition of anti-Con A antibody 
to Con A-challenged cells accelerated the rate of Con A capping and reduced mitogenic 
stimulation. The failure of high KT16 concentrations to inhibit thymocyte DNA synthesis 
correlates with a slow capping rate of Thy 1 relative to Con A receptor(s) (Corps et al., 
1982), although it should be noted that the capping studies were performed with a 
different anti-Thy 1 antibody, and may therefore not be comparable to the data described 
herein. However, lack of inhibition of proliferation by supramitogenic KT16 
concentrations could be a function of slow Thy 1 capping. 
The results for thymocytes contrast strongly with the situation in clone 4 where 
mitogenesis was strongly inhibited by supraoptimal KT16 concentrations. However, this 
difference may be explained on the basis of differing IL2r expression, as resting 
thymocytes express only very low levels or no IL2r, they are likely to be less susceptible 
to IL2-mediated inhibition. 
3.2.3 IL2-IL2r interactions in thymocyte mitogenesis 
The ability of TPA to enhance the mitogenicity of anti-Thy 1 and anti-T3 antibodies 
may reflect increased expression of IL2r stimulated by TP A (see above; Shackelford and 
Trowbridge, 1984; McCrady et al., 1988). If so, TPA must also have synergised with 
the antibodies to produce IL2, since the antibodies alone apparently stimulated little IL2 
production (i.e. the antibodies were weak mitogens in the absence of exogenous IL2). 
Alternatively, TPA in combination with the antibodies might have stimulated mitogenesis 
via an IL2-IL2r independent pathway. This possibility was examined using the anti-IL2r 
antibody PC61-53. 
Proliferation induced by Con A alone, or by KT16 plus TPA, was inhibited by greater 
than 80% at PC61-53 concentrations above 0.8µg/ml, but concentrations of PC61-53 up 
to 200µg/ml caused less than 60% inhibition of the stimulation evoked by Con A and 
TPA (Fig. 3.6). 0.8µg/ml PC61-53 only inhibited TPA plus 145-2Cl 1 mediated 
stimulation by approx. 50%, and 90% inhibition only occurred at PC61-53 concentrations 
above 50µg/ml . 
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FIGURE 3.6 Inhibition of thymocyte proliferation by anti-IL2r antibody. Thymocytes were cultured with the indicated concentrations of PC61-53 plus the 
following stimulatory ligand combinations: 0.8µg/ml Con A(•), 0.8µg/ml Con A+ 
lOnM TPA (.A), 20µg/ml KT16 + lOnM TPA (.6.) or 10µg/ml 145-2Cll + lOnM TPA (D), 
then assayed for DNA synthesis as described in Section 2.4. Results are expressed as a percentage of stimulation by these ligands in the absence of PC61-53. 
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Thus, TP A synergised with Con A or 145-2Cl 1 to stimulate thymocytes by a pathway 
with reduced sensitivity to PC61-53 compared with the pathway stimulated by Con A 
alone. These data suggest that TPA in synergism with Con A (or 145-2Cll) either 
stimulated proliferation via an IL2-independent pathway or amplified IL2r expression to a 
level at which PC61-53 could only partially block IL2-IL2r interaction. If this latter were 
true, increased amounts of PC61-53 should be effective at antagonising proliferation. 
Since this was not true for proliferation evoked by Con A plus TP A, it is most likely that 
this ligand combination stimulated proliferation via an IL2-independent pathway. 
Consistent with this, Kim et al. (1986) have demonstrated PC61-53-insensitive, TPA-
stimulated proliferation of a cytolytic T cell clone. If TPA does stimulate proliferation via 
a pathway other than IL2-IL2r interaction, then protein kinase C activation may not be 
sufficient to stimulate IL2 expression. In turn, this suggests that the failure of KT16 and 
145-2Cl 1 to stimulate IL2 secretion from thymocytes might not be due to an inability to 
activate protein kinase C, but rather a failure to induce some other required response, 
possibly activation of the lymphocyte-specific tyrosine kinase pp56lck (see below). 
3.2.4 Identity of the Con A receptor(s) 
Con A has been demonstrated to interact with a variety of cell surface glycoproteins 
including the T3 complex (see Section 1.2.2). Consistent with its ability to bind to T3, 
several similarities were observed between the effects of 145-2Cll (anti-TI antibody) and 
Con A, suggesting that at least some of the responses to Con A might be mediated via its 
interaction with T3 (although see Section 4.3.2). Co-incidence of the effects of Con A 
and 145-2Cl 1 was highlighted by comparison with the effects of the anti-Thy 1 antibody 
KT1 6. Contrasting effects were as follows: 
i Supraoptimal concentrations of Con A and 145-2Cl 1, but not KT16, inhibited 
mitogenesis, implying that supraoptimal Con A and 145-2Cl 1 concentrations caused 
rapid modulation of a surface receptor (e.g. by rapid capping) or generated responses 
antagonistic to DNA synthesis. 
ii Proliferation stimulated by synergistic combinations of either Con A or 145-2Cl 1 (but 
not KT16) with TPA was less inhibited by PC61-53 than that stimulated by Con A alone. 
I 
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iii While KT16 produced large sausage-like blasts (Fig. 3.7), Con A and 145-2Cll both 
caused formation of small round blasts, suggesting that both Con A and 145-2Cl 1 
recognise receptors of similar cell surface distribution and mobility. 
The possibility that T3 mediates the responses to Con A was further examined by 
assaying proliferation stimulated by ligand combinations. This technique was particularly 
useful since both KT16 and 145-2Cl 1 were only weakly mitogenic in the absence of IL2 
or TPA, and their effect on Con A-stimulated mitogenesis could therefore be evaluated. 
KT16 slightly enhanced activation of DNA synthesis by Con A or 145-2Cl l, but 145-
2Cll inhibited Con A-stimulated proliferation (Fig. 3.8). 145-2Cl 1 and Con A were 
present at roughly equal molar concentrations (1 lµM and 8µM respectively), resulting in 
an approximate 2 fold excess of 145-2Cl 1 binding moieties since Con A is tetrameric but 
IgM molecules are pentameric associations of subunits which are themselves dimers 
(11.2µ2). 145-2Cl 1-mediated inhibition of Con A could therefore reflect competition for 
an identical binding site, if the affinities of the binding site for the two ligands were 
similar. Alternatively, 145-2C 11-mediated cross-linking of T3 might result in more rapid 
capping of the Con A receptor, and thus cause an abbreviated response similar to that seen 
with supraoptimal concentrations of either of the ligands individually. 
Thus these data are consistent with the suggestion that Con A may interact with T3, 
but further evidence would be necessary to substantiate this hypothesis. In apparent 
contradiction, the ability of Con A to stimulate considerable proliferation in the absence of 
IL2 or TP A argues that Con A cannot be operating via T3, since anti-T3 is a weak 
mitogen in the absence of IL2 or TP A. The most probable explanation is that Con A is 
effective due to interactions both with T3 and with additional cell-surface glycoproteins, 
the latter not necessarily located on T3-bearing cells, but possibly on co-operating 
accessory cells. These additional interactions may stimulate secretion of potentiating 
lymphokines, such as interleukin 1 (see Section 1.2.3), from accessory cells. 
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IGURE 3. 7 Light micrographs of ligand-stimulated 
ALB/c thymocytes. BALB/c thymocytes were 
ultured for 48h. with the following ligands: 
ontrol (no addition), Con A (0.8µg/ml), KT 16 (20JJglml) 
and 145-2C 11 C 1 Oµg/ml) as described in Section 2.4. 1: 
then photographs were taken as described in Section 2.5. 
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FIGURE 3.8 Ability of ligand combinations to stimulate BALB/c thymocytes. Thymocytes were assayed for DNA synthesis (Section 2.4) after 48h incubation with the 
following ligands; medium (A), 0.8µg/ml Con A (B), 20µg/ml KT16 (C), lOµg/ml 145-2Cll (D), Con A + 145-2Cll (E), Con A + KT16 (F), 145-2Cll + KT16 (G). Results shown are the means (+/- standard deviation) of triplicate determinations. 
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3.3 Effect of anti-CD4 antibody on T cell proliferation 
The ability of the CD4 molecule to inhibit T cell proliferation was investigated using 
the anti-CD4 antibody KT6. KT6 alone stimulated no DNA synthesis in BALB/c 
thymocytes or clone 4, but was a potent antagonist of KTl 6-stimulated clone 4 
proliferation (50% at 6 ng/ml and 95% at concentrations above 20 ng/ml; Fig. 3.9a). In 
contrast, KT6 concentrations up to 2.5µg/ml had no effect on IL2-stimulated DNA 
synthesis in clone 4 (Fig. 3.9b), suggesting that IL2 and KT16 activated DNA synthesis 
in clone 4 by different mechanisms. Consistent with this, IL2 and KT16 evoked different 
patterns of early responses in clone 4 (see Chapter 4). 
The effect of KT6 on thymocyte proliferation was also examined (Fig. 3.10). KT6 
concentrations up to 20µg/ml had no effect on thymocyte mitogenesis stimulated by KT16 
plus TPA, and modulated Con A stimulation by less than +/-20%. The failure of KT6 to 
significantly inhibit thymocyte proliferation may have several explanations. Con A and 
KT16 may stimulate predominantly CD4- thymocytes, and thus anti-CD4 would be 
ineffective. However this seems unlikely as 80-90% of thymocytes are CD4+ (Scollay et 
al., 1984). Alternatively, CD4 may be in a different functional state in immature cells 
(thymocytes) compared with mature, peripheral cells or T cell clones. This possibility is 
consistent with the observation that treatment of murine thymocytes, but not mature 
peripheral T cells, with the phorbol ester TP A results in a rapid disappearance of CD4 
molecules from the surface of thymocytes, which persists for at least 72h (Wang et al., 
1987). Since CD4+ peripheral cells predominantly fail to express murine CDS, but 
murine thymocytes are 70-80% CD4+cns+ (Scollay et al., 1984), this difference in 
functional state may depend on the presence/absence of co-expressed CDS. Consistent 
with this, Blue et al. (1988) have reported potent inhibition of T3-induced [Ca2+]i 
increases in a CD4+cns- clone by an anti-CD4 antibody incapable of abrogating similar 
responses in a cn4+cng+ clone. 
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FIGURE 3.9 Effect of anti-CD4 antibody on clone 4 proliferation. 
Clone 4 cells were cultured with the indicated concentrations of KT6 plus 50ng/ml KTl 6 (A) or 50U/ml IL2 (B) for 96h, and DNA synthesis was assayed as described in Section 
2.4. Each point is the mean (+/- standard deviation) of triplicate (A) or duplicate (B) determinations. The data in A were generated by Dr. K. Tomonari and are included with his permission. 
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FIGURE 3.10 Effect of anti-CD4 antibody on BALB/c thymocyte proliferation. 
Thymocytes were cultured with the indicated concentrations of KT6 plus 0.8µg/ml Con A 
(A) or 20µg/ml KTi6 and lOnM TPA (B), and DNA synthesis assayed (Section 2.4). 
Each point is the mean(+/- standard deviation) of duplicate determinations. 
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A third highly speculative explanation hinges on the differential expression of class II 
MHC molecules on immature and partially activated T cells. MHC class II proteins are 
expressed on activated T cells and most T cell clones (which are considered to be partially 
activated since they express IL2r), but not on quiescent, immature cells such as primary 
thymocytes. Class II proteins probably interact with CD4 (Section 1.2.5) and interaction 
of these molecules on adjacent T cells (or between T cells and B lymphocytes or 
macrophages) may result in activation of the CD4-associated tyrosine kinase pp56kk, 
which may be involved in T cell mitogenesis (Section 1.5.3). Anti-CD4 antibody may 
destabilise/prohibit this interaction, thereby abrogating ligand-stimulated proliferation of 
mature T cells. However since quiescent thymocytes do not express class II molecules, 
such intercellular interaction cannot occur and thymocytes are therefore not sensitive to 
inhibition via CD4. Non-specific ligands such as Con A could activate pp56kk by co-
cross-linking CD4 with other molecules, and would therefore be free from a requirement 
for class II-bearing cells, and less sensitive to inhibition by anti-CD4. However, specific 
ligands such as KT16 would require class II:CD4 interaction, and thus KT16 would be 
mitogenic for activated but not immature, quiescent cells. This provides an elegant 
though highly speculative explanation for the failure of KT16 to stimulate appreciable 
thymocyte proliferation in the absence of exogenous IL2, and further suggests that 
tyrosine kinase activation may be a necessary precursor of IL2 secretion. This is also 
suggested by the recent demonstration that anti-Thy 1 antibody (07) can stimulate IL2 
secretion from a mutant T cell hybridoma in the absence of increases in [Ca2+]i or inositol 
phosphates (Sussman et al, 1988b). 
3,4 Summary 
The mitogenic responses to a panel of ligands have been characterised and compared in 
two murine T cell populations, a mature monoclonal helper T cell line, clone 4, and an 
immature heterogeneous T.cell preparation derived from BALB/c thymi. Both cell types 
have been challenged with four ligands; Con A, anti-Thy 1 antibody (KT16), anti-T3 
antibody (145-2Cl 1), and IL2. 
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Con A was a potent mitogen for BALB/c thymocytes. In comparison, KT16 and 145-
2Cll were weak mitogens but both synergised with IL2, suggesting stimulation of IL2 
secretion to be their main deficiency. In turn this suggested that both antibodies require 
an IL2-IL2r interaction to activate DNA synthesis. This was confirmed by the ability of 
anti-IL2r antibody PC61-53 to inhibit mitogenesis stimulated by either KT16 or 145-
2Cll in conjunction with TPA, or by Con A alone. However IL2 alone was not 
mitogenic for thymocytes presumably since the majority of resting thymocytes do not 
express IL2r. 
Several pieces of data, notably the inhibition by anti-TI antibody of Con A-stimulated 
DNA synthesis, suggested that the effects of Con A might be due to its interaction with 
the T3-Ti complex. However, since Con A was a potent mitogen in the absence of 
exogenous IL2 (cf 145-2Cll) it must be assumed to also interact with additional 
receptors, possibly on accessory cells, to augment IL2 production. 
Anti-CD4 antibody (KT6) had no effect on thymocyte proliferation stimulated by 
KT16 plus TPA, and little effect on the response to Con A. Since this antibody did 
inhibit KT16-induced clone 4 proliferation (see below), the CD4 molecule may exist in 
different functional states in the two cell populations, or may interact with different 
proteins on the surface of thymocytes or clone 4. 
The mature T cell, clone 4, was mitogenically stimulated by IL2 and KT16. These 
mitogens apparently worked via different mechanisms since proliferation induced by 
KT16 but not IL2 was sensitive to inhibition by anti-CD4 antibody. Furthermore optimal 
mitogenic concentrations of IL2 and KT16 were mutually antagonistic implying that they 
may generate distinct, mutually antagonistic responses. Despite this, KT16 required an 
IL2-IL2r interaction to activate DNA synthesis, as adjudged by the sensitivity of KT16-
stimulated proliferation to PC61-53. However, these data are not inconsistent since 
optimal mitogenic KT16 concentrations may generate insufficient IL2 to antagonise DNA 
synthesis. 
IL2-induced DNA synthesis was also inhibited by Con A, but neither Con A nor 145-
2Cl 1 were mitogenic for clone 4. The failure of Con A to stimulate clone 4 is consistent 
I 
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with the idea that Con A stimulates thymocyte mitogenesis via interaction with both T 
cells and accessory cells since no accessory cells are present in assays of clone 4 
proliferation. Equally however the apparent failure of Con A to stimulate clone 4 could be 
a consequence of IL2 over-production. 
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CHAPTER 4 
MITOGEN-STIMULATED INCREASES IN INOSITOL PHOSPHATES, 
[Ca2+Ji AND C·ID.li. mRNA IN T LYMPHOCYTES 
4.1 Con A-stimulated increases in inositol phosphates and [Ca2+]i in 
BALB/c thymocytes 
4.1.1 Assays of inositol phosphates 
Early studies of ligand-stimulated phosphoinositide metabolism characterised changes 
in lipid labelling rather than increases in inositol phosphates. Hokin and Hokin (1953) 
observed incorporation of [32P]phosphate into lipid on stimulation of pigeon pancreas 
slices with acetylcholine (ACh) and subsequently identified phosphatidylinositol as the 
lipid into which [32P]phosphate was incorporated (1964). This facilitated analysis since 
phosphoinositides could be specifically labelled with [3H]inositol prior to reaction, and 
products of phosphodiesteratic cleavage easily quantitated. Durell et al. (1968) 
demonstrated ACh-stimulated release of [3H]inositol phosphates from [3H]inositol-
labelled guinea pig brains. Inositol phosphates thus generated were crudely separated into 
inositol monophosphate, diphosphate and triphosphate peaks by high voltage paper 
electrophoresis, and quantitated by scanning. A more convenient separation protocol 
employing sequential elution from a Dowex anion exchange column was devised by 
Berridge et al. (1983). This separation protocol resulted in three fractions; inositol 
mono-, bis-, and _ tris-phosphate. Using this protocol, Taylor et al. (1984) analysed 
[3H]inositol phosphates extracted from Con A-stimulated BALB/c thymocytes. Inositol 
trisphosphate increased rapidly between O and 4 mins in .response to lµg/ml Con A, but 
then remained approx. constant for a further 10 mins. Total inositol phosphates increased 
rapidly from Oto 7 mins, more slowly between 7 and 10 mins, and remained constant 
between 10 and 14 mins. 
Subsequent to the characterisation of inositol phosphate production in Con A-
stimulated thymocytes, several novel inositol phosphates were identified including a 
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second InsP3 isomer Ins(l,3,4)P3 (Irvine et al., 1984, 1985), InsP4 (Batty et al., 1985), 
InsP5 and InsP6 (Heslop et al., 1985) (see Section 1.4.3). All of these novel inositol 
phosphates were initially separated by anion-exchange HPLC, by elution from a Partisil 
10 SAX column with a continuous formate gradient (pH adjusted to 3. 7 with 
orthophosphoric acid). However, Downes et al. (1986) subsequently designed a non-
HPLC separation of InsP4 from the InsP3 isomers using Biorad AG1-X8 anion exchange 
resin. A similar method devised by Wreggett and Irvine (1987) which employed Waters 
QMA SEP-PAKS is no longer utilisable since manufacture of the resin has ceased. 
An analysis of inositol phosphate extracts from BALB/c thymocytes was undertaken 
using anion-exchange HPLC to establish which of these novel inositol phosphates are 
present in resting and Con A-stimulated cells. After completion of this work, Stewart et 
al. (1986, 1987) reported the presence of InsP4 and InsP5 in [3H]inositol-labelled 
Jurkats, but no detailed time course data for inositol polyphosphate production in T cells 
comparable to the data presented here has been published, excepting an account of this 
work (Zilberman et al., 1987). 
4.1.2 The effect of Con A on inositol polyphosphates 
Thymocytes pre-labelled with [3H]inositol were incubated with lOµg/ml Con A, the 
optimal concentration for inositol phosphate accumulation (J.P.Moore, personal 
communication); extracted inositol phosphates were then assayed by HPLC. Quiescent 
thymocytes contained at least 5 fold more InsP5 than the combined amounts of InsP3 and 
InsP4, but no InsP6 could be detected (Fig. 4.1, and see Table 2.4). InsP5 did not vary 
by more than 10% after addition of Con A. These data suggest InsP5 may have no 
signalling function in thymocyte stimulation by Con A, but do not exclude the possibility 
of small, transient changes in InsP5 within 30s of Con A additi?n. 
The accumulation of InsP3 isomers and InsP4 is also shown. InsP4 increased rapidly 
for 2 mins, declined between 2 and 5 mins, then ipcreased slowly up to 20 mins. 
Ins( l,3,4)P3 rose rapidly between 1 and 2 mins, then accumulated monotonically, 
reaching -30% of InsP 4 at 20 mins. Ins(l ,4,5)P3 accumulation was transient, peaking 1 
min after Con A addition and declining to near basal within 5 minutes. 
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FIGURE 4.1 Time course of inositol polyphosphate production in Con A-stimulated 
thymocytes. 
BALB/c thymocyies were labelled with [3H]inositol (Section 2.7.1) and challenged with 
lOµg/ml Con A as described in Section 2.7.2. Reactions were quenched at the times 
indicated, and inositol phosphates extracted (Section 2.7.3), separated by anion-exchange 
HPLC (Section 2.7.Sa), and quantitated by liquid scintillation counting (Section 2.8). A 
and B show lOmin and 1 min time courses respectively. Amounts of inositol phosphates 
are expressed as a percentage of the total dpm in [3H]inositol-containing lipids in this and 
subsequent figures showing data from HPLC experiments. Each point is the mean of 
duplicate determinations in this and all subsequent HPLC experiments, but standard 
deviations are omitted for clarity. Symbols: D, Ins(l,4,5)P3; •, Ins(l,3,4)P3; •. InsP4; 
0, InsP5. 
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The increases in amounts of these inositol phosphates 1 min after stimulation were in 
the order InsP4 > Ins(l,4,5)P3 > Ins(l,3,4)P3, but it was not possible to distinguish the 
times at which the increases could be detected above background. All showed an initial 
detectable increase at 20s (Fig. 4.lb) consistent with the lag of -15s in the [Ca2+]i 
response to Con A in these cells (Hesketh et al., 1983b,1985), and no increases were 
detectable within 10s (data not shown). Therefore no substrate-product relationships 
could be inferred from the initial time courses, but the data were not inconsistent, subject 
to certain conditions (see below), with the interconversion scheme suggested by Irvine et 
al. (1986a); Ins(l,4,5)P3 --> InsP4 --> Ins(l,3,4)P3. 
Since TPA enhanced DNA synthesis activation by 0.8µg/ml Con A (Section 3.2.1), 
the effect on Con A-stimulated inositol phosphate accumulation of 10 min pre-incubation 
with lOnM TPA was determined (Fig. 4.2). The pattern of responses generated by the 
optimal mitogenic concentration of Con A (0.8µg/ml) was qualitatively similar to that seen 
with lOµg/ml Con A (Fig. 4.2a), but the Ins(l,4,5)P3 maximum occurred at 2 mins 
rather than 1 min and the amount of Ins(l,4,5)P3 only declined to -50% of maximum by 
5 mins. However, the approx. 2 fold reduction rendered the responses too small for 
accurate routine detection by HPLC. Therefore subsequent experiments were performed 
with 1 Oµg/ml Con A. 
TPApre-treatment slightly inhibited InsP4 production, but neither InsP3 isomer was 
significantly affected. Since InsP 4 was probably generated by Ins( l ,4,5)P3 
phosphorylation, TPA-mediated InsP4 reduction might have been due to preferential 
dephosphorylati?n of Ins(l,4,5)P3 in the presence of TPA. This would be consistent 
with data from the platelet system suggesting that Ins(l,4,5)P3 5'-phosphomonoesterase 
is stimulated by protein kinase C (Connolly et al., 1986a; Molina y Vedia and Lapetina, 
1986). 
The effect of TPA on Con A-stimulated InsP3 and InsP4 accumulation described here 
is inconsistent with the data of Taylor et al. (1984), who found that TPA increased counts 
in the Con A-stimulated "InsP3" fraction eluted from Dowex resin which consists of both 
InsP3 isomers and a substantial proportion of the InsP 4. 
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FIGURE 4.2 Effect of TP A on Con A-stimulated inositol phosphate accumulation. 
[3H]inositol-labelled thymocytes were challenged with 0.8µg/ml Con A after 10 mins pre-
incubation with medium (A) or lOnM TPA (B). Inositol phosphates were assayed as 
described in the legend to Fig. 4.1. Symbols: D, lns(l,4,5)P3; .&.,lns(l,3,4)P3; 
•: InsP4. 
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The experiments are not directly comparable since Taylor et al. pre-incubated cells with 
5mM Li+ to inhibit inositol-1-phosphate phosphomonoesterase and thereby maximise 
inositol phosphate accumulation (Berridge et al., 1982), but Li+ was omitted from the 
experiments described here to avoid peturbations of inositol phosphate interconversions. 
In addition, there may be disparities due to the different separation methods employed. 
Therefore cells were pre-incubated with or without Li+, challenged with Con A plus or 
minus TPA pre-treatment, and inositol phosphates separated on Dowex resin. No 
significant effect of TP A pre-treatment on any inositol phosphate fraction was observed, 
irrespective of whether cells were pre-incubated with u+ (data not shown). Thus the 
reason for the inconsistency between the data presented here and those of Taylor et al. is 
unclear. However, an inhibitory effect of TPA on ligand-stimulated inositol phosphate 
accumulation has been observed in a variety of systems other than T cells, including 
platelets (Tohmatsu et al., 1986). B cells (Bijsterbosch and Klaus, 1987; Hamett and 
Klaus, 1988), fibroblasts (Jamieson Jr. and Villereal, 1985; Brown et al., 1987) and 
vascular smooth muscle cells (Brock et al., 1985; Takata et al., 1988), implying that 
activated protein kinase C may have a role in negative feedback. 
4.1.3. The effect of [Ca2+]i on InsP3 kinase 
The time course data described above were not incompatible with the proposed 
interconversion scheme; Ins(l,4,5)P3 --> InsP4 --> Ins(l,3,4)P3, provided that the initial 
rate of Ins(l,4,5)P3 phosphorylation to InsP4 was greater than the rate of Ins(l,4,5)P3 
generation (necessary to explain the more rapid accumulation of InsP4 relative to 
Ins(l,4,5)P3). Fµrther, the observed transience of Ins(l,4,5)P3 accumulation suggested 
that Ins(l,4,5)P3 conversion to InsP4 (or possibly to InsP2) might be accelerated by a 
component of the Con A response. An alternative explanation for the observed 
Ins(l ,4,5)P3 transience might be that PtdlnsP2 hydrolysis was transient. However, this 
seemed unlikely since displacement of Con A from the cell surface with a-methyl 
mannoside resulted in rapid decreases in the InsP3 + InsP 4 pool at a rate similar to the 
initial rate of InsP3 + InsP 4 production, implying that Con A:receptor interaction 
generated continuous Ins(l ,4,5)P3 production (Zilberman et al., 1987). Therefore it 
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seemed more likely that lns(l,4,5)P3 metabolism was accelerated by some Con A-evoked 
event. Con A-induced [Ca2+]i elevation appeared to be a prime candidate, as [Ca2+]i was 
significantly elevated before onset of the decline in Ins(l,4,5)P3 (Fig. 4.3). 
The maximum rate of increase of [Ca2+]i stimulated by lOµg/ml Con A occurred 
between 1 and 2 mins after Con A addition, thus coinciding with the onset of 
Ins(l,4,5)P3 decline. Correspondingly, the later Ins(l,4,5)P3 peak in thymocytes 
stimulated with 0.8µg/ml Con A correlated with a slower rate of increase of [Ca2+]i (Fig. 
4.3b). 
These correlations suggested that changes in [Ca2+]i might regulate conversion of 
Ins(l,4,5)P3 to InsP4. This possibility was examined by manipulating [Ca2+]i by 
modulation of [Ca2+]o. When [Ca2+]0 was reduced to O.lµM by addition of lmM 
EGT A, [Ca2+ ]i increased only transiently in response to Con A and returned to near-basal 
level within 5 minutes (Fig. 4.3a). Thus extracellular EGTA reduced the absolute 
magnitude and abolished the persistent component of the [Ca2+]i response. Con A 
inositol phosphate responses were assayed in cells from the same [3H]inositol-labelled 
cell preparation in normal and low free Ca2+ (i.e. EGTA-containing) medium to assess 
the effect of [Ca2+]i on the Ins(l,4,5)P3 response (Fig. 4.4). In the presence of 
extracellular EGTA, Ins(l,4,5)P3 remained elevated up to 5 mins, instead of declining 
back to basal as in control cells, and the profile of InsP 4 accumulation was very similar to 
that of Ins(l,4,5)P3 accumulation. Ins(l,3,4)P3 accumulation at 5 mins was reduced by 
greater than 50%. The total amount of InsP3 + InsP4 was reduced by -40% compared 
with control cell~ at 5 mins, suggesting that receptor coupling to Ins(l,4,5)P3 formation 
might be modulated by extracellular calcium. (Fig. 4.4c) However, such modulation 
was only minor; total accumulation of inositol phosphates (which approximates to total 
PtdlnsP2 hydrolysis in the presence of Li+) was reduced only 15-20% by EGTA 
pretreatment. 
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FIGURE 4.3 Effect of Con A on [Ca2+]i in thymocytes Quin 2-loaded thymocytes prepared as described in Section 2.6.1 were challenged with 
lOµg/ml Con A (A) or 0.8µg/ml Con A (B) in medium containing 0.43mM free Ca2+ (•) 
or O.lµM free Ca2+ (D). Con A was added at time 0. Fluorescence intensity (FI) was 
measured continuously and FI values at minute intervals converted to [Ca2+]i as described 
in Section 2.6.3. Data for all [Ca2+]i measurement experiments are means of duplicate determinations unless otherwise stated. Standard deviations are not shown, but were 
usually less than 10% of the mean. 
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FIGURE 4.4 Effect of extracellular Ca2+ concentration on Con A-stimulated inositol phosphate accumulation 
[3H]inositol-labelled thymocytes were challenged with lOµg/ml Con A in medium 
containing 0.43mM free Ca2+ (A) or O.lµM free Ca2+ (B), reactions quenched at the 
times indicated, and inositol phosphates assayed as described in the legend to Fig. 4.1. Symbols: D, Ins(l,4,5)P3; •, Ins(l,3,4)P3; •, InsP4. 
C. Total InsP3+InsP4 accumulation in medium containing 0.43mM free Ca2+ (+) or 
O.lµM free Ca2+ (O). Subsequent experiments were performed in medium containing 
0.43mM free Ca2+ unless otherwise stated. 
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The increase in Ins(l,4,5)P3 accumulation and corresponding decrease in InsP4 
accumulation observed in EGTA-treated compared with control cells strongly suggested 
the conversion of Ins(l,4,5)P3 to InsP4 to be Ca2+-sensitive. To examine this further, 
the interconversion of [3H]Ins(l,4,5)P3 and InsP4 was assayed in a lysed cell 
preparation. The data in Figure 4.5 were generated in collaboration with Dr. Y. 
Zilberman and are included here with her permission. 
Fig. 4.5a shows the time course of Ins(l,4,5)P3 metabolism by lysed cells. Six 
minutes after cell lysis into medium containing [3H]Ins(l,4,5)P3, greater than 50% of the 
[3H] was present as [3H]InsP4 and by 20 mins this had increased to 70%. The amount of 
[3H]Ins(l,3,4)P3 started rising slowly at 6 mins, and was -30% of the amount of 
[3H] InsP 4 at 42 mins. A gradual decline in the total amount of InsP3 + InsP 4 was 
attributable to slow conversion to InsP and InsP2. 
The ability of the lysed cell preparation to phosphorylate Ins(l,4,5)P3 in the presence 
of ATP was employed to examine the effect of free calcium concentration on the 
Ins(l,4,5)P3 -> InsP4 conversion (Fig. 4.5b). Cells were lysed into medium containing 
[3H]Ins(l,4,5)P3 plus a range of free calcium concentrations, and reactions were 
quenched at 12 mins. The rate of Ins(l,4,S)P3 phosphorylation as judged by the ratio of 
InsP 4 to Ins(l ,4,5)P3 increased substantially between 0.1 and 16µM free Ca2+, but little 
Ins(l ,3,4)P3 accumulated at any calcium concentration, implying that InsP4 
dephosphorylation was independent of [Ca2+]. The [Ca2+] sensitivity of InsP3 kinase 
correlated well with the physiological range over which [Ca2+]i changed in Con A-
stimulated cells. 
T~en together these data suggest that Ins(l,4,5)P3 conversion to InsP4 is stimulated 
by Ins(l,4,5)P3-mediated release of intracellular calcium.stores, but give little clue as to 
the role of InsP4 in [Ca2+Ji homeostasis. If InsP4 modulates extracellular Ca2+ entry, as 
has been suggested (Irvine and Moor, 1986; Morris, A.J. et al., 1987), such a 
mechanism would facilitate switching from [Ca2+]i elevation by intracellular Ca2+ store 
release to maintenance of elevated [Ca2+Ji by extracellular Ca2+ entry. 
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FIGURE 4.5 Metabolism of [3H]Ins(l,4,5)P3 by lysed thymocytes. 
A. Time course of [3H]Ins(l,4,5)P3 metabolism. Thymocytes were lysed by dilution 
into hypo-osmotic medium containing 12.5nM [3H]Ins(l,4,5)P3, and Ca2+fEGTA added 
with Tris/KCl buffer at two minutes to adjust the free [Ca2+] to 50µM (Section 2.7.2). 
Reactions were terminated at the times indicated and inositol phosphates assayed as 
described in the legend to Fig. 4.1. 
B. [Ca2+] dependence of Ins(l,4,5)P3 phosphorylation. Thymocytes were lysed as 
above, · and Ca2+fEGTA added with Tris/KCl buffer at two minutes to give free Ca2+ 
concentrations as indicated. Reactions were terminated at 12 mins and inositol 
phosphates assayed as above. 
Symbols: D, Ins(l ,4,5)P3; A, Ins(l,3,4)P3; • , InsP4. 
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However, the demonstration of an Ins(l,4,5)P3-sensitive plasma membrane Ca2+ channel 
in Jurkats (Kuno and Gardner, 1987) and the observation that a PtdlnsP2-hydrolysing 
ligand (substance P) can stimulate Ca2+ 0 entry into a pancreatoma cell line in the absence 
of Ins(l,3,4,5)P4 accumulation, bring into question the involvement of InsP4 in Ca2+0 
influx. Furthermore, it is clear that some ligands can stimulate Ca2+ 0 entry without 
affecting inositol phosphate levels (e.g. EGF on 3T3 fibroblasts; Hesketh et al., 1988). 
Therefore the mechanism(s) by which ligands mediate Ca2+0 influx is (are) currently 
unclear. 
4.1.4 The effect of azide on Con A-stimulated inositol phosphate and 
[Ca2+]i increases 
The effect of azide · on inositol phosphate accumulation was examined as azide 
antagonised ligand-induced increases in [Ca2+]i. lOmM sodium azide reduced Con A-
stimulated [Ca2+]i increases, but itself caused a small [Ca2+]i elevation (Fig. 4.6). The 
azide-induced increase was due to intracellular store release, possibly mitochondrial, since 
it occurred in the presence of extracellular EGTA (data not shown), but was not 
Ins(l,4,5)P3-mediated (i.e. InsP3 and InsP4 were unchanged by 10 min incubation of 
thymocytes with lOmM azide). Pre-incubation with azide reduced the maximal [Ca2+]i 
induced by Con A from 700nM to -150nM, resulting in a signal comparable to that 
observedin the presence of lmM EGTA. The pattern of Con A-stimulated inositol 
phosphate production after azide pre-treatment was also similar to that generated in the 
presence of lmM extracellular EGTA. Ins(l,4,5)P3 amounts at 2 and 5 mins were 2-fold 
those in control c~lls, and Ins(l,3,4)P3 and InsP4 accumulation were reduced by greater 
than 50% at 5 mins (Fig. 4.7a versus b). 
Azide-induced ATP depletion might be expected to affect a number of activities 
including A TP-dependent ion channels, ATP-requiring phosphorylations, and, via 
reduction of A TP-GTP exchange, OTP-dependent processes .such as G-protein-
stimulated reactions. 
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FIGURE 4.6 Effect of sodium azide on Con A-stimulated [Ca2+]i increase. 11 11 Quin 2-loaded thymocytes prepared as described in Section 2.6.1 were challenged with 
lOµg/ml Con A (added at time 0) after 10 mins pre-incubation with medium (A) or lOmM [ 
sodium azide (B). [Ca2+]i was measured as described in.the legend to Fig. 4.3. this and 
subsequent experiments were performed in medium containing 0.43mM free Ca2+ unless 
otherwise stated. 
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FIGURE 4.7 Effect of sodium azide on Con A-stimulated inositol phosphate 
accumulation. 
[3H]inositol-labelled thymocytes were challenged with lOµg/ml Con A (added at time 0) 
after 10 min pre-incubation with medium (A) or lOmM sodium azide (B). Reactions were 
terminated at the times indicated and inositol phosphates assayed as described in the 
legend to Fig. 4.1. Symbols: D, Ins(l,4,5)P3; ._, Ins(l ,3,4)P3; • , IrisP4. 
C. Total InsP3+InsP4 accumulation in cells pre-treated with medium(+) or sodium azide 
(~) . 
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However, the marked similarity between azide and EGTA effects on Con A-stimulated 
InsP3 + InsP4 accumulation (compare Figs. 4.4c and 4.7c), suggests that azide-mediated 
inhibition could be mainly due to an effect on a plasma membrane Ca2+ channel (although 
the similarities could be purely coincidental). In turn, reduced Ca2+ 0 influx might prevent 
full activation of Ins(l,4,5)P3 kinase resulting in a higher ratio of Ins(l,4,5)P3 to InsP4. 
However, the azide-mediated reduction of both basal and stimulated amounts of PtdlnsP 
and PtdlnsP2 (15-20%; Taylor et al., 1984) may also contribute to the observed reduction 
in total InsP3 + InsP 4 accumulation. 
4.1.5 The effect of CGS9343B on Con Amstimulated inositol phosphate 
and [Ca2+Ji increases 
Ca2+-sensitive Ins(l,4,5)P3 kinase activity has now been demonstrated in a variety of 
cells other T cells including; turkey erythrocytes (Morris, A.J. et al., 1987), aortic smooth 
muscle cells (Yamaguchi et al., 1987; Rossier et al., 1987), platelets (Daniel et al., 1988), 
and rat hepatocytes (Biden et al., 1988). Calmodulin confers Ca2+-sensitivity to partially 
purified InsP3 kinase (Biden et al., 1987; Yamaguchi et al., 1988; Johanson et al., 1988), 
suggesting that the enzyme is activated by a Ca2+-calmodulin complex. Therefore it was 
of interest to determine the effect of the calmodulin antagonist CGS9343B (Norman et al., 
1987) on Con A-stimulated inositol phosphate accumulation. 
· CGS9343B pre-treatment (5 mins) caused a dose-dependent increase in the ratio of 
Ins(l,4,5)P3 to InsP4 in intact thymocytes stimulated with Con A for 2 mins (Fig. 4.8). 
A corresponding decrease in Ins(l,3 ,4)P3 over the same concentration range was 
presumed to reflect the reduced availability of InsP 4 for 5' dephosphorylation. The ability 
of CGS9343B to reduce Ins(l,4,5)P3 phosphorylation was consistent with the reported 
sensitivity of InsP3 kinase to calmodulin. However, ~e effect of CGS9343B may be 
partially due to antagonistic effects on Ins(l,4,5)P3-mediated Ca2+ release, since Hill et 
al. (1988a) have demonstrated CGS9343B-mediated inhibition of the latter in 
electropermeabilised rat liver epithelial cells. 
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FIGURE 4.8 Effect of CGS9343B on Con A-stimulated inositol phosphate 
accumulation. 
[3H]inositol-labelled thymocytes were challenged with lOµg/ml Con A for 2 mins after 5 
min pre-incubation with the indicated CGS9343B concentrations. After reaction 
termination, inositol phosphates were assayed as described in the legend to Fig. 4.1. 
Symbols: D, Ins(l,4,5)P3; •, Ins(l,3,4)P3; •, InsP4. 
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To test this possibility, attempts were made to measure the effect of CGS9343B on Con 
A-induced [Ca2+Ji elevation, but the assay was complicated by the fact that addition of 
small aliquots of 2mM stock solutions to salts solution resulted in light scattering due to 
CGS9343B precipitation. Resuspension of CGS9343B occurred gradually, resulting in 
an apparent [Ca2+Ji increase. Figure 4.9 shows traces illustrating this phenomenon, and 
also attempted assays of CGS9343B effect on ligand-induced [Ca2+Ji responses. 
CGS9343B may cause a reduction in stimulated [Ca2+]i, but this was impossible to 
quantitate. Therefore it was not possible to distinguish between calmodulin-stimulated 
Ca2+ store release and InsP3 kinase activity as the sites for CGS9343B action. 
4.2 . The effect of anti-Thy 1 and anti-T3 . antibodies on inositol 
phosphates and [Ca2+]i in BALB/c thymocytes 
4.2.1 Inositol phosphate responses 
Accurate analysis of inositol polyphosphate interconversions depended on the ability to 
resolve the various inositol phosphate isomers by HPLC. However, for evaluation of the 
PtdlnsP2-hydrolysing ability of ligands, a less sophisticated, less time-consuming assay 
was preferable. Therefore inositol phosphate extracts from thymocytes stimulated with 
anti-Thy 1 and anti-T3 antibodies were assayed using AG1-X8 anion exchange resin, as 
described by Downes et al. (1986). 
Both KT16 and 145-2Cl 1 stimulated inositol phosphate accumulation in BALB/c 
thymocytes. KT16 stimulated increases in all inositol phosphates (measured 10 mins 
after ligand addition), although only small increases in InsP4 were observed (Fig. 4.10). 
The index of stimulation increased over a similar concentration range as KT16-stimulated 
DNA synthesis (5-50µg/ml; Fig. 3.5a), suggesting a ~ausal link. 145-2Cll induced 
much larger responses (expressed as a percentage of unstimulated levels), with maximal 
accumulation occurring at concentrations greater than those required to evoke optimal 
DNA synthesis (Fig. 4.11). Above 12.5µg/ml 145-2Cl 1 both inositol phosphate 
responses and DNA synthesis were sub-maximal. 
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FIGURE 4.9 Effect of CGS9343B on the [Ca2+]i response to Con A. 
Quin 2-loaded thymocytes were challenged with lOµg/ml Con A after 3.5 min pre-
incubation with medium (A) or 25µM CGS9343B (B). A continuous recording of 
fluorescence intensity (arbitrary units) is shown. CGS9343B caused a similar increase in 
FI when added to medium in the absence of cells, suggesting the increases to be a light-
scattering effect due to precipitation of CGS9343B from the medium (not shown). 
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FIGURE 4.10 KT16-stimulated inositol phosphate accumulation in BALB/c 
thymocytes. _ 
[3H]inositol-labelled thymocytes were incubated with the indicated concentrations of KT16 for 10 mins (Section 2.7.2), reactions terminated and inositol phosphates extracted 
as described in Section 2.7.3. Inositol phosphates were separated on AG1 -X8 resin (Section 2.7.4) and oven-dried eluates counted in 15ml of scintillation fluid (Section 2.8). 
Each point in this and subsequent thymocyte inositol phosphate determinations is the 
mean (+/- standard deviation) of triplicate determinations. A,B,C and D show cpm in 
InsP, InsP2, InsP3 and InsP4 respectively. 
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FIGURE 4.11 145-2Cll-stimulated inositol phosphate accumulation in BALB/c 
thymocytes _ 
[3H]inositol-labelled thymocytes were incubated with the indicated 145-2Cl 1 
concentrations for 10 mins, then reactions terminated and inositol phosphates assayed as described in the legend to Fig. 4.10. A,B,C and D show cpm in lnsP, InsP2, InsP3 and InsP4 respectively. 
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The similarities in concentration dependence of ligand-induced inositol phosphate 
accumulation and DNA synthesis suggest a role for PtdlnsP2 hydrolysis in mitogenesis. 
However the threshold requirement must be quite low as 145-2Cll and KT16 were of 
similar mi to genie potency in the presence of IL2 or TP A (Section 3.2.2), but KTl 6 was a 
far less potent agonist of PtdlnsP2 hydrolysis than was 145-2Cl 1 in either the absence 
(Fig. 4.12) or presence (Fig. 4.13) of IL2 or TPA. 
It is of interest that 145-2Cll-induced InsP3 and InsP4 responses were slightly 
inhibited by 10 min pre-treatment with lOnM TPA (Fig. 4.13), as TPA had a similar 
effect on the Con A response (see Section 4.1.2). These data are consistent with the idea 
formulated in Chapter 3 that Con A evokes responses via interaction with T3. However, 
it is clear that Con A has additional effects not mimicked by anti-T3 antibody as Con A, 
but not 145-2Cl 1, is capable of inducing appreciable thymocyte proliferation in the 
absence of IL2 and TP A. 
Taken together these data suggest that PtdlnsP2 hydrolysis may be necessary for 
activation of DNA synthesis by KT16, Con A and 145-2Cl 1, although the threshold 
requirement may be quite low. However, since both KT16 and 145-2Cl 1 are poor 
mitogens in the absence of exogenous IL2, PtdlnsP2 hydrolysis may be insufficient to 
stimulate appreciable IL2 secretion. In turn this suggests that PtdlnsP2 hydrolysis is not 
the primary response capable of inducing all subsequent responses required for the 
lymphocyte Go -> S transition. 
4.2.2 [Ca2+]i responses 
The effect _of KT16 and 145-2Cl 1 on [Ca2+]i was examined using ligand 
concentrations optimal for both DNA synthesis and inositol phosphate accumulation. 
Both 20µg/ml KT16 and lOµg/ml 145-2Cl 1 induced [Ca2+]i increases (Fig. 4.14) . 
145-2Cl 1 induced a response of similar magnitude to that generated by lOµg/ml Con A 
(lµM cf 700nM), but the response to KT16 was slower than that evoked by 0.8µg/ml 
Con A and reached a maximum of less than 250nM. 
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FIGURE 4.12 Comparison of inositol phosphate responses to optimal mitogenic ligand 
concentrations. · 
[3H]inositol-labelled thymocytes were incubated with no addition (A), 0.8µg/ml Con A 
(B), 20µg/ml KT16 (C) or lOµg/ml 145-2Cl 1 (D) for 10 mins, then reaction terminated 
and inositol phosphates assayed as described in the legend to Fig. 4.10. 1,~.~ and !2 
show cpm in InsP, InsP2, InsP3 and InsP4 respectively. 
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FIGURE 4.13 Effect of IL2 and TPA on ligand-stimulated inositol phosphate 
accumulation in lf!ymocytes. 
[3H]inositol-labelled thymocytes were incubated with the following agents: no addition 
(A), 20U/ml IL2 (B), lOnM TPA (C), 20µg/ml KT16 (D), KT16 + IL2 (E), KT16 + 
TPA (F), 10µg/ml 145-2Cll (G), 145-2Cll + IL2 (H), l45-2Cll + TPA (I). Reactions 
were terminated after 10 mins and inositol phosphates assayed as described in the legend 
to Fig. 4.10. ~.~ .~ and Q show cpm in InsP, InsP2, InsP3 and InsP4 respectively. 
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FIGURE 4.14 Comparison of [Ca2+]i responses to Con A, KT16 and 145-2Cll. Quin 2-loaded thymocytes prepared as described in Section 2.6.1 were challenged with 
lOµg/ml Con A (D), 0.8µg/ml Con A (a), lOµg/ml 145-2Cll (A) or 20µg/ml KT16 (~). 
[Ca2+]i was measured as described in the legend to Fig. 4.3. 
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The time course of [Ca2+Ji elevation was compared with that of inositol phosphate 
generation in response to KT16 and 145-2Cll. InsP3 was unchanged 1 min after KT16 
addition, consistent with the slow initial increase in [Ca2+Ji, then increased monotonically 
between 1 and 20 mins (Fig. 4.15). InsP 4 increased rapidly between 1 and 2 mins, 
presumably due to partial activation of InsP3 kinase by Ins(l,4,5)P3-released Ca2+, then 
remained approximately constant. InsP and InsP2 production were delayed relative to 
InsP3 and InsP4, consistent with their being dephosphorylation products of InsP3 and 
InsP4, but increased monotonically between 5 and 20 mins. 
145-2Cl 1 stimulated much larger, more rapid increases in all inositol phosphates (Fig. 
4.16), correlating with the rapid 145-2Cll-induced [Ca2+]i increase. Amounts of InsP, 
InsP2 and InsP3 increased up to 10 mins. Subsequently InsP2 and InsP3 declined, while 
InsP increased. 
The ability of each ligand to mobilise [Ca2+]i was in proportion to its ability to evoke 
inositol phosphate accumulation i.e. 145-2Cl 1 was a potent agonist for both responses, 
while KT16 was only a weak agonist for either response. Furthermore the time courses 
of both responses were similar. Thus these data are consistent with a mechanism of 
[Ca2+]i elevation involving inositol phosphates. However, the inositol phosphate (if any) 
responsible for Ca2+ 0 influx could not be determined from these data. As concluded in 
relation to the inositol phosphate data, it is clear that only low levels of [Ca2+]i elevation 
are required for mitogenesis since KT16 and 145-2Cl 1 are of approx. equal mitogenic 
potency. 
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FIGURE 4.15 Time course of KT16-stimulated inositol phosphate accumulation in 
thymocytes. _ 
[3H]inositol-labelled thymocytes were incubated with medium (o) or 20µgAnl KT16 (a) 
and reactions terminated at the times indicated. Inositol phosphates were assayed as 
described in the legend to Fig. 4.10. A,B,C and D show cpm in InsP, InsP2, InsP3 and 
InsP4 respectively. · 
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FIGURE 4.16 Time course of 145-2CI1-stimulated inositol phosphate accumulation. 
[3H]inositol-labelled thymocytes were incubated with medium (D) or lOµg/ml 145-2Cll (•) and reactions terminated at the indicated times. Inositol phosphates were assayed as 
described in the legend to Fig. 4.10. A,B,C and D show cpm in InsP, lnsP2, InsP3 and 
lnsP4 respectively. 
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4.3 Ligand-induced increases in inositol phosphates and [Ca2+]i in 
clone 4 
4.3.1 Inositol phosphate responses 
It was of interest to determine the effect of IL2 on inositol phosphates in clone 4, as 
IL2 stimulates clone 4 proliferation. The effect of a range of IL2 concentrations on 
inositol phosphate accumulation was examined in two experiments. 10 min incubation 
with lOU/ml or 50U/ml IL2 had no significant effect on any inositol phosphate, but a 
supramitogenic concentration (500U/ml) slightly increased inositol phosphate amounts. 
In experiment I, InsP, InsP2 and InsP4 were increased 32%, 24% and 29% respectively; 
and InsP3 was marginally reduced (8% ). Qualitatively similar but even smaller effects of 
500U/ml IL2 were seen in experiment II. 
IL2 Concentration (U/ml) 
0 10 50 500 
Experiment I 
InsP 1076+/-67 1272+/-105 1115+/-9 1425+/-91 
InsP2 126+/-9 111+1-10 143+/-30 156+/-3 
InsP3 171 +/-2 179+/-8 202+/-13 157+/-33 
InsP4 356+/-8 368+/-7 336+/-2 459+/-37 
Experiment II 
InsP 756+/-6 737+/-7 780+/-l 830+/-32 
InsP2 135+/-6 155+/-6 129+/-6 156+/-7 
InsP3 130+1-6 137+/-9 108+/-4 119+/-3 
InsP4 241+/-24 246+/-6 244+/-8 284+/-ll 
TABLE 4.1 The effect of IL2 on inositol phosphate accumulation 
[3H]inositol-labelled clone 4 cells were incubated in salts solution with recombinant IL2 (0, 10, 50 or 500U/ml) for 10 min, after 10 min pre-incubation with 5mM LiCl. 
Reactions were quenched and inositol phosphates extracted and separated on AG1-X8 as 
described in Section 2. 7. Inositol phosphate fractions were counted for 3H as described 
in Section 2.8. 
· 
These data suggest that at concentrations relevant to mitogenesis, IL2 does not · 
stimulate PtdlnsP2 hydrolysis, although supramitogenic concentrations may elicit a small 
II' 
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response. Similar findings have been reported by Kozumbo et al. (1987) and 
Wickremasinghe et al. (1985). In contrast, Bonvini et al. (1987) demonstrated IL2-
induced inositol phosphate accumulation. However as these workers used a high IL2 
concentration (500U/ml) and failed to relate this to the concentration required for 
mitogenic stimulation, IL2-induced phosphoinositide metabolism may be unrelated to its 
ability to activate DNA synthesis. Therefore, at least in IL2r-expressing cells, PtdinsP2 
hydrolysis is not obligatory for mitogenesis. 
In contrast, both KT16 and 145-2Cl 1 did stimulate inositol phosphate accumulation in 
clone 4. KTl 6 stimulated inositol phosphate accumulation over a similar concentration 
range in clone 4 as in thymocytes (Fig. 4.17 cf Fig. 4.10). Significant responses were 
observed at concentrations greater than 3µg/ml, and the magnitude of these increased up 
to 20µg/ml, but declined at higher concentrations. Because KT16 concentrations required 
for PtdlnsP2 hydrolysis were 100 times greater than those optimal for DNA synthesis, the 
relationship between this response and KT16-induced mitogenesis is unclear. However, 
the differing cell density in the two assays (100-fold greater in the inositol phosphate 
assays) renders direct comparison impossible. Therefore it is not possible to rule out a 
role for PtdlnsP2 hydrolysis in KT16-stimulated proliferation of clone 4, particularly 
since in the thymocyte system (where both assays are performed at equivalent cell 
density) the optimal KT16 concentrations required for Ptd.InsP2 hydrolysis and DNA 
synthesis are coincident (Section 4.2.1). 
Figure 4.18 shows total inositol phosphates accumulated in response to 145-2Cl 1. 
Individual inositol phosphate fractions are not shown because labelling was too low in 
this experiment for the InsP2 and InsP3 data to be significant. However it is clear that 
145-2Cl 1 stimulated inositol phosphate accumulation with tbe maximal response evoked 
by lOµg/ml . The optimum concentration was similar to that for thymocytes (12.5µg/ml; 
see Fig 4.11). 
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FIGURE 4.17 KTl 6-stimulated inositol phosphate accumulation in clone 4 
[3H]inositol-labelled clone 4 cells (Section 2.7.1) were incubated with the indicated 
concentrations of KT16 for 10 mins (Section 2.7.2) then reactions terminated and inositol phosphates assayed as described in the legend to Fig. 4.10. Each point in this and 
subsequent clone 4 inositol phosphate determinations is the mean(+/- standard deviation) 
of duplicate determinations unless otherwise stated. A,B,C and D show cpm in InsP, InsP2, InsP3 and InsP4 respectively. 
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FIGURE 4.18 145-2Cl 1-stimulated inositol phosphate accumulation in clone 4. [3H]inositol-labelled clone 4 cells were incubated with the indicated concentrations of 145-2Cl 1 for 10 mins, reactions terminated and inositol phosphates assayed as described in the legend to Fig. 4.10. Each point is the mean of duplicate determinations of total inositol phosphates. 
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The time courses of inositol phosphate accumulation in response to 145-2Cl 1 and 
KT16 were also determined. KT16 stimulated greater InsP4 accumulation (relative to 
unstimulated amounts) in clone 4 than in thymocytes, but correspondingly less InsP3, 
suggesting that in thymocytes either Ins(l,4,5)P3 phosphorylation or dephosphorylation 
was more rapid. In clone 4, little InsP3 and InsP 4 accumulation occurred within 2 
minutes of addition of 20µg/ml KT16 (Fig. 4.19), although sufficient InsP accumulated 
to suggest that it might have been generated directly from Ptdlns, or that the rate of InsP3 
dephosphorylation exceeded the rate of PtdlnsP2 hydrolysis. The rapid increase in 
amounts of InsP3 and InsP 4 between 2 and 5 mins was succeeded by a small InsP3 
decline between 5 and 10 mins. The amount of InsP 4 remained approx. constant between 
5 and 10 mins. InsP and InsP2 increased monotonically between 2 and 10 mins. 
The patterns of inositol phosphate accumulation in response to lOµg/ml 145-2Cl 1 
were fairly similar in clone 4 and thymocytes (Fig. 4.20 cfFig. 4.16), but initial increases 
in inositol phosphate accumulation were slower in clone 4. Between 2 and 10 mins 
inositol phosphate accumulation in clone 4 was approximately monotonic. 
Con A (lOµg/ml) evoked a virtually identical pattern of inositol phosphate 
accumulation to 145-2Cl 1 (Fig. 4.21). Slow initial rates of inositol phosphate increase 
were followed by monotonic accumulation up to 10 minutes. However the stimulation 
index was significantly greater with Con A than with 145-2Cll, which was itself a more 
potent agonist of PtdlnsP2 hydrolysis than KT16. However this could not be related to 
their efficacy as mitogens, nor could the concentration dependence profiles of DNA 
synthesis and inositol phosphate responses be compared since neither Con A nor 145-
2Cll was mitogenic for clone 4. These data are consistent with two earlier suggestions. 
i PtdlnsP2 hydrolysis may be necessary but is not sufficient to activate DNA synthesis. 
ii The threshold amount of PtdlnsP2 hydrolysis required for DNA synthesis activation is 
quite small in comparison with the maximal amounts of PtdlnsP2 hydrolysis evoked by 
Con A. 
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FIGURE 4.19 Time course of KT16-stimulated inositol phosphate accumulation in 
clone 4. 
[3H]inositol-labelled done 4 cells were incubated with medium (D) or 20µg/ml KT16 (•) 
and reactions terminated at the indicated times. Inositol phosphates were assayed as described in the legend to Fig. 4.10. A,B,C and D show cpm in InsP, InsP2, InsP3 and InsP4 respectively. 
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FIGURE 4.20 Time course of 145-2Cll-stimulated inositol phosphate accumulation in 
clone 4. 
[3H]inositol-labelled clone 4 cells were incubated with medium (D) or lOµg/rnl 145-2Cl 1 
(•) and reactions terminated at the times indicated. Inositol phosphates were assayed as 
described in the legend to Fig. 4.10. A,B,C and D show cpm in InsP, InsP2, InsP3 and 
InsP4 respectively. 
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FIGURE 4.21 Time course of Con A-stimulated inositol phosphate accumulation in 
clone 4 
[3H]inositol-labelled clone 4 cells were incubated with lOµg/ml Con A and reactions 
terminated at the times indicated. Inositol phosphates were assayed as described in the 
legend to Fig. 4.10. A,B,C and D show cpm in InsP, InsP2, InsP3 and InsP4 
respectively. 
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4.3.2 [Ca2+Ji responses 
The ability of these li~ands to elevate [Ca2+Ji in clone 4 was also determined. [Ca2+Ji 
was unperturbed from its resting value of 1 lOnM by 50U/ml or 500U/ml IL2 (data not 
shown). The inability of IL2 to elicit a [Ca2+Ji response is consistent with its failure to 
increase InsP3 accumulation. 
In contrast, KT16 and Con A increased [Ca2+Ji to 250nM and 450 nM respectively 
within 3-4 mins of ligand addition (Fig. 4.22), consistent with their ability to cause 
PtdinsP2 hydrolysis. There was a 45-90s delay after ligand addition before onset of 
[Ca2+]i elevation, consistent with the slow initial increases in inositol phosphate, then a 
rapid rise succeeded by a gradual decline. At 10 mins after Con A or KT16 addition, 
[Ca2+]i was 333+/-40nM or 122+/-lOnM respectively. The persistent elevation with 
Con A might be related to its greater ability compared with KT16 to induce PtdinsP2 
hydrolysis. In this experiment Con A caused significantly greater maximal [Ca2+Ji than 
KT16. However in some experiments, maximal [Ca2+Ji stimulated by Con A and KT16 
were similar. 
Both Con A and KT16 caused transient [Ca2+Ji increases in the presence of lmM 
extracellular EGTA demonstrating that both could cause Ca2+-release from intracellular 
stores, consistent with the ability of both to elevate InsP3. 
An attempt was also made to determine the effect of 145-2Cl 1 on [Ca2+Ji in clone 4. 
However, inconsistent with its effect on inositol phosphate accumulation in clone 4, and 
on thymocyte [Ca2+Ji, no effect of 145-2Cl 1 on clone 4 [Ca2+]i could be detected. It 
appeared possible that this difference could be an artefact due to the fact that clone 4 was 
routinely cultured with irradiated CBA splenocytes and IL2, but for [Ca2+]i 
detetm?1ations cells were stimulated with IL2 alone to avoid quin 2-AME partitioning into 
dead CBA cell membranes. Therefore the ability of ligands to evoke inositol phosphate 
accumulation was compared in cells grown in the presence or absence of CBA cells 
(Table 4.2). 
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FIGURE 4.22 [Ca2+]i responses to Con A and KT16 in clone 4. 
Quin 2-loaded clone 4 cells (Section 2.6.3) were challenged with lOµg/ml Con A (A) or 
20µg/ml KT16 (B) in medium containing 0.43mM free Ca2+ (•) or O.lµM free Ca2+ (D) . 
[Ca2+Ji was measured as described in the legend to Fig. 4.3. Each point is the mean 
(+/- s~dard deviation) of duplicate determinations. 
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Inositol phosphate responses to KT16 were similar in cells grown with IL2 plus or 
minus CBA splenocytes. But despite the ability of 145-2Cl 1 to evoke substantial inositol 
phosphate accumulation in cells stimulated with CBA splenocytes, the 145-2Cl 1 
response of IL2-grown cells was virtually non-existent, suggesting that T3 may be down-
regulated or inactivated in cells cultured solely with IL2. In contrast, the response to Con 
A was similar to that observed in CBA-grown cells (data not shown), suggesting that Con 
A elicits its responses at least partially by interaction with receptors other than T3. 
Stimulation index of inositol phosphate fractions 
InsP InsP2 InsP3 InsP4 Ligand Growth stimulus 
KT16 IL2 + CBA cells 1.65 2.13 1.48 1.78 
KT16 IL2 alone 1.63 2.38 1.70 2.11 
145-2Cll IL2 + CBA cells 3.58 3.06 2.95 2.91 
145-2Cll IL2 alone 1.25 1.50 0.90 1.47 
TABLE 4.2 Effect of growth stimulus on inositol phosphate responses to KT16 and 145-2Cll 
Clone 4 cells cultured by stimulation with IL2 +1- CBA splenocytes were labelled with [3H]inositol, washed and pre-incubated as described in Section 2.7.1. Cells were 
challenged with anti-Thy 1 (20µg/ml) or 145-2Cll (lOµg/ml) for 10 mins, then reactions quenched, and samples processed as described in Section 2. 7.3. Inositol phosphate 
fractions were separated, dried and counted for 3H (Section 2.8). The stimulation index is the ratio; cpm in stimulated cells / cpm in unstimulated cells. 
Since Thy 1 responses are unaltered in IL2-grown cells, these data are inconsistent 
with reports that T3 j s necessary for Thy 1 functioning. Alcover et al. (1988a) have 
suggested that in the case of CD2 (another receptor apparently dependent on T3-Ti 
expression for its activity; Section 1.3.4) only a very low level of T3-Ti expression 
( <1,000 molecules/cell) is required for responsiveness to CD2-directed ligands. 
However, these authors fail to report whether these cells retain responsiveness to T3-
directed ligands. Therefore it is not possible to draw comparisons between their data and 
the results described here. However it seems unlikely that the T3-Ti complex would be 
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able to transduce signals in response to Thy 1 ligands but not anti-T3 antibodies. In 
contrast the demonstration by Kroczek et al. (1986a) that Thy 1 can elevate [Ca2+]i in 
Thy 1-transfected B cells suggests that T3-Ti expression is not obligatory for Thy 1-
mediated [Ca2+]i increases, and thus concurs with the data presented here. However it 
should not be inferred from the ability of KTl 6 to induce inositol phosphate accumulation 
in the absence of T3-responsiveness that Thy 1 can also stimulate proliferation of T3-
unresponsive cells. Indeed it has proved impossible to demonstrate proliferation in 
response to KT16 in Il..2-grown cells. 
4A Ligand-induced increases in C·.filli. mRNA in T lymphocytes 
The amount of c-myc mRNA in BALB/c thymocytes and clone 4 was assayed by 
Northern blotting fractionated RNA extracted from cells as described in Section 2.10. 
These experiments were performed in collaboration with Garry Menzel and are included 
with his permission. 
4.4.1 Ligand-induced increases in c-m.tt, mRNA in BALB/c thymocytes 
Quiescent BALB/c thymocytes contained a small amount of c-myc mRNA, which was 
unaltered by Il..2, consistent with the virtual absence of IL2r from the resting thymocyte 
surface. However, increases in c-myc mRNA were stimulated by Con A, 145-2Cl 1 and 
KT16. Con A-stimulated increases in c-myc mRNA were detectable within lh of Con A 
addition, and were maximal after 4-8h (Fig 4.23). The elevation of c-myc mRNA was 
sustained for at least a further 4h . 
The effect of 145-2Cll on c-myc mRNA is shown in Figure 4.24. Maximal increases 
were observed lh after 145-2Cl 1 addition and this increase was sustained up to 2h (the 
latest time point assayed). In contrast, c-myc mRNA accumulation was far slower in 
response to KT16. C-myc mRNA was assayed 0.5, 1 and 2h after KT16 addition, but 
only at 2h was any increase detected (Fig. 4.25). The relative rates of c-myc mRN A 
accumulation in response to KT16 and 145-2Cl 1 were in the same order as the relative 
rates of [Ca2+]i and inositol phosphate accumulation stimulated by these ligands. 
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FIGURE 4.23 Time course of -Con A-stimulated c-myc mRNA accumulation in 
thymocytes 
Thymocytes were incubated with 0.8µg/ml Con A for the indicated times, then reactions 
were terminated, and RNA was isolated, fractionated, transferred to nitrocellulose 
membrane, and probed with 32P-labelled c-rnyc cDNA as described in Section 2.10. 32p_ 
labelled nitrocellulose membranes were autoradiographed apd the intensities of the major 
band determined by scanning densitometry. 
A. Autoradiograph. B. Results from scanning densitometry (expressed as a percentage of 
the maximum response observed in this and all subsequent experiments). Similar results 
were obtained in several experiments. 
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FIGURE 4.24 Time course of 145-2Cll-stimulated c-myc mRNA accumulation in 
thymocytes. 
Thymocytes were incubated with lOµg/ml 145-2Cl 1 for the times indicated, then c-.rnyQ. 
mRNA assayed as described in the legend to Fig. 4.23. 
A. Autoradiograph. B. Results from scanning densitometry. Each point is the mean(+/-
standard deviation) of duplicate determinations in this and subsequent c-myc experiments. 
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FIGURE 4.25 Time course of KT16-stimulated c-myc mRNA accumulation in 
thymocytes. 
Thymocytes were incubated with 20µg/ml KT16 for the indicated times, then c-rnyc 
m.RNA assayed as described in the legend to Fig. 4.23. 
A. Autoradiograph. B. Results from scanning densitometry. 
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4.4.2 Ligand-induced increases in c-!!!l'..£ mRNA in clone 4 
Quiescent clone 4, like resting thymocytes, contained a low level of c-myc rnRNA. 
But clone 4 c-myc mRNA levels increased in a concentration-dependent manner in 
response to IL2. SOU/ml and lOOU/ml IL2 stimulated 64% and 94% respectively of the 
c-myc mRNA accumulation stimulated by 500U/ml IL2 after lh (Fig. 4.26a&b). The 
time course of c-myc mRNA accumulation in response to 50U/ml IL2 was also measured 
(Fig. 4.26c&d). An increase was first detectable at 30 mins, and accumulation was 
maximal at lh. By 2h the amount of accumulated c-myc mRNA had declined to 59% of 
the maximum observed. 
Time course data in response to 145-2Cll and KT16 are shown in Figs. 4.27 and 
428. The times taken to achieve maximal response were in the order, 145-2Cl 1 < IL2 < 
KTI6. The 145-2Cl 1-stimulated increase in c-myc mRNA was maximal at 30 mins, and 
declined to 40% of maximum by 2h (Fig. 4.27). In contrast, KT16-stimulated c-myc 
was maximal at the latest time point measured (4h; Fig. 4.28). The relative rates of 
responses to KT16 and 145-2Cll were thus similar for Ca2+, inositol phosphate and 
c-myc mRNA responses. Interestingly, although ligand-stimulated [Ca2+]i and inositol 
phosphate responses were slower in clone 4 than in thymocytes, the time taken to achieve 
maximal c-myc mRNA accumulation was less in clone 4 than in thymocytes. However as 
these data do not permit quantitation of absolute amounts of c-myc mRNA, it is not 
possible to compare initial rates of c-myc mRNA accumulation. Therefore the earlier 
maxima in clone 4 compared with thymocytes may simply represent greater RNAse 
activity in clone 4. 
The ability of both 145-2Cl 1 and KT16 to cause c-myc mRNA accumulation was 
consistent with their ability to mobilise [Ca2+]i since c-myc rpRNA accumulation can be 
stimulated by increased [Ca2+]i both in BALB/c thymocytes and 3T3 fibroblasts (Moore 
et al., 1986; Yamashita et al, 1986; Kaibuchi et al., 1986). However, th.e mechanism by 
which IL2 elevates c-myc mRNA is not clear, despite previous reports of c-myc 
responses to IL2 (Farrar et al., 1987; Depper et al., 1985; Reed et al., 1985), since IL2 
does not stimulate [Ca2+]i elevation. 
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FIGURE 4.26 Effect ofIL2 on c-myc mRNA accumulation in clone 4 
Clone 4 cells were stimulated for lh with the IL2 concentrations indicated (A and B) or 
with SOU/ml IL2 for the indicated times (C and D) then C-.ll.Y.£ mRNA assayed as 
described in the legend to Fig. 4.23. A and C show the autoradiographs and B and D II 
show the scanning densitometry data. II// 
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FIGURE 4.27 Time course of 145-2Cll-stimulated c-myc mRNA accumulation in 
clone 4. 
Clone 4 cells were incubated with lOµg/ml 145-2Cl 1 for the times indicated, then c-myc 
mRNA assayed as described in the legend to Fig. 4.23. 
A. Autoradiograph. B. Results from scanning densitometry. 
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FIGURE 4.28 Time course of KTI 6-stimulated c-myc mRNA accumulation in clone 4. 
Clone 4 cells wer~ incubated with 20µg/ml KT16 for the indicated times, then c-myc 
mRNA assayed as described in the legend to Fig. 4.23. 
A. Autoradiograph. B. Plot of the numbers obtained by scanning densitometry of all 
lanes except lane 6 where RNA was degraded during preparation. 
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There is evidence that activated protein kinase C can increase c-myc transcription 
(Moore et al., 1986; Lindsten et al., 1988). however the ability of IL2 to activate protein 
kinase C is controversial (Beckner and Farrar, 1986, 1987; Valge et al., 1988; Mills _et 
al., 1988). Therefore it cannot be assumed that IL2-stimulated c-myc mRNA 
accumulation is mediated by activated protein kin·ase C. 
The ability of all the ligands tested to induce c-myc m.RNA accumulation in cells for 
which they are mitogenic, despite their failure to produce identical responses, strongly 
suggests that increases in c-myc mRNA may be important for DNA synthesis. This 
conclusion is supported by experiments utilising anti.sense myc oligonucleotides and anti-
myc ~tibodies (see Section 1.6). However, the rapid c-myc mRNA accumulation 
induced by 145-2Cll was apparently insufficient to activate DNA synthesis, as 145-
2Cll was not mitogenic for clone 4. Therefore c-myc mRNA accumulation may be 
necessary but is not sufficient to activate DNA synthesis in T lymphocytes. 
4.5 Summary 
Ligand-induced modulations of T lymphocyte [Ca2+]i, inositol phosphates and c-myc 
m.RNA have been examined in two murine T cell populations; BALB/c thymocytes and 
clone 4, a helper T cell line. Ligands employed were first screened for their mitogenic 
potential (Chapter 3), then ligand effects on early responses were characterised. Table 
4.3 summarises the results of these studies, and for comparison also shows the mitogenic 
response to each ligand. 
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i) THYMOCYTES 
LIGAND 
Con A KT16 145-2Cll 
Response 
InsPx +++ + ++ 
Ca2+ +++ + +++ 
c-mycmRNA ++ + + 
DNA synthesis: 
Ligand alone ++ + + 
+IL2 +++ ++ ++ 
+TPA +++ ++ +++ 
ii) CLONE4 
LIGAND 
Con A KT16 145-2Cll 
Response 
InsPx +++ + ++ 
Ca2+ ++ ++ n.d. 
c-mycmRNA n.d. + + 
DNA synthesis: 
Ligand alone + 
+IL2 · n.d. 
+anti-CD4 n.d. n.d. 
TABLE 4.3 T cell responses to a panel of ligands 
Key: +++ = large response 
++ = moderate response 
+ = small response 
-= no response 
n.d. = not determined 
I 
IL2 I 
II I 
+++ 
IL2 
+++ 
+++ 
n.d. 
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CHAPTER 5 
THE EFFECT OF INHIBITORY RECEPTOR INTERACTIONS ON 
EARLY RESPONSES TO MITOGENS IN T LYMPHOCYTES 
5 .1 The effect of inhibitory receptor interactions on stimulated inositol 
phosphate accumulation 
5 .1.1 The effect of IL2 on ligand-stimulated inositol phosphate accumulation 
5.1.2 The effect of anti-CD4 antibody on ligand-stimulated inositol phosphate 
accumulation 
5.2 The effect of inhibitory receptor interactions on stimulated [Ca2+]i 
increases 
5.2.1 The effect of IL2 on ligand-stimulated [Ca2+]i increases 
5.2.2 The effect of anti-CD4 antibody on ligand-stimulated [Ca2+]i increases 
5.3 The effect of inhibitory receptor interactions on stimulated c-myc mRNA 
accumulation 
5.3.1 Mutual interactions of anti-Thy 1 antibody and IL2 
5.3.2 The effect of anti-CD4 antibody on stimulated c-myc mRNA 
accumulation 
5. 4 Molecular mechanisms of inhibitory receptor interactions 
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CHAPTER 5 
THE EFFECT OF INHIBITORY RECEPTOR INTERACTIONS ON 
EARLY RESPONSES TO MITOGENS IN T LYMPHOCYTES 
During characterisation of the mitogenic responses of clone 4 and BALB/c thymocytes 
(Chapter 3), it became apparent that the response to one ligand was often abrogated by a 
second ligand. IL2 and the anti-Thy 1 antibody KT16, although both mitogenic for clone 
4 individually, were mutually antagonistic. Furthermore, clone 4 proliferation induced by 
KT16, but not by IL2, was sensitive to inhibition by the anti-CD4 antibody KT6. In 
contrast, thymocyte proliferation evoked by Con A (or KT16 plus TPA) was insensitive 
to KT6, and IL2 synergised with Con A, KT16, and the anti-T3 antibody 145-2Cll. 
145-2Cll (a poor mitogen for thymocytes in the absence of IL2 or TP A) reduced Con A-
stimulated [3H]thymidine incorporation into BALB/c thymocytes. 
The antagonism between 145-2Cll and Con A was interpreted as evidence of a 
common binding site for the two ligands on the thymocyte cell surface (Section 3.2.4), 
but the mechanism by which the other inhibitory receptor interactions occurred was not 
immediately apparent. This was investigated by examining the effect of inhibitory 
receptor interactions on the early biochemical responses described in Chapter 4. These 
studies aimed not only to identify the molecular mechanisms by which inhibition was 
achiev_ed, but in so doing to identify responses obligatory for activation of DNA 
synthesis. 
5.1 The effect of inhibitory receptor interactions on stimulated inositol 
phosphate accumulation 
5.1.1 The effect of IL2 on ligand-stimulated inositol phosphate 
accumulation 
The failure of IL2 to elicit appreciable inositol phosphate accumulation (Section 4.3.1) 
made it possible to determine the effect of IL2 on the inositol phosphate response to 
KT16. IL2 caused partial inhibition of the increases in all inositol phosphate fractions in 
149 
response to KT16 (Fig. 5.1). 50 and 500U/ml IL2 caused similar reductions in inositol 
phosphate accumulated 10 mins after KTl 6 addition, but less inhibition was observed 
with IOU/ml IL2. SOU/ml IL2 inhibited stimulation of InsP, InsP2, InsP3 and InsP4 
accumulation by 63%, 50%, 63% and 71 % respectively. 
The effect of IL2 on responses to Con A was also determined, despite the failure of 
Con A to induce clone 4 proliferation, to assess the generality of IL2-mediated inhibition 
of PtdinsP2 hydrolysis. Con A-stimulated inositol phosphate accumulation in clone 4 
was also inhibited by IL2 (Fig. 5.2), but the inhibition was not as pronounced as the 
effect on the KT16 response. SOU/ml IL2 inhibited Con A-stimulated accumulation of 
InsP, InsP2, InsP3 and InsP4 by 15%, 7%, 31 % and 18% respectively. Similar 
inhibitions were observed at all IL2 concentrations tested. The ability of IL2 to inhibit 
PtdinsP2 hydrolysis stimulated by Con A demonstrated that IL2-mediated inhibition was 
not peculiar to stimulation through the Thy 1 molecule. The mechanism by which IL2 
antagonised PtdinsP2 hydrolysis was unknown. However, as KT16 evoked small 
inositol phosphate responses (relative to Con A or 145-2Cll), it is possible that IL2-
mediated inhibition reduced PtdinsP2 hydrolysis to below a critical threshold level 
necessary for activation of DNA synthesis. Therefore, the IL2-mediated reduction in 
PtdlnsP2 hydrolysis might be sufficient to explain the ability of IL2 to inhibit KTl 6-
stimulated clone 4 proliferation. 
S.1.2 The effect of anti-CD4 antibody on ligand-stimulated inositol 
phosphate accumulation 
In addition to the antagonistic effect of IL2 on clone 4 mitogenesis, KT16-activated 
DNA synthesis was also inhibited by the anti-CD4 antibody KT6. Therefore the effect of 
KT6 on KT16-stimulated inositol phosphate accumulation in clone 4 was determined. An 
anti-CDS antibody (15D5) of identical isotype to KT6 (rat IgG2a) was used to control for 
effects of any interaction of the Fe portion of KT6 with Fe receptors on clone 4. 
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FIGURE 5.1 Effect of IL2 on KT16-stimulated inositol phosphate accumulation. 
[3H]inositol-labelled clone 4 cells were incubated for 10 mins with medium ( o) or 
20µg/ml KT16 (•) and the indicated concentrations of IL2. Reactions were terminated 
and inositol phosphates assayed as described in the legend to Fig. 4.10. A, B, C and D 
show cpm in InsP, InsP2, InsP3 and InsP4 respectively. 
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FIGURE 5.2 Effect of IL2 on Con A-stimulated inositol phosphate accumulation. 
[3H]inositol-labelled clone 4 cells were incubated for 10 mins with medium ( o ) or 
lOµg/ml Con A <• and the indicated concentrations of IL2. Reactions were terminated 
and inositol phosphates assayed as described in the legend to Fig. 4.10. A,B,C and D 
show cpm in InsP, InsP2, InsP3 and InsP4 respectively. 
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15D5 had no effect on Con A-stimulated inositol phosphate accumulation over the 
concentration range 1-lOOµg/ml (Fig. 5 .3 ). Therefore all effects of KT6 were assumed to 
be due to its specific interaction with CD4. 
KT6 alone (5µg/ml) caused no PtdinsP2 hydrolysis but totally inhibited KT16-
stimulated accumulation of all inositol phosphate fractions at all time points tested (Fig. 
5.4). However, the small response to KT16 made it difficult to detect any small residual 
response in the presence of KT6. Therefore the effect of KT6 on the much greater 
responses to 145-2Cll and Con A was also determined. 
KT6 was a potent antagonist of Con A-stimulated inositol phosphate accumulation. In 
the presence of KT6 little increase was detectable up to 2 mins, but subsequently slow 
monotonic accumulation occurred up to 10 mins, when amounts of inositol phosphates 
were 10-20% of those in cells not treated with KT6 (Fig. 5.5). The time of KT6 addition 
relative to Con A addition was not critical for inhibition. The percentage inhibition of 
each inositol phosphate was very similar when KT6 was added simultaneously with or 5 
mins prior to Con A (Table 5.1). 
KT6 addition 
Simultaneous 
5 min pre-treatment 
Percentage inhibition of inositol phosphate fraction 
InsP InsP2 InsP3 InsP4 
84% 
86% 
71% 
77% 
66% 
74% 
65% 
68% 
TABLE 5.1 Comparison of the effect on inositol phosphate accumulation of KT6 added 
at different times 
[3H]inositol-labelled_ clone 4 cells were washed into salts solution and pre-incubated as 
described in Section2.7, then challenged with lOµg/ml Con A for 10 mins. KT6 
(5µg/ml) was added simultaneously or 5 min prior to Con A. Reactions were quenched 
and inositol phosphates extracted and separated using AG1-X8 resin as described in Sections 2.7.2-4. Inositol phosphate fractions were dried and counted for 3H (Section 2.8). Percentage inhibition was calculated as [(cpm in Con A sample-cpm in inhibited 
sample )x 100] / [ cpm in Con A sample-cpm in unstimulated cells] 
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FIGURE 5.3 Effect of anti-CD8 antibody on Con A-stimulated inositol phosphate 
accumulation. 
[3H]inositol-labelled clone 4 cells were incubated for 10 mins with lOµg/ml Con A after 5 
min pre-incubation with the indicated concentrations of 15D5 (a) or KT6 (o). Reactions 
were terminated and inositol phosphates described as in the legend to Fig. 4.10. Results 
are expressed as a percentage of the stimulated increases seen in cells treated with Con A 
alone, and are the means of duplicate determinations. A, B, C and D show the results for 
InsP, InsP2, InsP3 and InsP4 respectively. 
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FIGURE 5.4 Effect ofKT6 on KT16-stimulated inositol phosphate accumulation. 
[3H]inositol-labelled ~lone 4 cells were incubated with 20µg/ml KT16 in the presence 
(0) or absence (a) of 5µg/ml KT6 for the times indicated. Reactions were terminated 
and inositol phosphates assayed as described in the legend to Fig. 4.10. A,B,C and D 
show cpm in InsP, InsP2, InsP3 and InsP4 respectively. 
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FIGURE 5.5 Effect of KT6 on Con A-stimulated inositol phosphate accumulation. 
[3H]inositol-labelled clo~e 4 cells were incubated with lOµg/ml Con A in the presence 
(D) or absence (a) of 5µg/ml KT6 for the times indicated. Reactions were terminated 
and inositol phosphates assayed as described in the legend to Fig. 4.10. A,B,C and D 
show cpm in InsP, InsP2, InsP3 and InsP4 respectively. 
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KT6 also antagonised the inositol phosphate response to 145-2Cl 1 (Fig. 5.6). 
Simil~ to its effect on the response to KT16, KT6 totally abolished 145-2Cll-stimulated 
inositol phosphate accumulation. This was interesting by comparison with the partial 
inhibition of the response to Con A, since data presented earlier in the thesis suggested 
that Con A might trigger responses by interacting· with T3 (Section 3.2.4) However, the 
ability of Con A to elicit inositol phosphate responses in IL2-grown cells in the absence of 
a response to T3 (Section 4.3.2) suggested that Con A might stimulate PtdlnsP2 
hydrolysis via interaction with receptors other than or in addition to T3. This would be 
consistent with the difference in effect of KT6 on responses to Con A and 145-2Cl 1. 
The additional Con A receptor(s) could be less sensitive or even insensitive to CD4-
mediated inhibition. To investigate this, the effect of KT6 concentrations on Con A-
stimulated inositol phosphate accumulation (measured at 10 mins) was determined. 
Increasing KT6 concentrations up to lOOµg/ml mediated no greater inhibition than that 
caused by lµg/ml (Fig. 5.7). Concentrations greater than lOµg/ml increased the amount 
of InsP 4 to greater than that stimulated by Con A alone, but did not have similar effects on 
the other inositol phosphates. 
The enhanced InsP4 accumulation at high KT6 concentrations might be due to 
activation of InsP3 kinase by CD4-mediated increases in [Ca2+]i, as cross-linking of CD4 
with antibody has been shown to cause [Ca2+]i increases (Ledbetter et al., 1987b; Carrel 
et al., 1988). This is not inconsistent with the failure to observe KT6-induced [Ca2+Ji 
increases (Section 5.2.2) since these experiments only examined the effect of 5µg/ml 
KT6. These data suggest that Con A may cause inositol phosphate accumulation by 
interaction with at least two receptors, distinguishable on the basis of sensitivity to CD4-
mediated inhibition. 
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FIGURE 5.6 Effect of KT6 on 145-2Cl l-stimulated inositol phosphate accumulation. 
[3H]inositol-labelled clone 4 cells were pre-incubated with medium (a) or Sµg/ml KT6 
(CJ) for 5 mins, then lOµg/ml Con A added and reactions terminated at the indicated 
times. Inositol phosphates were assayed as described in the legend to Fig. 4.10. A,B,C 
and D show cpm in InsP, InsP2, InsP3 and InsP4 respectively. 
A 
z 
0 
i= 
i:c 
:f 
:z: 
::..e 0 
D 
z 
0 
E 
al 
:f 
~ 
::..e 0 
158 
100 B 100 
80 80 
z 
60 0 60 i= 
i:c 
40 :f 40 ~ 
::..e 0 
20 20 
1 10 100 1 10 100 
J,Jglml KT6 pglml KT6 
100 C 60 
80 40 
z 20 
60 0 i= 0 m 
40 :f -20 ~ 
';ft -40 20 
-60 
-80 
1 10 100 0 1 10 100 
JJglml KT6 JJglml KT6 
FIGURE 5.7 Concentration dependence of KT6-mediated inhibition of inositol 
phosphate accumulatipn. 
[3H]inositol-labelled clone 4 cells were pre-incubated for 5 mins with the indicated KT6 
concentrations, then incubated for a further 10 mins with lOµg/ml Con A. Reactions 
were terminated and inositol phosphates assayed as described in the legend to Fig. 4.10. 
Results are expressed as percentage of inhibition relative to cells treated with Con A 
alone, and are the means of duplicate determinations. A, B, C and D show the results for 
InsP, InsP2, InsP3 and InsP4 respectively . . 
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These results are reminiscent of data from fibroblasts indicating that different mitogen 
receptors couple to PtdlnsP2 hydrolysis via G-proteins of differing sensitivities to 
inhibition by pertussis toxin (Taylor et al., 1988), and suggest that different Con A 
receptors might couple to PtdlnsP2 hydrolysis via G-proteins of differing sensitivity to 
CD4-mediated modulation. However there are no data to support the hypothesis that the 
antagonistic effects of KT6 are due to modulation of the G-protein(s) responsible for 
receptor coupling to PtdlnsP2 hydrolysis. Furthermore the failure of KT6 to cause 
inhibition of Con A-stimulated PtdlnsP2 hydrolysis in BALB/c thymocytes (Fig. 5.8) 
comparable to that observed in clone 4 is consistent with the hypothesis that KT6-
mediated inhibition is due to destabilisation of interaction between CD4 and MHC class II 
molecules (Section 33). There are however no data to support this hypothesis other than 
differential sensitivity of class II-expressing (clone 4) and non-expressing cells 
(thymocytes) to CD4-mediated inhibition. 
5.2 The effect of inhibitory receptor interactions on stimulated [Ca2+Ji 
increases 
5.2.1 The effect of IL2 on ligand-stimulated [Ca2+Ji increases 
The ability of IL2 to antagonise ligand-stimulated inositol phosphate accumulation 
suggested .that IL2 might also reduce stimulated [Ca2+Ji increases. However, despite 
substantial inhibition of KT16-induced inositol phosphate accumulation, IL2 had only a 
small effect on KT16-stimulated [Ca2+Ji elevation (Fig. 5.9a). Maximal [Ca2+Ji was 
reduced 15nM by simultaneous addition of 50U/ml IL2, but the initial rate of increase and 
subsequent rate of decline were unaffected. 
The initial rate of [Ca2+Ji increase in response to Con A was also unaltered by IL2 
(Fig. 5.9b). However, in the presence of simultaneously added IL2, [Ca2+Ji declined 
more rapidly between 5 and 10 mins. This effect was more marked when IL2 was added 
5 mins prior to Con A, suggesting that IL2 might activate a response antagonistic to 
[Ca2+]i elevation in a time-dependent manner. 
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FIGURE 5.8 Effect of KT6 on Con A-stimulated inositol phosphate accumulation in 
BALB/c thymocytes. -
[3H]inositol-labelled thymocytes were pre-incubated for 5 mins with the indicated KT6 
concentrations then incubated for a further 10 mins with lOµg/ml Con A Reactions were 
terminated and inositol phosphates assayed as described 'in the legend to Fig. 4.10. 
Results are expressed as a percentage of the stimulated increases seen in cells treated with 
Con A alone, and are the means of triplicate determinations. A, B, C and D show the 
results for InsP, InsP2, InsP3 and InsP4 respectively. 
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FIGURE 5.9 Effect of IL2 on ligand-stimulated increases in [Ca2+]i. 
Quin 2-loaded clone 4-cells (Section 2.6.2) were challenged with 20µg/ml KT16 (A) or 
lOµg/~ Con A (B) added simultaneously with medium (a) or 50U/ml IL2 (D). [Ca2+]i 
was measured as described in the legend to Fig. 4.3. Each point is the mean of triplicate 
determinations. 
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5.2.2 The effect of anti-CD4 antibody on ligand-stimulated [Ca2+]j 
increases 
The effect of KT6 on KT16-induced [Ca2+]i elevation was examined by pre-treating 
clone 4 cells with 5µg/ml KT6 for 5 mins prior to KT16 addition. KT6 antagonised both 
total Ca2+ responses and [Ca2+]i increases occurring in the presence of lmM EGTA (Fig. 
5.10), but itself had no effect on [Ca2+]i. The initial rate of [Ca2+]i increase and 
maximum [Ca2+]i achieved were both reduced by KT6 pre-treatment and the time taken to 
attain the maximum [Ca2+]i was increased. The maximum response was reduced from 
262+/-23nM to 164+/-17nM, and the intracellular response was reduced from a maximum 
of 138+/-SnM to 122+/-SnM. 
Con A-induced [Ca2+]i elevation was also antagonised by KT6. Pre-treatment with 
KT6 reduced the initial rate of Con A-induced [Ca2+]i increase, and increased the time 
taken to reach maximum from 5. mins to greater than 10 mins. Little [Ca2+]i increase was 
observed up to 2 mins, consistent with the delay in inositol phosphate accumulation. 
Intracellular Ca2+ release was also slowed and the maximum reduced from 129+/-3nM to 
115+/-4nM. Neither KT16- nor Con A-induced [Ca2+]i increases were inhibited by the 
control antibody 15D5. 
KT6 pre-treatment had no significant effect on [Ca2+Ji increases evoked by 0.8 or 10 
µg/ml Con A in thymocytes (Fig. 5.11), consistent with the failure of KT6 to inhibit Con 
A-stimulated inositol phosphate accumulation in thymocytes. 
The ability of KT6 to antagonise [Ca2+]i increases in the presence ofEGTA suggests 
that KT6 can inhibit release of intracellular Ca2+ stores, consistent with its ability to 
inhibit InsP3 accumulation. However, the residual KT16-stimulated [Ca2+]i increase in 
the presence of EGT A is inconsistent with the total inhibition of inositol phosphate 
accumulation. A possible explanation for this inconsistency might be that in the presence 
of KT6, KT16 stimulates a residual accumulation of inositol phosphates of insufficient 
magnitude to be detected above basal levels, but sufficient for a limited mobilisation of 
intracellular Ca2+ stores. 
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FIGURE 5.10 Effects of KT6 and 15D5 on ligand-stimulated [Ca2+Ji increases in clone 4. 
Quin 2-loaded clone 4 cells (Section 2.6.2) were challenged with 20µg/ml KT16 (A-C) or 
lOµg/ml Con A (D-F) after 5 mins pretreatment with medium(•), 5µg/ml KT6 (D) or 
5µg/ml 15D5 (.6.). Experiments were performed in mediwn containing 0.43mM free Ca2+ 
(A, C, D and F) or O. lµM free Ca2+ (B and E). [Ca2+Ji was measured as described in 
the legend to Fig. 4.3. Each point is the mean of triplicate determinations. 
The abscissas in A-F show intracellular free calcium concentration (nM). 
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FIGURE 5.11 Effect of KT6 on Con A-stimulated [Ca2+]i increase in BALB/c 
thymocytes. 
Quin 2-loaded thymocytes (Section 2.6.1) were challenged with lOµg/ml Con A (•,o) or 
0.8µg/ml Con A (A,.A) after 5 mins pretreatment with medium(• ,A) or 5µg/ml KT6 
(D,.A). [Ca2+]i was measured as described in the legend to Fig. 4.3. Each point is 
the mean of triplicate determinations. 
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These data contrast with those of Rosoff et al. (1987a) who found that the anti-CD4 
antibody Gkl .5 inhibited extracellular Ca2+ entry but not intracellular Ca2+ release or 
inositol phosphate accumulation stimulated by Con A or antigen. From their results 
Rosoff et al. concluded that Gkl.5 might function by inhibiting a plasma membrane-
associated Ca2+ transporter. However, this hypothesis is inconsistent with the observed 
inhibition of [Ca2+]i increase in the presence of EGTA described above. Despite the 
probability that Gkl.5 and KT6 recogise different epitopes on CD4, it is difficult to 
explain their markedly different effects. 
5.3 The effect of inhibitory receptor interactions on stimulated c-In.X£ 
mRNA accumulation 
S.3ol Mutual interactions of antim Thy 1 antibody and IL2 
Determination of the effect of IL2 on ligand-stimulated [Ca2+Ji or inositol phosphate 
increases in clone 4 was facilitated by the failure of IL2 alone to induce such responses. 
However assay of the effect of IL2 on KTl 6-stimulated c-myc mRNA accumulation was 
complicated by the ability of IL2 to induce a much greater response than KT16 (Section 
4.4.2). 
IL2-stimulated c-myc mRNA accumulation was virtually abolished by simultaneous 
addition of the anti-IL2r antibody PC61-53 (7+/-1 % of IL2 alone), but was unchanged 
(91+/-10%) by simultaneous addition of20 µg/ml KT16 (Fig. 5.12). These data suggest 
that KT16-mediated inhibition of IL2-activated DNA synthesis in clone 4 is not due to a 
reduction in c-myc mRNA accumulation (at least at this time of measurement-lh after 
ligand addition), and is therefore likely to be due to inhibition of an event distal to, or on a 
separate pathway from, c-myc mRNA accumulation. The identity of this KT16-sensitive 
event is unclear, as the "signals" required for IL2-induced T cell proliferation are not well 
understood (see below). The data support the conclusion (Section 4.4) that c-myc 
transcription may be necessary but is not sufficient for DNA synthesis, as KT16 
abrogates IL2-induced proliferation without reducing IL2-stimulated c-myc mRNA 
accumulation. 
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FIGURE 5.12 Effect of ligand combinations on c-myc mRNA in clone 4. 
Clone 4 cells were imcubated with medium (A), 50U/ml IL2 (B), 20µg/ml KT16 (C), 
20µg/ml PC61-53 (D), IL2 + KT16 (E), or IL2 + PC61-53 (F) for lh, then c-myc 
mRNA assayed as described in the legend to Fig. 4.23. 
1· Autoradiograph ~ . Results from scanning densitometry. 
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The ability of IL2 to antagonise clone 4 proliferation stimulated by KTl 6 is clearly not 
due to a reduction in stimulated c-myc mRNA accumulation. However, the increased 
response in cells challenged with KT16 plus IL2 relative to KT16-stimulated cells could 
be antagonistic to KTl 6-mediated proliferation. 
5.3.2 The effect of anti°CD4 antibody · on stimulated C·!ll.ll m RN A 
accumulation 
The effect of KT6 on c-myc mRNA accumulation induced by KT16 or IL2 is shown 
in Figure 5.13. Consistent with the hypothesis that KT16 and IL2 stimulate c-myc 
mRNA accumulation via different pathways, KT6 had little effect on the response to IL2 
(91+/-1% cf 100+/-5%), but reduced the KT16 response by-60%. KT6 alone did not 
stimulate c-myc mRNA accumulation. 
This result is consistent with the suggestion (Section 4.22) that KT16 may evoke a c-
myc response via elevation of inositol phosphates and [Ca2+Ji, since KT6 partially 
antagonised all three responses. However, as PtdlnsP2 hydrolysis is unlikely to be the 
primary response to KT16 (Section 4.2.1), it is possible that KT6 inhibits an alternative 
response to KT16 which is capable of activating transcription of the c-myc gene. A 
possibJe candidate for this response might be tyrosine kinase activation, which occurs 
rapidly in T cells in response to T3- and Thy I-directed antibodies and antigen (Klausner 
et al., 1987; Section 1.5.3). However specific stimulation of c-myc transcription by an 
activated tyrosine kinase has not yet been demonstrated. 
5.4 Molecular mechanisms of inhibitory receptor interaction 
It is not possible to deduce the mechanism by which KT16 antagonises IL2-stimulated 
clone 4 proliferation from these data, as no effect of KTl 6 on any IL2 response has been 
demonstrated. However, the abilities of both IL2 and KT6 to antagonise ligand-
stimulated increases in [Ca2+Ji and inositol phosphate suggested that IL2 and/or KT6 
might cause cAMP accumulation, since cAMP is known to inhibit [Ca2+Ji and inositol 
phosphate responses in T cells (Taylor et al. , 1984; Lerner et al. , 1988). 
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FIGURE 5.13 Effect of KT6 on ligand-stimulated c-myc mRNA accumulation in clone 
4. 
Clone 4 cells were incubated with medium (A), 20µg/ml KT16 (B), KT16 + 5µg/ml KT6 
(C), 50U/ml IL2 (D),. IL2 + KT6 (E) or KT6(F) for lh, then c-myc mRNA assayed as 
described in the legend to Fig. 4.23. 
6· Autoradiograph. ~- Results obtained from scanning densitometry. 
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Cyclic AMP has been characterised as a potent anti-proliferative agent in T 
lymphocytes stimulated with lectins or antigen, using both cAMP analogues such as 8-
BrcAMP and cAMP-elevating agents including forskolin and prostaglandin E1 (PGE1) 
(Novogrodsky et al., 1983; Nel et al., 1988; Ling and Kay, 1975). Therefore the effect 
of forskolin on KT16-activated clone 4 DNA synthesis was examined. Forskolin 
inhibited KT16-stimulated [3H]thymidine incorporation into clone 4 by greater than 99% 
(2,508+/-1,220 and 11+/-3 cpm stimulated by lOOng/ml KT16 +J- lOOµM forskolin 
respectively). Therefore the hypothesis that IL2 and/or KT6 elevate cAMP would be 
consistent with, and sufficient explanation for, their effects on KT16-stimulated 
mitogenesis. However, IL2-activated DNA synthesis was also antagonised by forskolin 
in a concentration-dependent manner (Fig. 5.14). These data suggest that neither KT6 
nor IL2 cause cAMP elevation. This was confirmed by direct assay of cAMP levels in 
cells challenged with a variety of ligands. 
IBMX had no effect on basal cAMP levels but enhanced forskolin-stimulated cAMP 
accumulation; cAMP concentrations were 0.397 and 0.188 pmol cAMP/106 cells in cells 
stimulated with forskolin +J- IBMX respectively. Therefore the ability of ligands to 
elevate cAMP was assayed in the presence of IBMX to maximise cAMP accumulation, 
and a forskolin sample was included in each experiment as a positive control. KT6 
(5µg/m1) or KT16 (20µg/ml) had no effect on resting [cAMP] (Table 5.2a). However, 
SOU/ml IL2 caused a reduction of basal [cAMP] (Table 5.2b and other experiments). 
The inability of either KT6 or IL2 to elevate [ cAMP] is consistent with the conclusions 
inferred from forskolin effects on clone 4 mitogenesis. The ability of IL2 to reduce basal 
[cAMP] is consistent with reports that IL2 reduces both basal and PGE1-stimulated 
adenylate cyclase activity in the murine T cell clone CT6 (Beckner and Farrar, 1986, 
1987). However, since neither IL2 nor KT6 elevate cAMP, the mechanism by which 
they antagonise KT16-activated DNA synthesis is unclear. 
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FIGURE 5.14 Effect of forskolin on IL2-stimulated clone 4 proliferation. 
Clone 4 cells were cultured with SOU/ml IL2 plus the indicated forskolin concentrations 
· for 96h and DNA synthesis assayed as described in the legend to Fig. 3.1 . Each point is 
a single determination. 
a) 
b) 
Addition 
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Forskolin 
0 
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pmol cAMP / 1()6 cells 
0.023 
0.023 
0.020 
0.764 
0.032 
0.012 
0.195 
TABLE 5.2 Ability of ligands to elevate cAMP in clone 4 
Clone 4 cells were incubated for 15 mins with various ligands, then reactions were 
terminated and cAMP was assayed as described in Section 2.9. Results in a and bare 
from separate experiments. Each result is the mean of duplicate determinations. 
Several responses to IL2 have been described; c-fos, c-myc, and c-myb proto-
oncogene mRNA accumulation are well characterised (Farrar et al., 1987; Reed et al., 
1985; Depper et al., 1985; Pauza, 1987) and a variety of proteins are phosphorylated in 
-
response to IL2 including the ribosomal S6 protein and proteins of Mr 26kDa, 27kDa, 
63kDa, 67kDa, 68kDa and 85kDa (Evans and Ferrar, 1987; Evans et al., 1987; Ishii et 
al., 1987; Kohno et al., 1986; Mire et al., 1985; Mire-Sluis et al., 1989). These proteins 
are predominantly phosphorylated on serine or threonine although IL2 also stimulates 
tyrosine phosphorylation (Saltzman et al., 1988; Morla et al., 1988). Thus IL2 activates 
both an unidentified tyrosine kinase and a serine/threonine kinase. The identity of the 
serine/threonine kinase is also unclear. While an early report suggested that IL2 activated 
protein kinase C (Farrar and Anderson, 1985), recent demonstrations of protein kinase C-
independent IL2-induced proliferation (Mills et al., 1988; Valge et al., 1988) question the 
involvement of protein kinase C activation in proliferative responses to IL2. 
Furthermore, although there are conflicting reports of the ability of IL2 to elevate cAMP 
in lymphocytes (Knudsen et al., 1987; Beckner and Farrar, 1986, 1987; Wickremasinghe 
et al., 1986), IL2 failed to elevate cAMP in clone 4. Thus it appears likely that the 
activated serine/threonine kinase is neither protein kinase C nor cAMP-dependent kinase. 
Few early responses to IL2 other than these protein phosphorylations and oncogene 
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accumulation have been reported. Therefore the mechanisms by which IL2 induces 
proliferation and abrogates KT16-stimulated DNA synthesis are unclear. 
The mechanism by which KT6 antagonises responses to KT16, Con A and 145-2Cll 
is also unknown. It was suggested above that KT6 might destabilise interaction between 
CD4 and MHC class II molecules thereby abrogating the activation of the tyrosine kinase 
pp56lck. For this to be the sole reason for the inhibitory effects of KT6, activated 
tyrosine kinase must be sufficient to stimulate Ptd.InsP2 hydrolysis. However, although 
the ability of activated tyrosine kinase to stimulate inositol phosphate accumulation has 
been inferred from experiments involving mutant EGF receptors (Honneger, et al., 1987; 
Moolenaar et al., 1988), it is clear that Ptd.InsP2 hydrolysis is not an automatic 
consequence of tyrosine kinase activation, as both EGF and insulin stimulate the latter bl!,t 
not the former response (Besterman et al., 1986). Therefore it is not certain whether 
inhibition of tyrosine kinase activation would be sufficient to abrogate all ligand-induced 
responses. Alternatively KT6 might be inhibitory due to transduction of a negative 
signal. However other than cAMP there are no obvious candidate biochemical responses 
capable of antagonising [Ca2+]i and inositol phosphate responses. 
Ro~off et al. (1987a) suggested that anti-CD4 antibody inhibited influx of extracellular 
Ca2+. However, although consistent with their data, this explanation is inadequate to 
explain the ability of KT6 to inhibit inositol phosphate accumulation (Section 5.2.2), 
unless in clone 4 Ptd.InsP2 hydrolysis is secondary to, and activated by, [Ca2+]i elevation 
due to influx of extracellular Ca2+. The ability of ligands to stimulate increases in [Ca2+ Ji 
in the presence of extracellular EGTA (Section 4.3.2) and the ability of KT6 to inhibit 
these ligand-stimulated increases (Section 5.2.2) is incompatible with a mechanism of 
Ca2+-stimulated phospholipase C. Therefore it is unlikely that the antagonistic effects of 
KT6 are due to direct inhibition of a plasma membrane Ca2+ channel. 
CD4 is associated with a small fraction of T3-Ti on the cell surface, and further 
association is stimulated by T3-Ti-directed ligands (Anderson et al. , 1988; Rivas et al. , 
1988). Both TI-Ti and CD4 are modulated in response to ligands directed at the antigen 
receptor (Acres et al., 1986; Saisawa et al., 1987). Conversely CD4-directed ligands 
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might be expected to cause modulation of the surf ace expression of the antigen receptor 
and possibly other mitogen receptors which might also interact with CD4. Therefore the 
antagonistic effects of KT6 might be due to premature modulation of mitogen receptors. 
Of the possible explanations considered above for the ability of KT6 to inhibit 
responses to a variety of ligands several appear plausible, but it is not possible to 
distinguish between them on the basis of the data presented here. Nonetheless, KT6 has 
proved a useful tool for mitogenic analysis. Data presented in Chapter 4 suggested that 
increases in [Ca2+]i and inositol phosphates were insufficient to stimulate IL2 secretion 
and T cell proliferation. However, the observed inhibition of these responses by an 
antibody antagonistic to mitogenesis suggests these responses may be important for 
mitogenic stimulation of T cells through Thy 1 and the antigen receptor. Furthermore, the 
inhibition of c-myc mRNA accumulation by KT6 suggests either that KT6 antagonises an 
event necessary for both PtdlnsP2 hydrolysis and c-myc transcription or that there is a 
causal -link between these two responses. In contrast, study of the mutual antagonism of 
IL2 and KTl 6 has so far yielded no information on the mechanism by which these two 
ligands activate DNA synthesis. However it is possible that further study of the 
mechanism by which mutual antagonism is achieved may contribute to our knowledge of 
the events obligatory for IL2-activated DNA synthesis. 
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